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Abstract 
 
The introduction to the thesis discusses the control of phosphate balance and considers 
recent developments in the field. The concept of novel circulating substances which 
influence, and perhaps regulate, plasma phosphate (‘phosphatonins’), and which are 
important in tumour-induced hypophosphataemia, hereditary hypophosphataemias and, 
potentially, in normal phosphate physiology, is introduced. Finally, the isolation of the 
putative phosphatonin MEPE, and the current state of knowledge about this molecule, is 
described. 
The initial practical studies deal with the development and validation of a novel 
micromethod for measurement of phosphate and, simultaneously, other anions in 
biological fluids, using capillary electrophoresis. The accuracy and reproducibility of the 
method are demonstrated, and the method is compared with an established micromethod 
for measurement of individual ions. Finally, capillary electrophoresis is applied to the 
measurement of phosphate and other anions in urine, plasma and tubular fluid samples.  
In the next section, renal clearance experiments are performed in anaesthetized rats, in 
order to assess the effects of intravenously administered MEPE and to compare them with 
those of parathyroid hormone. MEPE is shown to be markedly phosphaturic. It does not 
alter glomerular filtration rate, blood pressure, plasma phosphate concentration or filtered 
phosphate load, but does cause large, dose-dependent increases in absolute and fractional 
phosphate excretion.  
The final series of experiments uses micropuncture methods in anaesthetized rats, in 
which fluid is collected from individual proximal convoluted tubules. The phosphaturic 
effect of MEPE is confirmed, and is shown to result, at least in part, from a reduction in 
fractional phosphate reabsorption in the proximal convoluted tubule, without a change in 
filtered phosphate load. 
The results obtained in these studies are discussed in relation to previous knowledge. 
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 Phosphate homeostasis 
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1 Introduction  
 
Phosphate is the most abundant intracellular anion, and the human body contains about 
600-900g of phosphorus. Of this, 80% is in the form of calcium salts in the bones, making 
the skeleton rigid. The remaining 20% is widely distributed in all the fluids and tissues of 
the body, with less than 0.1% of total body phosphate in the plasma. 
Phosphate is vital to life. The major source of energy for cellular reactions is ATP; 
phosphate is a component of lipids, proteins, RNA and DNA; and protein phosphorylation 
and dephosphorylation is central to many control mechanisms. Therefore, control of 
phosphate balance is a key metabolic process, and phosphate regulatory pathways exist in 
organisms from yeast to man (Silver, 2003). 
Whilst the key issue in the regulation of phosphate balance in mammals is usually how to 
get rid of excess phosphate, the situation in many lower animals is different. The 
phosphate concentration in many aquatic environments is extremely low - in the 
micromolar or even nanomolar range. In some systems, for example freshwater lakes in 
North America, phosphate is the limiting nutrient (Karl, 2000), and it has been suggested 
that low phosphate levels in Earth’s early oceans acted as a brake on the evolution of 
multicellular organisms (Bjerrum & Canfield, 2002; Hayes, 2002). There is evidence that 
phosphorus availability provides the ultimate limit on the total amount of life in the 
oceans (Tyrrell, 1999). Thus, bacteria and yeasts have evolved extensive systems for the 
active uptake of phosphate from the surrounding environment (Wykoff & O’Shea, 2001). 
Many of these same mechanisms have been adapted to regulate phosphate balance in 
multicellular organisms (Werner & Kinne, 2001).  
 
1.1 Phosphate balance in humans 
 
The average British man consumed about 50mmol/day of phosphorus in the year 2000; 
the figure for women was 35mmol/day (Food Standards Agency, 2003). Slightly more 
recent figures from the USA are strikingly similar (US Department of Agriculture, 2004). 
Almost all of this is in the form of phosphate.  Food items with high phosphate content 
include milk and dairy products, meat, fish and other proteins, and cereals. The modern 
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trend to eat more processed food may increase the average phosphate intake, as the 
phosphate content of these foods is especially high (Uribarri & Calvo, 2003). A crossover 
trial in graduate students found that they consumed twice as much phosphate when their 
diet was mainly processed food than when they consumed similar but unprocessed food 
(Raines Bell et al, 1977). Interestingly, the pre-meal serum phosphate levels of these 
students were the same, despite the two-fold difference in phosphate intake. Similarly, in 
another dietary manipulation study, a very low phosphate diet left early morning fasting 
values for serum phosphate similar to those of subjects on a normal phosphate diet, 
although there were differences in post-prandial levels (Portale et al, 1989). This is in 
contrast to the situation in experimental animals such as rats, where serum phosphate can 
be greatly reduced by restricting intake (for example, Slatopolski et al, 1996). This may 
simply reflect the fact that it is possible to control the diet of rats in a way which is 
unacceptable in human subjects.  
 
The control of uptake of phosphate from the gut is currently not very well understood, but 
in health about 60-80% of ingested phosphate is absorbed from the lumen of the 
gastrointestinal tract (reviewed in Weisinger & Bellorin-Font, 1998). This uptake mainly 
takes place in the small intestine, and can occur by either the paracellular route (through 
tight junctions) or the transcellular route. The transcellular route, mediated by apical 
sodium-phosphate co-transporters, is thought to be the more important (Eto et al, 2006).  
 
There is a circadian pattern to human serum phosphate concentrations, with plasma 
phosphate rising from a low in the mid-morning to a peak in the middle of the night. A 
study of healthy volunteers who gave blood every two hours and urine every four hours 
showed significant differences in serum phosphate depending on the time of day (from a 
minimum of 0.9mmol/L at 11am to maximum of 1.3mmol/L at 3am) (Kemp et al, 1992). 
Interestingly, and in contrast to the findings of Portale and colleagues discussed above, 
there was no obvious relationship to meals (unlike, for example, the circadian rhythm of 
serum glucose concentration). These findings imply that there is extensive tissue uptake of 
phosphate after meals followed by release during subsequent periods. Urinary phosphate 
excretion also varied in a circadian way, but less strikingly and there was more variation 
between individuals. Urinary excretion did not vary directly in proportion to serum 
concentration. A more recent study observed rises in serum phosphate that seemed to 
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occur after meals (Horwitz et al, 2003), but the number of subjects was too small to draw 
firm conclusions. A circadian rhythm to serum phosphate concentrations has also been 
reported in rats (Bielesz et al 2006), although the changes were relatively modest and 
phosphate concentrations were reported only for the normal working day. 
Calcium and phosphate concentrations in human (and rodent) plasma are close to the 
saturation point for mineral precipitation; indeed, the solubility coefficient of calcium 
phosphate in water can be exceeded in some situations. Thus, moderate increases in serum 
phosphate might potentially lead to widespread vascular and soft tissue calcification. This 
could of course with equal accuracy be termed ‘phosphateification’, as the mineral is 
calcium phosphate, although this hardly trips off the tongue. As well as active control of 
serum phosphate levels, discussed more fully below, a number of proteins in the soft 
tissues and circulating in the serum seem to be able to inhibit mineralization (Schinke et 
al, 1999). The serum protein fetuin has been shown to act as an inhibitor of unwanted 
mineralization; mice deficient in this protein develop widespread and severe ectopic 
calcification (Schäfer et al, 2003), which is much more evident when they are fed a high-
phosphate diet (Westenfeld et al, 2007). Low concentrations of this protein are associated 
with excess mortality in dialysis patients (Ketteler et al, 2003). 
 
1.1.1 Hyperphosphataemia  
 
Despite evidence of some regulation of phosphate uptake from the gastrointestinal tract, 
the main control of the concentration of phosphate in the serum, and of overall long-term 
phosphate balance, is exerted by the kidneys. Significant hyperphosphataemia is rare in 
people with normal kidney function. In contrast, in people with renal failure there is 
usually little change in phosphate intake whereas phosphate removal from the body is 
difficult; therefore many patients with end-stage renal failure have significant 
hyperphosphataemia.  
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1.1.1.1 Hyperphosphataemia in chronic renal failure 
 
In a study of a large number of patients with significant renal impairment but not requiring 
dialysis (average estimated creatinine clearance 47ml/min), there was a strong positive 
relationship between serum phosphate and mortality, with each 0.33mmol/L increase in 
serum phosphate increasing mortality by 25%; mortality was increased once serum 
phosphate rose above 1.15mmol/L (within the normal range) (Kestenbaum et al, 2005). It 
must be said however that clinical information in this retrospective study may not be very 
accurate and not all confounders have been ruled out. 
Registry data from the UK (UK renal registry report, 2006) and the USA (USRDS report, 
2007) show that 40% or more of dialysis patients have hyperphosphataemia (even when 
defined by the generous criterion of plasma phosphate >1.8mmol/L; in fact the upper limit 
of the normal range in adults is usually considered to be 1.45mmol/L, so by this measure 
even more patients would be hyperphosphataemic). Conventional haemodialysis or 
peritoneal dialysis does not suffice to remove the average phosphate intake and it is 
necessary for almost all dialysis patients to take phosphate binding medication, aiming to 
reduce gastrointestinal phosphate uptake, and for them to follow a diet aimed at reducing 
phosphate intake. 
Patients with end-stage renal failure undergoing dialysis have rates of death from 
cardiovascular disease which are at least ten times those of age-matched members of the 
general population, and in young patients this figure rises to up to 100 times (UK renal 
registry report 2006; Ansell et al 2007). Dialysis patients have multiple conventional risk 
factors for cardiovascular disease, including hypertension, dyslipidaemia and a high 
incidence of diabetes, but all these factors combined are not sufficient to account for the 
increased risk (Locatelli et al, 2003).  It has been suggested that persistent 
hyperphosphataemia may provide part of the explanation for this additional risk (Block et 
al, 2002). Dialysis patients are prone to severe and widespread vascular calcification 
(Blacher et al, 2001; Oh et al 2002), and numerous studies have found a correlation 
between the degree of vascular calcification and serum phosphate levels or 
calcium/phosphate product (calculated simply by multiplying serum calcium by serum 
phosphate) (Shigematsu et al, 2003). Vascular calcification occurs at a younger age in 
dialysis patients than in the general population and is more widespread and severe. 
Vascular calcification and consequent increased vascular stiffness are strong predictors of 
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cardiovascular and all-cause mortality in dialysis patients (Blacher et al 2001). Studies of 
human vascular endothelial cells show that when grown in medium containing excess 
phosphate they lay down extracellular matrix proteins and mineralise these proteins (Jono 
et al, 2000) - in effect mimicking bone formation and providing a potential mechanism by 
which excess plasma phosphate might lead directly to mineralization and excess mortality. 
It is of particular note that the raised phosphate concentrations used in these experiments 
were only 2mmol/L - similar to those seen in many dialysis patients. 
In a study that compared dialysis patients with higher and lower serum phosphate levels, 
hyperphosphataemic patients (with serum phosphates > 2mmol/L) were more 
hypertensive and had a higher cardiac output (Marchais et al, 1999). It is not clear which 
of these changes are primary and which secondary to the greater arterial stiffness seen in 
patients with vascular calcification. It has been suggested that vascular calcification in 
diabetic dialysis patients is more related to glycaemic control than to serum phosphate 
levels (Ishimura et al, 2002), although the number of diabetic patients in this study was 
small.  
Longitudinal studies  of phosphate control in patients with end-stage renal failure (that is, 
studies in which patients were grouped according to their serum phosphate levels at the 
beginning of the study and then followed up) have shown a relationship between serum 
phosphate levels and mortality, patients with the highest phosphate levels having the 
highest death rates (Block et al, 1998). Although highly consistent (the relationship has 
been seen in several US cohorts, in the UK, in Europe and in China), the magnitude of the 
increased mortality risk is relatively modest. In the original paper by Block et al, the 
highest quartile of serum  phosphate was associated with a relative risk of 1.27, whilst in 
another study (Leggat et al, 1998) the relative risk associated with a grossly elevated 
serum phosphate, >2.5mmol/L, was only 1.13. A more recent study showed a relative risk 
of death of 1.82 in patients with a serum phosphate >2.26mmol/L compared to those with 
levels of <1.78mmol/L (Stevens et al, 2004 ). Supporting this is a longitudinal study from 
London’s group (London et al, 2003) which showed that arterial medial calcification was 
strongly correlated with mean serum phosphate levels in long-term haemodialysis 
patients, and that medial calcification in turn was strongly correlated with the risk of 
death, mainly from cardiovascular causes. All these studies are based on stratifying 
patients into high or low phosphate groups on the basis of an initial phosphate value, 
which will lead to significant regression dilution bias (where the effect seen is reduced in 
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magnitude by the misclassification of patients initially- see MacMahon et al, 1990). A 
large long-term follow-up study with repeated phosphate determinations (at least monthly) 
would allow clearer connections between average or peak serum phosphate levels and 
clinical outcomes, but no such study has yet been performed. One study with repeated 
phosphate measurements, but of moderate size and with mean follow-up of only two 
years, confirmed an association of serum phosphate with mortality, with the hazard ratio 
for death in the highest quartile for serum phosphate of 1.6 (Melamed et al, 2006).  
There is the additional complicating factor that serum phosphate is correlated with both 
nutritional status and patient compliance. Low phosphate may indicate inadequate 
nutrition, whilst elevated phosphate levels are often interpreted as indicating that the 
patient is not rigorous in following their diet or taking their medication, and thus may 
have other risk factors for mortality, for example poor blood pressure control (Leggat et 
al, 1998). 
 
It has been suggested that vascular calcification in haemodialysis patients relates to the 
large amount of calcium many of them take by mouth, in the form of calcium carbonate 
(as gastrointestinal phosphate binder), aiming to reduce hyperphosphataemia. This leads 
to increased gastrointestinal uptake of calcium and thus (in the absence of appreciable 
renal calcium losses) a state of ongoing positive calcium balance. There is also the 
possibility that many dialysis patients are in positive calcium balance during dialysis itself 
(Gotch et al, 2007). Numerous comparisons have been made between calcium-containing 
phosphate binders and newer, non-calcium-containing binders, including sevelamer and 
lanthanum. It has been shown that vascular calcification progresses less rapidly in dialysis 
patients given non-calcium-based phosphate binders (Chertow et al, 2002 ; Kakuta et al, 
2007), although others have found that progression of cardiac valve calcification is not 
different between calcium carbonate- and sevelamer-taking patients, provided their lipids 
are similar (Qunibi et al, 2007) . Some  have (perhaps cynically) suggested that these 
analyses relate in part to the desire of pharmaceutical companies to sell phosphate binders 
which do not contain calcium (Nolan & Qunibi, 2003), these latter being under patent and 
expensive. A recent analysis of patients randomised to sevelamer or to calcium-based 
binders found no difference in all-cause mortality, but sub-group analyses suggested that 
mortality might be higher in older patients taking calcium-based binders (Suki et al, 
2007). What is beyond dispute is that none of the currently available phosphate binding 
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regimes is particularly effective and most dialysis patients remain significantly 
hyperphosphataemic, with most studies suggesting that calcium acetate gives equivalent 
or better control of serum phosphate levels than sevelamer (reviewed in Qunibi et al, 
2004).  
As well as the possible direct harm caused by hyperphosphataemia, morbidity and 
mortality in dialysis patients have been shown to be increased by hyperparathyroidism 
(Melamed et al, 2006; Block et al, 2004). Although numerous factors contribute to 
hyperparathyroidism in renal impairment, persistently elevated plasma phosphate values 
are a major cause; most patients with renal impairment have both elevated PTH levels and 
hyperphosphataemia (see section 1.2.1. for a discussion of the inter-relationship between 
parathyroid hormone and plasma phosphate). In this context there is some interesting 
preliminary evidence that lowering serum parathyroid hormone and phosphate levels with 
the new therapeutic agent cinicalcet, (which acts as a calcimimetic at the calcium-sensing 
receptor on the parathyroid cell, and therefore reduces parathyroid hormone secretion 
directly and serum phosphate indirectly, by reducing bone breakdown) may reduce the 
risk of cardiovascular hospitalisation in dialysis patients (Cunningham et al, 2005); long-
term clinical trials investigating the effects  of this drug on the mortality of dialysis 
patients are in progress. There is experimental evidence (in rats which had been 
parathyroidectomised and then implanted with a minipump delivering controlled doses of 
PTH) that hyperphosphataemia causes myocardial hypertrophy and impaired renal 
function even when PTH is not elevated (Neves et al, 2004). 
The risk of cardiac valvular calcification in dialysis patients has been found to correlate 
with their serum phosphate (Rubel & Milford, 2003); unfortunately this study is another in 
which patients are grouped according to a single value of phosphate at baseline and then 
followed up. The mechanism of valvular calcification is thought to be similar to that of 
arterial calcification, so this finding supports the view that raised serum phosphate is 
associated with an increased risk of abnormal mineral deposition at numerous sites. 
Finally, there is evidence from a number of experimental models that hyperphosphataemia 
can promote the progression of chronic renal failure (Laouari et al 1997). There is also 
evidence that animals with chronic renal failure treated with phosphate-lowering 
medication have slower progression of renal disease (Nagano et al 2003). In accord with 
this, higher serum phosphate is associated with a more rapid decline in GFR in patients 
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with poor renal function approaching dialysis, as compared to patients with good control 
of serum phosphate (Voormolen et al, 2007).  
 
Whether mortality within human populations with normal renal function is correlated with 
serum phosphate levels is not yet established. However, a recently published analysis of 
vascular risk factors in participants in the Framingham Offspring study found that those in 
the upper quartile for serum phosphate had a risk of vascular events of 1.55 as compared 
to those in the lowest quartile; this increased risk persisted even if analysis was limited to 
those with an estimated glomerular filtration rate of over 90ml/min and after adjustment 
for other recognised vascular risk factors (Dhingra et al, 2007). Very few patients had 
serum phosphate concentrations outside the normal range in this study, and the results 
were unchanged by their exclusion.  
1.1.1.2 Hyperphosphataemia and calciphylaxis 
 
Calciphylaxis, a syndrome of tissue necrosis and vascular calcification, was first described 
in detail by Gipstein, Coburn and Adams in the 1970s (Gipstein et al, 1976). They 
investigated patients with chronic renal failure and painful ischaemic ulcers of the skin or 
extremities, and found medial calcinosis of the arteries (that is, calcium deposits within 
the arterial wall). Unfortunately, parathyroid hormone assays were not available in 1976, 
but most of the patients were assumed to have secondary hyperparathyroidism; some 
improved dramatically when their parathyroid glands  were removed. These authors also 
noted that all the patients had, at some point in their illness, greatly elevated serum 
phosphate concentrations. There are suggestions that the syndrome has become more 
common in recent years, although this may in part reflect longer average survival of 
dialysis patients (Don & Chin, 2003). Calciphylaxis has recently been more descriptively 
renamed calcific uraemic arteriopathy (Rogers et al, 2007). The condition has occasionally 
been reported in patients without renal failure and with a normal serum phosphate and 
calcium/phosphate product (Nigwekar et al, 2008), but this is most unusual, and 
hyperphosphataemia is regarded as playing a central role in the syndrome (Rogers et al, 
2007); raised serum phosphate was the most significant risk factor for calciphylaxis in a 
multivariate analysis of patients in the largest single-centre study (Fine & Zacharias, 
2002).  
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1.1.1.3. Acute hyperphosphataemia 
 
Acute hyperphosphataemia may also lead to death; the most common situation in which 
this can occur is iatrogenic, when patients with poor ability to regulate phosphate (that is, 
with renal impairment or renal failure) are given phosphate-based medication as laxatives 
before colonoscopies or surgery (Tan et al, 2002). In a (probably small) proportion of 
cases a considerable amount of phosphate is taken up from the bowel and acute phosphate 
poisoning occurs. In one case in which such a patient was investigated by means of a renal 
biopsy (Desmeules et al, 2003), the biopsy was found to contain calcium-phosphate 
crystals blocking the renal tubules.  
 
 
1.1.2 Hypophosphataemia 
 
Since almost all foods contain phosphate, deficiency is rare in the developed world. When 
it does occur, severe hypophosphataemia can be life threatening; the subject has been 
thoroughly reviewed by Knochel (1977) and somewhat more recently by Subramanian 
and Khardori (2000). Severe hypophosphataemia usually occurs in patients with 
underlying phosphate depletion, for example poor nutrition, alcoholism or excessive use 
of phosphate-binding antacids. Hypophosphataemia can also, rarely, be caused by 
inherited conditions (see section 1.4.1), by renal phosphate wasting associated with kidney 
transplants or kidney stones (see section 1.4.2), or as a consequence of factors secreted by 
certain cancers (see section 1.4.3). 
1.1.2.1 Hypophosphataemia in malnutrition 
 
Studies in malnourished children have suggested that hypophosphataemia is common in 
this situation. Severely malnourished children with kwashiorkor were reported in one 
study to have a 12% incidence of severe hypophosphataemia (Manary et al, 1998); in 
another study over half the children had values below the normal range (Waterlow & 
Golden, 1994). Manary et al found that children with a very low serum phosphate 
(<0.32mmol/L) were at a much greater risk of death (mortality more than 60%) than 
children with serum phosphates nearer the normal range (mortality 22%). Some of the 
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deaths in these children were sudden and might have been due to heart rhythm 
disturbances or acute cardiac failure (which might have been caused directly by the low 
serum phosphate levels). In another study by the same group, also investigating severe 
malnutrition in young children, the overall mortality rate was 25% and about a quarter of 
all deaths were attributed in whole or in part to severe hypophosphataemia (Manary & 
Brewster, 2000). For a condition that is so common (admittedly usually far from academic 
medical centres), it is disappointing that there is so little literature in this area. 
Hypophosphataemia is recognised as the key abnormality in the re-feeding syndrome. 
Total body phosphate is often low in malnourished patients. The resumption of eating (or 
administration of an intravenous glucose infusion) after a period of starvation causes 
plasma phosphate, often already low, to be reduced further as a result of increased 
phosphate uptake by cells, where it is required for increased protein and fatty acid 
synthesis. This precipitates severe hypophosphataemia and can cause respiratory and 
cardiac failure associated with rhabdomyolysis and leucocyte dysfunction; the syndrome 
can be fatal (Hearing, 2004). In a large retrospective study (Kagansky et al, 2005), 
hypophosphataemia was shown to be associated with the risk of death of elderly patients 
admitted to hospital, and was strongly associated with tube feeding and with intravenous 
glucose infusion, suggesting that many cases were caused by the re-feeding syndrome. 
 
1.1.2.2 Hypophosphataemia in critical illness 
 
In intensive care patients there is considerable evidence that hypophosphataemia is 
common, and that mortality is inversely correlated with serum phosphate; for example, in 
patients undergoing liver resection, mortality was four times higher in patients with a 
post-operative serum phosphate <0.5mmol/L than in those with a serum phosphate 
>0.8mmol/L (Giovannini et al, 2002). It is not clear, however, whether the relationship 
between severe hypophosphataemia and mortality is causal in critical illness: the authors 
of the study cited above suggest that hypophosphataemia might either be a cause of poor 
outcome or might be an early sign of complications. It has been shown that infusing the 
cytokines interleukin-6 and tumour necrosis factor-α into mice leads to 
hypophosphataemia (Barak et al, 1998), so adverse outcomes associated with low serum 
phosphate levels in critical illness might be consequences of high levels of these cytokines 
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rather than due to the low phosphate per se. In a study of intensive care patients, 
hypophosphataemia, defined as a serum phosphate <0.8mmol/L, was found in 29% of 
patients (Zazzo et al, 1995). These patients had a mortality of 30% compared to 15% in 
those patients with a normal serum phosphate, but the hypophosphataemic patients were 
more ill, in that they were more likely to have sepsis and require parenteral nutrition. In an 
extension of this study, glucose-1-phosphate was infused into eight patients with moderate 
or severe hypophosphataemia. In all eight, serum phosphate rose into the normal range 
(above it in one patient) and cardiac output (measured by thermodilution via a right heart 
catheter) improved significantly. This is the most convincing part of the study, and it 
suggests that control of serum phosphate is of considerable importance in this situation. In 
a similar (and equally small) study (Bollaert et al, 1995), critically ill patients on 
ventilators with serum phosphate <0.65mmol/L were infused rapidly with 20mmol of 
phosphate, which increased serum phosphate considerably. Mean blood pressure rose 
significantly after phosphate infusion, as did left ventricular stroke work - an indication of 
myocardial contractility. Despite these suggestive results, no clear consensus about the 
value or otherwise of routine phosphate supplementation in critically ill patients has been 
reached (Bugg & Jones, 1998). 
 
 
In summary, normal control of serum phosphate depends on adequate renal function. 
Patients with renal failure often have significantly raised serum phosphate levels. There is 
considerable evidence that this raised serum phosphate is correlated with mortality, and 
there are plausible mechanisms by which hyperphosphataemia might contribute to 
premature death. It is not yet clear whether serum phosphate levels alter mortality in 
persons without renal impairment, but there is some evidence that they might. 
Hypophosphataemia is usually associated with undernutrition. It is also associated with 
poor outcome in several patient groups; however, it has not been conclusively 
demonstrated that it is hypophosphataemia that causes mortality in these groups.  
 
1.2 Preservation of normal phosphate balance 
 
Normal phosphate balance in man is maintained partly by regulation of uptake from the 
gastrointestinal tract, but principally by regulation of reabsorption of phosphate from the 
renal tubule. Phosphate is generally agreed to be freely filtered at the glomerulus 
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(Grimellec et al, 1975). Most is then actively reabsorbed in the proximal tubule; this 
process is under the control of a number of factors, in particular parathyroid hormone 
(Samiy et al, 1965; reviewed in Biber et al, 2000). The reabsorptive mechanism is specific 
and can be saturated. There is no evidence for tubular phosphate secretion, even under 
situations of phosphate loading (Handler, 1962). 
Although much is known about how phosphate enters the renal tubular cell (by means of 
sodium-phosphate co-transporters on the apical brush-border membrane), little is known 
about how it leaves through the basolateral membrane into the circulation. Similarly, 
phosphate uptake from the gastrointestinal tract is mainly by means of sodium-phosphate 
co-transporters on the apical membrane of enterocytes, but little is known of how 
phosphate exits from these cells.  
1.2.1 Parathyroid hormone and vitamin D 
 
As indicated above, serum phosphate in human populations is regulated within the range 
0.8 to 1.5 mmol/L, despite very variable phosphate intakes. It is generally agreed that the 
principal phosphate regulatory hormone is parathyroid hormone (PTH). There is a 
complicated inter-relationship between serum phosphate, PTH and vitamin D (see Fig. 1.1 
and text below). PTH is synthesised as a preprohormone, processed, and secreted as a 
linear peptide by specialised cells in the parathyroid glands. PTH secretion is increased by 
a high phosphate diet and (as demonstrated in explanted parathyroid glands) by high 
serum phosphate (Almaden et al, 1998) and diminished by low serum phosphate 
(Felsenfeld et al, 2007); these effects are both genomic and post-transcriptional 
(Slatapolski et al, 1996). The release of PTH is markedly increased by low serum calcium 
and suppressed (though not completely halted) by high serum calcium. PTH synthesis and 
PTH secretion are both inhibited by the active form of vitamin D, calcitriol (see below).  
 
PTH has widespread effects on phosphate. It increases the gastrointestinal uptake of 
phosphate, via raised calcitriol levels; it increases the production of calcitriol by up-
regulating the enzyme 1α−hydroxylase in the kidney (see below); it increases the amount 
of phosphate lost in the urine by its actions on renal proximal tubular cells; and it 
stimulates bone breakdown, releasing phosphate into the plasma.  It has significant, 
perhaps more striking, effects on serum calcium since it increases bone calcium loss and 
gastrointestinal calcium uptake (see Fig 1.1). PTH also has a number of less well 
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understood actions on the vascular system and elsewhere (Ogata et al, 2003); for example, 
prolonged exposure causes left ventricular hypertrophy which does not seem to be caused 
simply by hypertension (Piovesan et al, 1999).  
Fig. 1.1 Interactions between PTH, calcitriol, calcium and phosphate  
 
Primary proliferative changes in the parathyroid glands leading to inappropriate excessive 
secretion of PTH (hyperparathyroidism) are not uncommon (Wermers et al, 1998). 
Interestingly, patients with mild hyperparathyroidism (PTH around twice the upper limit 
of normal) have modest hypercalcaemia but usually normal serum phosphate levels 
(Bilezikian & Silverberg, 2004), suggesting the existence of effective counter-regulatory 
systems able to compensate for the phosphaturic effects of modestly increased circulating 
PTH.  (Note also in the section below on a clinical trial of subcutaneous PTH in 
osteoporosis, the absence of reported effects on serum phosphate.) It is clear that the main 
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clinical problems faced by patients with an excess of PTH are related to raised serum 
calcium rather than low serum phosphate (Peacock, 2002). In particular, patients with 
primary hyperparathyroidism do not often develop bone disease or myopathy; it is stated 
in Peacock’s review that this is because they do not become phosphate depleted, although 
no reference is provided for this statement. 
 
There is some evidence that PTH release may be stimulated by ingestion of oral phosphate 
via a humoral or nervous signal originating in the gastrointestinal tract, as well as by 
alterations in plasma phosphate; there are also data suggesting that the gastrointestinal 
tract may also produce other circulating phosphaturic substances. In uraemic rats fed a 
high-phosphate diet, duodenal infusion of the (non-absorbable) phosphate analogue 
phosphoformate induced a four-fold increase in PTH within 5min, without any change in 
plasma phosphate or calcium (Martin et al, 2005). It has recently been reported that 
instillation of phosphate into the duodenum in normal rats causes a rapid and large 
increase in renal phosphate excretion (Berndt et al, 2007). This effect occurs within 15 
minutes and occurs without changes in serum phosphate; the effect is not altered by renal 
denervation and occurs in thyroparathyroidectomised animals. These workers assayed for 
changes in PTH and for alterations in the levels of the putative phosphate-regulating 
proteins fibroblast growth factor- 23 and frizzled-related protein-4 (see sections 
1.4.3.3.1.and 1.4.3.3.3) and did not find any. These findings suggest a secreted substance 
originating in the small bowel and altering renal phosphate reabsorption; the nature of this 
substance (dubbed by the authors ‘intestinal phosphatonin’) and whether it has any actions 
on bone remain matters of conjecture. 
 
Intravenous infusions of large doses of PTH in humans with normal renal function 
(Horwitz et al, 2003) and in rats (Brunette et al, 1973) lead (at least in the short term) to 
phosphaturia and reduced serum phosphate. PTH stimulates bone formation and 
resorption in humans; intermittent (daily) subcutaneous injection of the fragment PTH 1-
34 have been shown to increase bone density and reduce the risk of further fractures in 
post-menopausal women with a history of fracture and osteoporosis (Neer et al, 2001). 
This finding is somewhat odd because continuous exposure to raised PTH levels, in 
primary hyperparathyroidism, causes reduced bone density and increases fracture risk; it is 
generally believed that short-term (less than two hours a day) exposure to elevated PTH is 
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anabolic for bone while long-term raised levels are catabolic (Potts, 2005). It is interesting 
that no mention of serum phosphate is made in this paper describing low-dose 
administration of PTH to over 1600 patients; it is probably reasonable to assume that there 
were no significant effects on serum phosphate levels. 
 
The rate-limiting phosphate pathway in the renal tubule, and therefore in phosphate 
balance overall, is the type 2a sodium-phosphate co-transporter (NaPT2a) in the proximal 
tubular cell apical membrane (reviewed in Murer et al, 2001; see section 1.3.2 for a 
detailed discussion). It was demonstrated many years ago by means of micropuncture 
experiments that most renal phosphate reabsorption is in the early part of the proximal 
tubule (Brunette et al, 1973), and this is regulated by controlling the number and activity 
of these sodium-phosphate co-transporters.  PTH regulates renal phosphate reabsorption 
by down-regulation of NaPT2a co-transporters; shortly after injection of PTH, the amount 
of NaPT2a present in the apical membrane decreases sharply, with the transporter protein 
being internalized and then degraded in the lysosomal compartment. There is currently no 
evidence for recycling of NaPT2a, although recycling back into the apical membrane has 
been demonstrated for other transporters. Thus, recovery of phosphate absorption depends 
on synthesis of new protein. PTH is able to act via both a protein kinase C- and a protein 
kinase A-dependent pathway (Hattenhauer et al, 1999), and has been shown to be active 
from both the luminal and basolateral sides of the mouse isolated proximal tubule 
(Traebert et al, 2000). It has been demonstrated that the luminal actions of PTH are 
mediated via the protein kinase C pathway, whilst the basolateral actions are mediated via 
both protein kinase C and protein kinase A pathways (Hattenhauer et al, 1999). No data 
exist to assess the relative importance of luminal and basolateral actions of PTH in the 
intact organism, but, as PTH is partially filtered at the glomerulus, luminal actions 
(especially in the more proximal tubule) may be of physiological significance. The 
interaction between PTH and the NaPT2a co-transporter is dealt with in more detail in 
section 1.3.2. 
1.2.1.1 Vitamin D 
 
Vitamin D is a steroid hormone with a complex metabolic and regulatory pathway (Dusso 
et al, 2005). When ultraviolet light strikes the skin, photons are absorbed by the steroid 7-
dehydrocholesterol, splitting its beta-ring and forming vitamin D3 (cholecalciferol). This 
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pro-hormone is then transported to the liver where a hydroxyl group is added by the liver 
enzyme, 25-hydroxylase. This leads to the formation of 25-hydroxyvitamin D3 (calcidiol, 
sometimes written 25-(OH) D3). Vitamin D can also enter the body via the gastrointestinal 
tract in food; the predominant form in food is vitamin D2 (ergocalciferol) which is also 
converted to 25-hydroxyvitamin D3 by 25-hydroxylase in the liver. The liver releases 
calcidiol into the circulation and it is acted on in the kidney (and in other tissues such as 
the skin and the prostate) by the enzyme 1α−hydroxylase to form 1α-,25-
dihydroxyvitamin D3 (calcitriol; sometimes written 1,25 (OH)2D3). Calcitriol interacts with 
a specific, high-affinity vitamin D receptor widely distributed in many tissues. Calcitriol 
formed in the kidneys circulates throughout the body, while that produced in other tissues 
seems mostly to have more local, paracrine functions. Calcitriol is by far the most active 
form of vitamin D; however, the greater chemical stability of calcidiol means that assays 
to measure vitamin D status in humans are usually aimed at measuring this compound. 
Figure 1.2 illustrates the relationships between the various forms of vitamin D.  
The first step in the inactivation of vitamin D is 24-hydroxylation by the enzyme vitamin 
D 24-hydroxylase, present in the kidney and also in osteoblasts. This converts calcidiol to 
24,25-(OH)2D3 and calcitriol to 1,24,25-(OH)3D3. Although there is evidence that 24,25-
(OH)2D3 has some biological effects, it is much less active than calcitriol and no high-
affinity receptor for it has yet been identified. The amount of calcitriol produced by the 
kidney reflects the activities of both the 1α-hydroxylase and 24-hydroxylase enzymes, as 
these are competing for the same substrate. Calcitriol administration (to mice) has been 
shown to increase 24-hydroxylase enzyme activity and mRNA abundance in the kidney 
(Akeno et al, 1997). 24-hydroxylase activity is also increased by high serum phosphate 
and reduced by PTH. 
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Fig. 1.2 Formation of calcitriol  
 
High levels of active vitamin D (calcitriol) stimulate uptake of both calcium and 
phosphate from the gut. Calcitriol also stimulates sodium-phosphate co-transport in the 
renal tubular brush border in both intact rats and isolated renal tubule preparations 
(reviewed in Dusso et al, 2005); it directly suppresses PTH production by the parathyroid 
glands; and it also indirectly suppresses PTH by raising serum calcium, which then has a 
suppressive effect on the parathyroid glands. Low serum phosphate is a direct stimulant of 
renal 1α-hydroxylase activity, and thus leads to increased levels of calcitriol. Other 
regulators of renal 1α-hydroxylase activity are thought to be calcitriol itself, which 
inhibits enzyme activity, PTH and serum calcium (Moosgaard et al, 2007). Calcitriol 
levels are increased by PTH and by hypocalcaemia. In experiments using infusions of 
PTH and calcium chelators into dogs, in which PTH levels and calcium could be 
manipulated independently, it was shown that, when PTH is present to excess, alterations 
in plasma calcium determine whether calcitriol levels rise or fall (Hulter et al, 1985). This 
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suggests that the plasma calcium level can override PTH as a regulator of active vitamin D 
levels under certain circumstances. 
As well as its role in the control of calcium and phosphate balance, vitamin D affects cell 
growth and is implicated in the development of some cancers and in modulation of the 
immune response (Dusso et al, 2005).  
 
1.2.2 Other agents affecting renal phosphate handling 
 
As well as PTH and vitamin D, a number of other factors have been shown to affect renal 
phosphate excretion. In most cases it seems unlikely that they control phosphate excretion, 
but they may nevertheless have an important influence under certain circumstances. 
Glucagon 
Glucagon is both phosphaturic and natriuretic; the phosphaturia has been shown to be 
mediated by cAMP, which is thought to be generated in the liver by glucagon and freely 
filtered at the glomerulus, passing into the renal tubule and acting from the luminal side of 
renal tubular cells (Bankir et al, 2002).  
Thyroxine 
Hypothyroidism is associated with a low serum phosphate concentration and thyroxine 
has been shown to increase the renal reabsorption of phosphate, by increasing the amount 
of NaPT2a protein in the proximal tubule brush-border membrane. Northern blot analysis 
confirmed that this effect was mediated by increasing the amount of mRNA for NaPT2a 
(Alcalde et al, 1999).  
Growth hormone 
Growth hormone increases serum phosphate and renal phosphate reabsorption, probably 
through an effect (at least in the rat) on NaPT2a numbers (Woda et al, 2004). Epidermal 
growth factor, the production of which is raised by growth hormone, has been reported to 
stimulate sodium-phosphate co-transport in isolated perfused renal tubules, but to inhibit 
sodium-phosphate co-transport in opossum kidney (OK) cells and in primary cultures of 
proximal tubule cells (Han et al, 2003). 
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Serotonin 
It has been suggested that endogenous serotonin (5-hydroxytryptamine) may enhance 
phosphate reabsorption by stimulating proximal tubular cell phosphate transport (Gross et 
al, 2000). 
Tubular calcium 
Urinary phosphate excretion may also be related to (renal tubular) luminal calcium 
concentration. A calcium-sensing receptor is found in the apical membrane of the 
proximal tubule, and the expression of this receptor is reduced by a high phosphate diet 
and by PTH infusion. Exactly how this relates to the interlinked regulation of tubular 
calcium and phosphate handling is unclear (Rouse & Suki, 1985), but stimulation of these 
calcium receptors has been shown to inhibit the action of PTH on proximal tubular 
phosphate transport (Ba et al, 2003).  Tubular calcium also appears to have effects on 
renal sodium handling, but this is mediated by actions in the loop of Henle and distal 
tubule (reviewed in Huang & Miller, 2007) 
Glucocorticoids 
Patients with Cushing’s syndrome (glucocorticoid excess) are often hypophosphataemic. 
It has been show that dexamethasone (at least in adrenalectomised rats) causes 
phosphaturia, doing so by inhibition of sodium-dependent phosphate transport in the renal 
brush-border membrane (Webster et al, 1986).  
Parathyroid hormone related protein (PTHrP) 
The first 34 amino-acids of PTHrP are very similar to those of PTH, and PTHrP is 
expressed widely in many parts of the body (Strewler, 2000). It acts through the same 
receptor as PTH and, when infused in equal amounts, causes a similar degree of 
phosphaturia (Horwitz et al, 2003; Saito et al, 1993). PTHrP is often secreted in excess by 
lung tumours and can cause severe hypercalcaemia, but evidence suggests that it does not 
circulate in healthy people and that its main physiological roles are widespread local 
paracrine/autocrine actions on cell proliferation (Santos et al, 2001), without any 
significant action on renal phosphate handling. 
Stanniocalcin 
Stanniocalcin is a calcium-regulating hormone of bony fishes, known to stimulate 
phosphate reabsorption in the fish kidney. A similar sequence has been isolated from a 
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human lung cDNA library, named STC1, expressed in a bacterial system and injected into 
fish and rats (Olsen et al, 1996). In fish it caused reduced gill calcium transport, whilst in 
rats it caused a dose-dependent increase in renal phosphate reabsorption. Polyclonal 
antibodies raised against the human stanniocalcin protein bound to cells in the distal renal 
tubules of humans, suggesting this as a possible site of expression of the protein.  Work on 
the stanniocalcins has disclosed a wide range of effects related to cell growth and 
differentiation, but it seems that the protein probably does not circulate in healthy humans, 
rather acting as a paracrine agent. Recent work has suggested a role for STC1 in 
endothelial gene expression and leukocyte migration in the kidney (Chakraborty et al, 
2007). 
1.2.2.1 Phosphatonins 
 
The realisation that phosphate excretion depends not only on PTH and vitamin D but also 
on other factors, disturbance of which leads to the hereditary hypophosphataemic 
syndromes  and also tumour-related hypophosphataemia (see section 1.4), led to the 
coining of the term ‘phosphatonin’ (reviewed in Kumar, 1997). ‘Phosphatonin’ is used to 
describe previously unrecognised substances which circulate in both normal and 
pathological states and which reduce serum phosphate by causing phosphaturia. Although 
at one time it was thought that one single new hormone might be found which would 
account for all phosphate-losing states and might additionally have a role in normal 
human physiology, it now seems more likely that there are a number of such substances 
with overlapping or interlocking functions. Current candidate phosphatonins have been 
identified from phosphate-wasting tumours (frizzled related protein-4, fibroblast growth 
factor-7, fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein) and 
from the inherited phosphate-wasting disorders (fibroblast growth factor-23). These 
agents will be discussed in the context of human disorders of phosphate metabolism 
below.  
 
1.3 Sodium-phosphate co-transporters 
 
Phosphate is transported across cell membranes by a group of sodium-phosphate co-
transporters, abbreviated to NaPTs. Currently, three main subtypes are recognised. NaPT1 
is present on most cells of humans, rats and mice and seems to be responsible for 
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‘housekeeping’ phosphate transport, ensuring supplies of phosphate for cellular 
metabolism. The NaPT2 co-transporters seem to be responsible for high-capacity 
phosphate transport, NaPT2a and NaPT2c in the kidney and NaPT2b in the gut. The 
activity of these three subtypes controls serum phosphate, as phosphate enters the body 
from the bowel and leaves it in the urine. Although there is still much to be learned about 
these processes, it seems that most of the control is at the level of the renal proximal 
tubule NaPT2a co-transporter, perhaps with some contribution from renal NaPT2c. The 
NaPT3 group of proteins is less well understood currently, and their place in phosphate 
physiology remains a matter for speculation.  
 
1.3.1 Sodium-phosphate co-transporter type 1 (NaPT1) 
 
NaPT1 seems to be expressed in almost all cell types. Renal NaPT1 gene expression is not 
modulated by dietary phosphate intake (Tenenhouse et al, 1998) or by PTH (Zhao & 
Tenenhouse, 2000), in contrast to NaPT2a (see below). Levels of NaPT1 mRNA and 
protein were unchanged in the proximal tubules of  NaPT2a knock-out mice, despite the 
grossly abnormal urine and serum phosphate levels (Zhao & Tenenhouse, 2000), which is 
perhaps an argument against NaPT1 having a role in phosphate regulation.  
Hepatocyte nuclear factor 1α (HNF1α) is a protein found in many polarised epithelia, 
including the renal tubule; it transactivates a number of target genes including those 
coding for albumin, α1-antitrypsin and fibrinogens. Knock-out mice (HNF1α -/-) have a 
renal Fanconi syndrome, with aminoaciduria, glycosuria and phosphaturia. It has been 
shown that mRNA for NaPT2a in the kidneys of these mice is present in broadly normal 
amounts, but mRNA for NaPT1 is greatly reduced due to the absence of an activating 
effect of HNF1α (Cheret et al, 2002). This interesting finding appears to show that, in 
contrast to the generally held view, NaPT1 is a functionally important phosphate co-
transporter in the kidney, although of course it does not necessarily mean that NaPT1 is a 
regulated phosphate transporter.  
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1.3.2 Sodium-phosphate co-transporter type 2a (NaPT2a) 
 
The NaPT2a co-transporter has so far been found only in the proximal tubule and the 
osteoclast; it is absent from the bowel. The co-transporter is present largely in the 
convoluted part of the proximal tubule, decreasing toward the straight part. It is not found 
in the glomeruli, distal tubule or collecting ducts (Traebert et al, 1999b; Custer et al, 
1994). NaPT2a localises to the apical (luminal) brush border of the proximal tubule and is 
not seen in the basolateral membrane. The transporter is a low affinity, high capacity 
system with closely related gene sequences in humans, rats, mice and other multicellular 
organisms (reviewed by Hernando et al, 2001). Homologues are generally not found in 
bacteria, although a similar protein has been found in the organism that causes cholera 
(Lebens et al, 2002); the suggestion has been made that it is an adaptation to survival in 
the human intestine where phosphate is plentiful. 
A mouse knock-out of NaPT2a has been genetically engineered by Tenenhouse’s group 
(Beck et al, 1998). This mouse has a moderately low serum phosphate, an increased 
fractional excretion of phosphate (FEPi of about 12% compared with about 4% in wild-
type mice), and grows poorly with abnormal bones. Serum calcitriol is elevated 
(presumably to defend serum phosphate) and there is hypercalcaemia and hypercalciuria, 
which are assumed to result from increased bowel absorption of calcium under the 
influence of the raised calcitriol. Serum PTH is low, most likely suppressed by the 
hypercalcaemia and raised calcitriol. The animals do not develop rickets, and the 
abnormal bones become more normal as the animal ages. Renal brush-border membrane 
vesicles from NaPT2a null mice had about 30% of the sodium-dependent phosphate 
uptake of wild-type mice, which was interpreted by these workers as showing that 
NaPT2a is normally responsible for 70% of sodium-dependent phosphate uptake in the 
proximal tubule. Further experiments with this knock-out (Zhao & Tenenhouse, 2000) 
have shown that PTH has no effect on serum phosphate and only a minimal effect on 
fractional phosphate excretion and brush-border membrane vesicle sodium-phosphate co-
transport, supporting the idea that the effects of PTH on renal phosphate excretion in mice 
are mediated via changes in NaPT2a. As indicated above, levels of NaPT1 mRNA and 
protein were unchanged in the knock-out mice; however, NaPT2c protein expression was 
increased in these animals - see section 1.3.4 (Tenenhouse et al, 2003). 
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Normal rats fed a low-phosphate diet have raised levels of NaPT2a protein, as assayed by 
Western blot of crude kidney brush-border membrane preparations. This effect occurs 
without a measurable change in serum PTH concentration (Laouari et al, 1997). 
Correspondingly, rats given a high-phosphate diet have a reduced amount of proximal 
tubular NaPT2a (Takahashi et al, 1998). Proximal tubule brush-border membrane vesicles 
from chronically thyroparathyroidectomised rats exhibit greater sodium-dependent 
phosphate uptake than is found in vesicles from sham-operated rats (Takahashi et al, 
1998). Changing the diet of these thyroparathyroidectomised animals from low to high 
phosphate caused a rapid decrease in brush-border membrane vesicle phosphate uptake 
(over a period of only four hours). Immunohistochemical studies of the renal cortex 
confirmed that this effect was accompanied by a reduction in the amount of NaPT2a at the 
brush border. Clearly, the signal causing internalisation of the NaPT2a protein cannot 
have been carried by PTH in these animals, so this provides definite evidence that there is 
a non-PTH-dependent mechanism for the internalisation of NaPT2a in proximal tubular 
cells in response to dietary changes, as well as the recognised PTH-dependent mechanism. 
Other workers have shown that longer-term adaptation to alterations in dietary phosphate 
(over periods of days or weeks) are by means of changes in protein synthesis, but rapid 
changes can be made in a matter of hours by changes in NaPT2a transporter numbers in 
the brush-border membrane without new protein synthesis (Levi et al, 1994).  
1.3.2.1 Trafficking of NaPT2a  
 
NaPT2a is located only at the apical membrane of proximal tubular cells; phosphate can 
be effectively transported out of the renal tubular lumen only if this polarity is maintained 
(Hernando et al 2001 AP43). Work by Murer’s group using green fluorescent protein-
tagged NaPT2a has shown that the N-terminal region of the protein is not required for 
apical localisation, whilst the C-terminal end, which is required, contains a PDZ-binding 
motif (Bacic et al, 2004). Interactions between NaPT2a and the apical proteins NHERF1, 
NHERF2, PDZK1 and PDZK2 have been demonstrated and it is thought that these factors 
may help anchor the transporter to the brush-border membrane. 
PTH leads to an increase in urinary phosphate excretion by decreasing the cell surface 
expression of NaPT2a. Work with biotin-labelled NaPT2a in OK cells demonstrated that 
the transport protein was internalised in response to a PTH signal (Jankowski et al, 1999) 
as the first step in the PTH-mediated regulation of tubular phosphate transport. NaPT2a 
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removal from the apical brush-border membrane is very rapid: within 60 minutes of 
exposure to PTH, most of the brush-border NaPT2a has disappeared, as assessed by 
immunofluorescence (Lotscher et al, 1999). 
Considerable work has been done on the mechanism of retrieval of NaPT2a from the 
brush-border membrane. In mice with specific defects in the renal expression of megalin, 
a protein of importance in protein endocytosis in the proximal tubule, 
immunofluorescence studies found that steady-state levels of NaPT2a were raised 
(Bachmann et al, 2004). This correlated with reduced urinary phosphate excretion in the 
knock-out animals and suggests that there is active turnover and withdrawal of NaPT2a 
under basal conditions. Administration of PTH to these renal megalin knock-out animals 
was without effect - the absence of megalin prevented any response to exogenous PTH. 
However, there is no evidence of a direct interaction between megalin and NaPT2a, so the 
precise connection between them remains unclear.  
A mouse knock-out for the ClC-5 intracellular H+/Cl- exchanger (an animal model for 
Dent’s disease, which is caused by absence of the human ClC-5 protein) had significantly 
increased renal phosphate losses. Immunostaining demonstrated abnormal localization of 
the NaPT2a in the proximal tubule, with NaPT2a staining being mostly in subapical 
vesicles in the knock-out mice, rather than on the brush border as seen in wild-type 
animals. The abnormalities were not seen in the early S1 segment, but became more 
striking further down the proximal tubule (Piwon et al, 2000). The authors’ hypothesis is 
that the phosphaturia seen in these animals is due to increased luminal activity of PTH, 
which is not undergoing the normal process of megalin-mediated endocytosis and instead 
is available to cause increased internalization of NaPT2a and consequent reduced tubular 
phosphate reabsorption.  
Murer and co-workers (Karim-Jimenez et al, 2000) have investigated the molecular 
domains required to allow PTH to trigger internalisation of the NaPT2a protein in the 
model system of the OK cell. They showed by generating NaPT2a/NaPT2b chimeras that 
neither N nor C terminal region was required for internalisation, but that an area in the 
middle of the molecule containing a dibasic amino-acid motif, present in NaPT2a but 
absent from NaPT2b, was required 
It has been shown, by use of inhibitors of the lysosomal and proteosomal pathways in OK 
cells, that NaPT2a is transported to, and degraded in, the late endosomes/lysosomes, and 
that this process is increased by exposing the cells to PTH (Pfister et al, 1998). The 
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process requires microtubule rearrangement and can be partly inhibited by the microtubule 
toxins colchicine and taxol (Lotscher et al, 1999). The actions of PTH on proximal tubular 
expression of the sodium-hydrogen exchanger 3 require the presence of the regulatory 
protein NHERF-1, but studies on OK cells expressing truncated forms of NHERF-1 
showed no change in NaPT2a activity, suggesting that this regulatory protein is not 
involved in the trafficking of NaPT2a (Lederer et al, 2003). In contrast, mice with a null 
mutation for NHERF-1 have mislocalisation of the NaPT2a protein, with immunostaining 
showing that it is distributed within the cell rather than at the cell membrane. This 
corresponds with a large increase in the fractional excretion of phosphate (Shenolikar et 
al, 2002). These contrasting findings (OK cells with truncated NHERF-1 have normal 
NaPT2a activity, while NHERF-1 knock-out mice have reduced activity) may simply 
reflect species differences, or may point to the difficulty of generalising from model 
systems using immortalised mammalian cell lines. 
Recent work (in mice) has suggested that PTH acts by inducing dissociation of a complex 
formed between NHERF-1 and NaPT2a; phosphorylation of a specific serine in a PDZ 
domain of NHERF-1 seems to cause dissociation of the NHERF-1/NaPT2a complex and 
thereby allow retrieval of NaPT2a from the brush-border membrane. This phosphorylation 
can be performed by protein kinase C (which is activated by luminal PTH, see section 
1.2.1) and also by other phosphatases (Hernando et al, 2007). 
Interestingly, high-affinity phosphate-transport  proteins are found in the plasma 
membrane of yeast cells under low-phosphate conditions but rapidly trafficked from the 
membrane to vacuoles when phosphate is added to the environment (Lau et al, 2000), 
indicating that trafficking is an important regulated activity even in lower organisms. 
 
 
1.3.3 Sodium-phosphate co-transporter type 2b (NaPT2b) 
 
In the small bowel, another type 2 sodium-phosphate co-transporter has been identified, 
and localised to the enterocyte brush border (Hilfiker et al, 1998). This protein has been 
named the type 2b NaPT. Messenger RNA for this transporter has been identified in the 
lung, large bowel, liver and kidney, as well as in the small bowel.  
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NaPT2b protein has been localised by immunohistochemistry to the luminal epithelium of 
the alveolar cells in the lung (Traebert et al, 1999ii), where it was hypothesised that it 
might be involved in phosphate uptake for the synthesis of surfactant. Recently, mutations 
in the gene have been found in patients with the rare disease pulmonary alveolar 
microlithiasis (Huqun et al, 2007). One patient with this disease and a proven mutation in 
NaPT2b was found to have normal renal phosphate reabsorption (although the authors do 
not say how this was measured) and all patients in whom it was tested had normal serum 
phosphate levels (Corut et al, 2006); these findings suggest that renal control of phosphate 
is enough to maintain normal serum phosphate levels even if the main gastrointestinal 
regulatory system is absent; further studies on these patients would be of interest. The 
purpose of NaPT2b mRNA in the liver, kidney and large bowel remains unknown.  
  
The important regulators of phosphate uptake in the small intestine that have so far been 
identified are a low-phosphate diet and calcitriol - each increasing intestinal phosphate 
absorption. It has been shown (in mice) that a low-phosphate diet or vitamin D 
administration causes increased expression of NaPT2b protein in the intestinal brush-
border membrane (Hattenhauer et al, 1999). This effect is seen in animals fed a low-
phosphate diet for a week; however, four hours of a low-phosphate diet are not enough to 
cause a measurable increase in NaPT2b transporter numbers. This observation led to the 
suggestion that the effects of a low-phosphate diet on the bowel may be mediated entirely 
via changes in vitamin D levels, in contrast to the rapid effects of PTH in the kidney 
mediated directly via PTH receptors. Interestingly, the amount of mRNA for NaPT2b was 
the same in animals on high or low phosphate diets and in the presence or absence of 
exogenous vitamin D, suggesting a post-genomic means of regulation of transporter 
numbers. Injection of animals with large doses of calcitriol increases subsequent small 
intestine phosphate uptake; this effect was associated with an increase in jejunal NaPT2b 
protein expression in both mice and rats (Marks et al, 2006). 
 
1.3.4 Sodium-phosphate co-transporter type 2c (NaPT2c) 
 
Children and young animals need a significant positive phosphate balance to provide the 
phosphate required for bone and other tissues (Spitzer & Barac-Nieto, 2001). Fractional 
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phosphate excretion in humans is only about 1% in newborns, about 5% in infants on 
human milk and about 20% in adults. During post-natal life no new nephrons are formed 
in humans, but GFR increases by increase of the GFR of each nephron. Absolute 
phosphate reabsorption by each nephron increases, but the maximum concentration of 
filtered phosphate which can be reabsorbed falls, during development (Kruse et al, 1982). 
Children have higher serum phosphate levels than adults, but there is an important 
difference between rodent and human physiology here, in that rodents grow throughout 
life and never fuse their epiphyses. The adult rodent may therefore have a positive 
phosphate balance more similar to a human child or adolescent than to an adult human. 
Nevertheless, it has been shown that even in rats there is twice as much NaPT2 (as 
assessed by Western blotting) in the proximal tubule of juvenile animals than in adults 
(Woda et al, 2001), initially leading to the suggestion that the greater phosphate 
reabsorption in young animals might be due to larger amounts of NaPT2a transporter.  
Segawa and colleagues were the first to report the cloning of a growth-related sodium-
phosphate co-transporter from both rat and human kidneys, which they called NaPT2c 
(Segawa et al, 2002). This protein was localised (in the rats) by immunohistochemistry to 
the apical membrane of the proximal tubule, and was found to be much more strongly 
expressed in weaning animals than in either newborns or adults (note that this does not 
correspond exactly with fractional phosphate reabsorption, which is highest in newborns, 
see above). The gene (at least as assessed by Northern blotting) was expressed only in the 
kidney.  
The same group also cloned NaPT2c from mice. Sequence analysis showed 95% 
similarity to the rat sequence and 86% similarity to a human sequence assumed to be a 
homologue. Northern blot analysis of poly (A)-RNA from various tissues suggested that 
mRNA for NaPT2c was found only in the kidney, although RT-PCR suggested that 
transcripts were also to be found in the heart, placenta and spleen. No explanation or 
resolution of this difference between the two methods was offered (Ohkido et al, 2003). 
Western blotting of brush-border membrane vesicles showed that this transporter protein 
was greatly increased in animals fed a low-phosphate diet, and reduced to almost zero by a 
high-phosphate diet, suggesting that the transporter may be functional and regulated by 
changes in phosphate intake. Hybrid depletion experiments were performed in which 
antisense oligonucleotides were injected into Xenopus oocytes expressing poly(A)-RNA 
from mice on control and low-phosphate diets, and oocyte phosphate uptake was 
  42 
measured. These showed no effect of NaPT2c antisense oligonucleotide in oocytes 
injected with RNA from control animals, but a significant fall in phosphate uptake in 
oocytes expressing RNA from phosphate-depleted animals (Ohkido et al, 2003). This 
might be taken to suggest that NaPT2c-mediated phosphate transport is only important 
when animals are phosphate depleted.  
The NaPT2c protein has been shown to be internalised from the brush-border membrane 
of the renal proximal tubular cell in response to a high-phosphate diet in rats, just as 
NaPT2a is (Segawa et al, 2005). This response seems to be slower than the internalisation 
of NaPT2a; no change was demonstrated in the amount of brush-border membrane 
NaPT2c two hours after a high oral  phosphate intake, whereas NaPT2a was already 
reduced by this time; at four and six hours the amounts of both were reduced. PTH has 
also been shown to affect internalisation of NaPT2c; NaPT2c protein and mRNA levels 
were increased in thyroparathyroidectomised rats, while injection of PTH into intact rats 
led to a reduction in NaPT2c in the tubular brush-border membrane, as assessed by 
immunoblots (Segawa et al, 2007). Again, this effect was not seen at two hours but was 
significant at 4, 8 and 12 hours. 
 
Tenenhouse’s group hypothesised that NaPT2c might be responsible for the remaining 
phosphate reabsorption in their NaPT2a knock-out mice (see section 1.3.2). They 
demonstrated that whilst overall brush-border membrane vesicle sodium-dependent 
phosphate uptake is greatly reduced in NaPT2a knock-outs, NaPT2c protein abundance 
(determined by Western blotting) is increased by more than two-fold (Tenenhouse et al, 
2003). Interestingly, they also demonstrated that in Hyp mice (which carry a deletion of 
the Phex gene and are homologues of human X-linked hypophosphataemic rickets; see 
section 1.4.1.1) there was no increase in NaPT2c amounts despite hypophosphataemia. 
This suggests that adaptive up-regulation of NaPT2c requires Phex activity. 
Mutations in the human NaPT2c gene have been shown to cause the syndrome hereditary 
hypophosphataemic rickets with hypercalciuria (HHRH; see section 1.4.1.3 below). The 
fact that humans without effective NaPT2c protein have moderate reductions in serum 
phosphate and quite significant bone disease has been  interpreted as showing that the role 
of NaPT2c in overall phosphate balance may be more important than had previously been 
appreciated (Bergwitz et al, 2006). There is some preliminary evidence that phosphate 
metabolism in osteoblasts is abnormal in HHRH patients (Yamamoto et al, 2007); this is a 
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little hard to explain given that others have found that NaPT2c is absent from bone, but 
might represent secondary changes in osteoblasts due to either prolonged 
hypophosphataemia or exposure to abnormal levels of phosphate regulatory hormones.   
 
1.3.5 Sodium-phosphate co-transporters type 3 (NaPT3s) 
 
The receptors for two viruses, the gibbon ape leukaemia virus (named Glvr-1) and rat 
amphotophic virus (named Ram-1), turned out to be related. Both genes have been found 
to code for cell surface proteins which act as sodium-phosphate co-transporters. The 
proteins were renamed PiT-1 and PiT-2 (although this can cause confusion, as there is a 
nuclear factor important in pituitary function called pit-1) and were found to be 60% 
amino acid sequence identical, with only very weak homology to the type 1 and type 2 
sodium-phosphate co-transporters discussed above. These proteins have now been named 
NaPT3s. The two proteins are widely distributed in rat tissues, including the liver, kidney, 
heart and muscles. In humans, PiT1 and PiT2 have been found in all tissues investigated 
and they are generally viewed as further ‘housekeeping’ transporters (Böttger et al, 2006). 
PiT1 and PiT2 are expressed in bone matrix vesicles and may have an important role in 
bone mineralization; mineralization in osteoblast cultures can be increased or reduced, 
respectively, by over- and under-expression of PiT-1 (Yoshiko et al, 2007). It has also 
been shown that PiT-1 is important in the vascular calcification seen in 
hyperphosphataemia; such calcification can be reduced by transfecting vascular smooth 
muscle cells with PiT-1- specific small interfering RNA (Li and Giachelli, 2007).  
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1.4 Human disorders of phosphate metabolism 
 
1.4.1 Hereditary hyperphosphaturias 
 
1.4.1.1 X-linked hypophosphataemia (XLH) 
Online Mendelian Inheritance in Man (OMIM) 307800  
This is the commonest (that is to say, the least rare) of the inherited renal phosphate-
wasting states in humans, and was first described by Winters and colleagues in the 1950s 
(Winters et al, 1958). This classic paper was reviewed, and discussed in the light of 
subsequent findings, by Scriver and colleagues (1991). The syndrome is characterized by 
growth retardation, rickets/osteomalacia, hypophosphataemia, abnormal renal phosphate 
reabsorption and failure of vitamin D1
In a large retrospective study of patients with X-linked hypophosphataemia, no evidence 
was seen for genetic heterogeneity (Whyte et al, 1996). Male and female cases had no 
significant differences in phosphate concentrations or any other parameter of mineral 
metabolism, and female cases were (as expected in an X-linked dominant disease) roughly 
twice as frequent. This is a little difficult to reconcile with the subsequent discovery that 
 to rise in response to low serum phosphate. Serum 
calcium levels are normal. The mutated gene has been isolated from XLH patients and the 
gene product has been named ‘protein with homology to endopeptidases on the X 
chromosome’, or ‘PHEX’. The PHEX gene has some expression in many tissues 
(parathyroids, lung, brain, muscle) but has its highest levels of expression in bone; it is not 
expressed in the kidneys (Beck, 1997). Exactly how abnormalities of this gene result in 
the XLH phenotype remains unclear, although the homology between the sequence of the 
PHEX gene and endopeptidase sequences has led to the hypothesis that the PHEX protein 
cleaves a circulating protein that affects renal phosphate handling. PHEX protein has been 
shown experimentally to cleave PTHrP but not PTH, endothelin or numerous other 
peptides (Boileau et al, 2001).  
                                                 
1 Vitamin D is usually measured in humans by determination of 25-hydroxyvitamin D 
(calcidiol). The main active form is 1α-,25-dihydroxyvitamin D (calcitriol); calcidiol is 
converted to calcitriol by the enzyme 1α-hydroxylase, mainly in the kidney. Most 
experimental work in this area is performed using calcitriol if there is renal impairment; 
other forms of vitamin D are often used if renal function is normal. I have used ‘calcitriol’ 
in this thesis if this compound was used or measured, and ‘vitamin D’ if any form of 
vitamin D other than calcitriol was used or measured, or if the authors do not specify.  
  45 
the mutation is in a proteolytic enzyme - because female cases still have a normal copy of 
the PHEX gene, while male cases do not; one would therefore expect females to be less 
affected or indeed not affected at all. This observation remains unexplained at present 
(although it is worth noting that the same phenomenon is also seen in the Hyp model 
discussed below). 
A mouse model for this disease, known as the Hyp mouse, was discovered by a 
combination of chance and close observation at the Jackson Laboratory in the 1970s 
(Eicher et al, 1976). The Hyp mouse was found to carry an X-linked dominant mutation 
causing hypophosphataemia, rickets, reduced stature and renal phosphate wasting, and the 
almost exact resemblance to human X-linked hypophosphataemia was noted immediately. 
The presence of this mouse model helped to stimulate research interest in this area during 
the 1980s, when few other human diseases had as exact a model available. Nesbitt and co-
workers (Nesbitt et al, 1992) carried out an elegant series of cross-transplantation 
experiments to investigate the basis of the metabolic abnormalities in these mice. They 
removed both native kidneys and transplanted one new kidney into each animal. In normal 
mice transplanted with a single normal kidney in this way, serum phosphate and tubular 
reabsorption of phosphate were no different from values in uninephrectomised controls. If 
a normal mouse received a transplant from a Hyp mouse, serum phosphate again was 
identical to that of control animals, as was the tubular reabsorption of phosphate. 
However, Hyp mice transplanted with a kidney from either other Hyp mice or normal 
animals had persistently low serum phosphates and reduced tubular reabsorption of 
phosphate compared with controls. These results show that the primary abnormality in the 
Hyp mouse does not lie in the kidney (although the phenotype is largely caused by renal 
phosphate wasting) but must be a circulating factor which can also cause phosphate 
wasting in normal kidneys. More recent work with this model has shown a reduction in 
NaPT2a mRNA and protein in the kidney, and also evidence for disordered regulation of 
vitamin D in these animals: in wild-type mice, low serum phosphate stimulates the 
activity of 1α−hydroxylase, whilst in Hyp mice it has exactly the opposite effect (Azam et 
al, 2003). Even though we now know the underlying genetic defect in Hyp mice, this 
observation is puzzling. 
A database has been set up listing all known mutations in the PHEX gene, with the aim of 
allowing phenotype-genotype correlations and facilitating research on this gene (Sabbagh 
et al, 2000) (this is available online at phexdb.mcgill.ca). Almost all possible sorts of 
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mutation have been shown to cause disease: frameshifts, missense and nonsense 
mutations, abnormal splicing and deletions. These have been shown to result in 
abnormalities in the trafficking and/or conformation of the PHEX protein, or in its 
endopeptidase activity (Sabbagh et al, 2003). This range of types and location of 
mutations, with little evidence of variability in phenotype, suggests that the mutations are 
likely to cause non-function of the gene product rather than aberrant function.  
 
1.4.1.2 Autosomal dominant hypophosphataemia (ADHR) 
OMIM 193100 
This disorder was first clearly distinguished from X-linked hypophosphataemia in the 
1970s by Scriver and colleagues (Scriver et al, 1977) and was characterised in a large 
kindred as recently as 1997 (Econs & McEnery, 1997). The disease can present in 
childhood with rickets and skeletal deformity but can also present in adulthood with 
hypophosphataemia and weakness or bone pain. Some people with unequivocal 
hypophosphataemia were asymptomatic and were identified only as part of the family 
studies. Intriguingly, several male subjects had bone problems and low serum phosphate 
concentrations in childhood which improved in adulthood, with an absence of symptoms 
and low-normal serum phosphates. In all affected patients there is hypophosphataemia 
with (inappropriately) normal vitamin D levels, just as there is in XLH.  
Genome-wide linkage analysis of a large kindred affected by ADHR allowed the 
abnormal gene to be localised to chromosome 12p13 (Econs et al, 1997). Subsequent 
positional cloning demonstrated that the syndrome is caused by mutations in a gene 
belonging to the fibroblast growth factor family, which has since been named FGF-23 
(The ADHR consortium, 2000 and see below). Analysis of the mutations found in patients 
with ADHR has shown that they are mis-sense mutations, which render the protein less 
sensitive to protease cleavage than wild-type FGF-23 (White et al, 2001). The precise 
mechanism by which this leads to phosphaturia is not yet clear, although it has been 
shown that FGF-23 mutants suppress renal phosphate reabsorption by reducing sodium-
dependent phosphate transport in the renal brush-border membrane, independently of PTH 
(Saito et al, 2003).  
A recent paper has documented FGF-23 levels in people known to have FGF-23 
mutations, and in control subjects (Imel et al, 2007). A large number of people with 
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definite FGF-23 mutations were not hypophosphataemic: only 16/42 subjects with ADHR 
mutations had low serum phosphates at the time of FGF-23 measurement. FGF-23 
measurements in persons with ADHR mutations were widely scattered; some people with 
ADHR mutations had very high FGF-23 levels while many others had values in the 
normal range. In two patients in whom successive samples over a period of months were 
available, there were different patterns of FGF-23 concentration; one patient always had 
very high levels, but in the other the levels began high but subsequently normalised for no 
obvious reason. I think the conclusion must be that levels of FGF-23 are subject to some 
other forms of control which have not yet been discovered, and phosphate levels do not 
depend on FGF-23 levels in a straightforward way even in people with ADHR. 
 
1.4.1.3 Hereditary hypophosphataemic rickets with hypercalciuria (HHRH) 
OMIM 241530 
This syndrome was first described in 1985 by Liberman’s group in Israel (Tieder et al 
1985). (The Middle East is a fertile ground for discovery of recessive genetic diseases, 
due to the presence there of many groups with a tradition of first cousin marriages.) The 
syndrome  is characterised by rickets, poor growth and short stature, increased renal 
phosphate loss, hypercalciuria with normal serum calcium levels, raised vitamin D levels, 
increased gastrointestinal uptake of calcium and phosphate (probably owing to the raised 
vitamin D) and low or low/normal PTH levels despite very low serum phosphate.  The 
clinical and biochemical abnormalities can be overcome by giving phosphate 
supplements, with the exception of the renal phosphate leak. This led to the hypothesis 
that the renal phosphate leak is the primary abnormality, with all the other changes being 
secondary. Note that in this syndrome, in contrast to XLH, ADHR and tumour-induced 
osteomalacia (see sections 1.4.1.1, 1.4.1.2 and 1.4.3), there is a significant (appropriate) 
increase in calcitriol levels. In one kindred (van den Heuvel et al, 2001), mutations in 
NaPT2a were specifically excluded as a cause of the syndrome; it was subsequently 
shown simultaneously by two groups, working independently but using very similar 
search strategies using genome-wide linkage scanning, that the syndrome was caused by 
mutations in the NaPT2c gene (Bergwitz et al, 2006; Lorenz-Depiereux et al, 2006). 
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1.4.1.4 Autosomal recessive hypophosphataemic rickets (ARHR) 
OMIM 241520 
 
This syndrome was described for the first time in 2006 by Feng and colleagues in two 
unrelated kindreds (Feng et al, 2006). In each kindred, affected individuals had renal 
phosphate wasting, low, but not very low, serum phosphate (0.7-0.9mmol/l) and rickets. 
PTH was normal, as were serum and urinary calcium levels. Serum calcitriol levels were 
inappropriately normal for the level of hypophosphataemia. Parents and siblings of 
affected individuals showed no abnormality of calcium, phosphate, PTH or calcitriol 
levels. This syndrome is differentiated from HHRH (above) by the normal vitamin D and 
urinary calcium levels. Based on the similarity between this syndrome and a mouse 
knock-out of the gene for dentin matrix protein-1 (Dmp-1; a protein of importance in bone 
mineralization), the authors hypothesised that a mutation in the human gene DMP-1 might 
be the cause of these patients’ abnormalities. They were able to demonstrate such 
mutations, a frame-shift in one kindred and nucleotide substitution in a presumed critical 
sequence in the other. DMP-1 is a member of the SIBLING group of proteins (see section 
1.4.3.3.4) and is found mainly in mineralised tissues. The authors found greatly elevated 
serum FGF-23 levels in the Dmp1-null mouse but more modestly elevated values in the 
patients with ARHR (less than twice normal on average, and two of four patients within 
the normal range). How DMP-1 mutations elevate FGF-23, and whether other 
phosphaturic substances are also elevated in this syndrome, are not yet known. 
 
1.4.1.5 McCune-Albright syndrome and fibrous dysplasia of bone 
OMIM 174800 
 
Fibrous dysplasia of bone is characterised by replacement of normal bone by fibrous 
tissue with irregular trabeculae of woven bone irregularly distributed within it. It can 
affect a single bone or multiple bones and can occur as part of the McCune-Albright 
syndrome, a triad of café-au-lait spots, precocious puberty and fibrous dysplasia, often 
with other endocrine abnormalities (Ringel et al, 1996). The McCune-Albright syndrome 
is due to activating mutations in the α subunit of the G protein that stimulates cAMP 
formation via adenylate cyclase, known as Gs (Weinstein et al, 1991). These mutations 
lead to the constitutive activation of adenylate cyclase and consequent increased signalling 
through the intracellular cyclic AMP pathway. The mutations are also seen in fibrous 
dysplasia of bone, with the difference between the two syndromes thought to lie in the 
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time at which the mutation occurred. Mutation events occurring during the early stages of 
embryogenesis lead to an individual with mosaic populations of normal and mutated cells 
in many organs and consequently the many and various features of McCune-Albright 
syndrome. Persons in whom the mutation occurs in late development and in osteoid 
precursors have abnormalities limited to bone. Hypophosphataemia and renal phosphate 
wasting are often seen in patients with fibrous dysplasia of bone, and it is thought that a 
phosphaturic factor released from the abnormal bone circulates in these patients. The 
mechanisms linking increased intracellular cAMP and release of a phosphaturic factor are 
not understood, although it has been reported that there is increased expression of the c-fos 
proto-oncogene in the bone of patients with fibrous dysplasia (Candeliere et al, 1995). 
This gene interacts with nuclear transcription factors and leads to alterations in the 
expression of many other genes. It is quite possible that a number of different factors with 
activity in the renal proximal tubule might be circulating in patients with fibrous dysplasia 
of bone. 
A study of 42 patients with McCune-Albright syndrome/fibrous dysplasia of bone found 
that 20 of them had some degree of renal phosphate wasting (Collins et al, 2001). 
Interestingly, even larger proportions of these patients had proteinuria (86%) and 
aminoaciduria (94%). The proteinuria was mild and reported to be tubular, although the 
data to support this were not given in the paper. The aminoaciduria was non-specific. 
These results strongly suggest that many patients with fibrous dysplasia of bone have a 
generalised dysfunction of proximal renal tubular function, perhaps caused by a 
circulating factor produced by bone. The possibility that there is a primary renal 
abnormality in these patients should also be considered: as the mutation is post-zygotic 
and sufferers are mosaics, there might be genetic abnormalities in the kidneys. Mutated 
protein has been detected at post mortem in the kidneys of at least some patients with 
McCune-Albright syndrome (Weinstein et al, 1991 as cited above), and it might exert a 
local effect, perhaps by means of raised levels of cAMP, which is known to cause 
phosphaturia (Bankir et al, 2002). 
A paper by Riminucci and colleagues attempted to make the case that the renal phosphate 
wasting found in fibrous dysplasia of bone is due to FGF-23 (Riminucci et al, 2003). They 
elegantly showed that FGF-23 is expressed in fibroblasts and osteoblasts in dysplastic 
bone from fibrous dysplasia patients, and also in active remodelling bone (at a recent 
fracture site) from normal persons, whilst it is expressed at very low levels in normal 
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bone. The serum FGF-23 concentration in patients with fibrous dysplasia correlated both 
with the overall disease burden and with phosphaturia. The relationship was statistically 
robust but there were considerable variations; some patients with significantly elevated 
FGF-23 levels had normal renal phosphate handling. In a study of bone biopsies from 
patients with fibrous dysplasia, FGF-23 protein could be found by immunostaining in 4 
out of 12 cases; these four cases had lower average serum phosphate values than patients 
without FGF-23 staining, but in only one case was serum phosphate outside the normal 
range (Kobayashi et al, 2006). 
 
Although the evidence that FGF-23 is the sole implicated circulating factor in 
phosphaturic patients with fibrous dysplasia of bone is not conclusive, it is clear that 
mutations affecting intracellular cAMP in bone are able to trigger the release of a factor 
which can cause renal phosphate leak and, in at least some patients, other abnormalities of 
proximal tubular function.  
 
1.4.1.6 Jansen’s metaphyseal chondrodysplasia 
OMIM 156400 
 
This very rare autosomal dominant condition is characterised by dwarfism (due to 
abnormalities of the metaphyseal growth plate) and hypercalcaemia with a low serum 
phosphate, decreased tubular phosphate reabsorption and low PTH levels. The syndrome 
is caused by activating mutations of the gene encoding the PTH/PTHrP receptor (Schipani 
et al, 1999). It is thought that the bone growth abnormalities reflect activation of 
intracellular pathways normally triggered by PTHrP, while the renal and other metabolic 
abnormalities reflect over-activation of intracellular pathways normally affected by PTH. 
The sum of cases in the world literature is less than 20. 
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1.4.2 Other hyperphosphaturic syndromes 
 
1.4.2.1 Post-transplant hypophosphataemia 
 
Up to 50-80% of patients receiving renal transplants develop hypophosphataemia 
(Moorhead et al, 1974). This has been attributed to a combination of hyperparathyroidism 
(which is very common), calcitriol deficiency (not so common, at least if the graft works 
well, the (actually rather modest) phosphaturic effect of glucocorticoids and tubular 
toxicity of ciclosporin (reviewed by Massari, 1997). Some patients with marked, 
persistent hypophosphataemia do not have hyperparathyroidism and it has long been 
thought that there may be circulating phosphaturic factors other than PTH in these patients 
(Levi, 2001).  
Falkiewicz and colleagues (Falkiewicz et al, 2003) observed that hypophosphataemia was 
common in patients treated with either of the immune suppressants tacrolimus or 
ciclosporin but was less severe in those treated with tacrolimus. This would suggest that 
post-transplant hypophosphataemia might be mostly an effect of the toxicity of these 
drugs on the renal tubules rather than any endogenous circulating factor. Unfortunately, 
however, the data were so confusingly presented that it is impossible to determine whether 
these conclusions, given in the text, could be substantiated; furthermore, the doses of 
corticosteroid given to the two groups of patients differed greatly. A second paper by the 
same workers, probably reporting further on the same group of patients, does not make 
their findings any clearer (Falkiewicz et al, 2006). Other workers have reported that the 
(relatively) new immune suppressive drug rapamycin is another cause of impaired renal 
phosphate handling after renal transplantation (Schwartz et al, 2001). 
A carefully conducted study by Rosenbaum et al (Rosenbaum et al, 1981) investigated 
patients with stable kidney function more than six months after a kidney transplant. These 
patients were transplanted during the 1970s and so were taking steroids, but neither 
ciclosporin nor tacrolimus. About a third of patients had a low serum phosphate 
(<0.83mmol/L). Individual patient PTH levels were not given; however, the average 
serum PTH was no different from that in transplant recipients with normal serum 
phosphate levels, although both groups had higher serum PTH values than healthy 
controls. Tubular reabsorption of phosphate, determined during infusion of increasing 
doses of phosphate, was lower in the hypophosphataemic group than in patients with 
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normal serum phosphate levels. In some patients, renal phosphate handling could be 
restored to normal by infusions of calcium, which reduced PTH levels. However, in 
others, calcium infusion, despite lowering PTH, failed to reverse the renal phosphate 
transport defect. The results indicate a long-lasting abnormality in renal phosphate 
handling in many patients after renal transplantation, which in some cases is due to, and in 
others independent of, PTH. 
Green and co-workers (Green et al, 2001) set out to look for a circulating phosphaturic 
factor in the serum of patients after a renal transplant. They studied a range of patients - 
some on dialysis, some with advanced renal failure but not yet on dialysis, and two groups 
of transplant patients: one early after transplant (within one month of a successful graft) 
and a second transplanted group 9-12 months after a graft. Mean serum phosphate in the 
early post-transplant group (0.3mmol/L) was markedly reduced compared to all the other 
groups, with a fractional excretion of phosphate of almost 70%. This led the authors to 
suggest that a phosphaturic factor might be circulating in this group of patients. They took 
serum from all patients and added it to opossum kidney (OK) cells, then measured 
sodium-dependent phosphate uptake. They found that serum samples from dialysis 
patients, pre-dialysis patients and early post-transplant patients were all able to inhibit 
sodium-phosphate co-transport. However, they found a rapid and significant increase in 
type 2 phosphate co-transporter abundance, as assessed by Western blotting. Over a 
longer time-course, an increase in co-transporter mRNA was also found. It is difficult to 
square the increase in co-transporter numbers and mRNA message with the decrease in its 
biological activity, especially as most other experiments seem to find that activity and co-
transporter numbers are closely linked. Indeed, it was reported in the same paper that PTH 
added to OK cells causes a reduction both in sodium-dependent phosphate transport and in 
co-transporter protein. The authors suggested that the circulating factor found in post-
transplant patients acts in a unique way on sodium-phosphate co-transporters, increasing 
transcription while reducing activity.  
Elevated FGF-23 levels have been reported in renal transplant recipients (Evenepoel et al, 
2007). These authors found that almost all transplant patients had transient 
hypophosphataemia after their graft; significant persistent hypophosphataemia was seen in 
patients who had raised levels of both FGF-23 and  PTH. A second research group looked 
at FGF-23 levels on the day of transplant and regularly thereafter; in general, FGF-23 
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levels fell after a successful transplant and there was a significant inverse association 
between FGF-23 levels after the transplant and serum phosphate levels (Bhan et al, 2006). 
 
1.4.2.2 Renal phosphate wasting and kidney stones 
 
Prie’s group has a long-standing interest in a possible connection between increased 
urinary phosphate concentrations and nephrolithiasis (kidney stones). Kidney stones are 
commonly made of calcium phosphate in combination with calcium oxalate. It is known 
that a major risk factor for calcium-containing stones is a raised urinary calcium excretion, 
and some of these patients also have a renal phosphate leak. It has been hypothesised that 
the renal phosphate leak is the primary problem in some patients, leading to low serum 
phosphate, consequent stimulation of vitamin D production and increased bowel uptake of 
calcium and phosphate. This increased uptake of calcium would then lead to 
hypercalciuria. Prie et al investigated 230 patients with calcium stones (Prie et al, 2001), 
comparing maximal phosphate reabsorptive capacity (TmPi) and other renal parameters 
with corresponding values in 105 control subjects with no known kidney stones. They 
found that 10% of patients had hyperparathyroidism and a low TmPi. However, another 
20% of the patients had a low TmPi yet normal serum PTH levels. This study shows that a 
low TmPi is not an uncommon finding in patients with kidney stones. Interestingly there 
was a normal distribution of TmPi in both normal subjects and stone formers, with no 
evidence of a bimodal distribution. The authors (reasonably) suggested that this finding 
indicates a complex series of influences on renal phosphate threshold, rather than just a 
few simple genetic traits. Syndromes characterised by renal phosphate wasting without 
changes in vitamin D (such as tumour-induced osteomalacia; see section 1.4.3) are rarely 
accompanied by kidney stones (Prie et al, 2004). In another large retrospective study, 
almost 10% of patients assessed in a renal stone clinic were found to have low serum 
phosphates and a renal phosphate leak but normal PTH levels (Levy et al, 1995), again 
suggesting a primary abnormality of the proximal tubule and/or unrecognised circulating 
phosphaturic factors in these patients.  
Another publication by Prie and co-workers (Prie et al, 2002) reported that the primary 
sequence of the NaPT2a gene was abnormal in two patients with low serum phosphate 
and either kidney stones or osteoporosis. Prior to this, no clinical phenotype had been 
reported as due to an abnormality of the NaPT2a gene, despite the fact that it is regarded 
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as the most important regulated phosphate transporter in the kidney. Twenty patients with 
a renal phosphate leak but a normal PTH level had their NaPT2a genes sequenced. 
Eighteen of them were found to have no abnormality of the coding sequence of NaPT2a, 
but two different heterozygous abnormalities were found in two unrelated patients. One of 
these patients had kidney stones and a low serum phosphate but no other clinical 
abnormalities (he was of normal height and had no reported skeletal problems). The other 
patient had osteoporosis and a daughter with skeletal problems, but did not have kidney 
stones. Subsequent work by Murer’s group (Virkki et al, 2003) has cast some doubt on the 
significance of the original findings.  This second group was unable to reproduce the 
original findings that these sequence changes had functional consequences in terms of 
phosphate transport, particularly when expressed heterozygously. This raises the 
possibility that these sequence changes are simply neutral polymorphisms of little 
functional significance, and emphasizes that the mechanism of renal phosphate leak in 
stone-formers is not yet understood. 
FGF-23 levels are raised in some patients with low serum phosphate levels and renal 
stones; however, in many others FGF-23 levels are within the range found in control 
subjects (Rendina et al, 2006). 
 
1.4.3 Tumour-induced osteomalacia (TIO) 
 
In this rare syndrome there is a combination of acquired renal phosphate wasting, low 
serum phosphate levels, low or low-normal calcitriol levels (calcitriol production would 
normally be stimulated by low serum phosphate, so normal levels are unphysiological in 
this situation) and a tumour, usually of mesenchymal origin. Surgical removal of the 
tumour results in rapid reversal of the renal abnormalities and normalisation of phosphate 
balance. The syndrome has obvious similarities to the genetic forms of 
hypophosphataemic rickets. It is unclear, and this should be borne in mind throughout the 
discussion below, whether there is one or several circulating phosphaturic factors and 
whether these factors are the same or different in different patients. 
Although most cases of TIO are associated with mesenchymal tumours of relatively low 
malignant potential, there are case reports of hypophosphataemia and renal phosphate leak 
associated with small cell lung cancer (Robin et al, 1994), acute myeloid leukaemia 
(Liamis & Elisaf, 2000) and multiple myeloma (Dash et al, 1997). As these patients are 
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often terminally ill, little clinical information is available and the presumed circulating 
factors causing phosphaturia are entirely uncharacterised. It is of note, however, that both 
the myeloma patients had remission of their phosphaturia after chemotherapy treatment.  
 
1.4.3.1 Pathogenesis of tumour-induced osteomalacia 
 
Jonsson and co-workers tested extracts of tumours removed from four patients with 
oncogenic (tumour-induced) osteomalacia for their ability to inhibit phosphate uptake by 
opossum kidney (OK) cells (Jonsson et al, 2001). They found a range of phosphate uptake 
inhibition, with uptake inhibited by 55% by one active extract, by about 30% by two 
others and no significant inhibition by the remaining extract. Interestingly, although 
normal kidney extract produced no change in phosphate uptake in their assay, liver 
extracts produced 20% inhibition which reached statistical significance (no comment is 
made in the paper about this finding). Normal bone was not tried in this assay, although 
the tumours were of bone/soft tissue origin and so this would have been an appropriate 
control tissue. Further studies on the most active extract suggested that the active factor 
was of low molecular weight and resistant to trypsin and protease K.  An earlier study 
(Cai et al, 1994), using medium obtained from tumour-cell cultures derived from a single 
patient, also demonstrated inhibition of phosphate uptake by OK cells.The active 
substance had a molecular weight between 8kD and 25kD and could be degraded by 
heating to boiling point. A study  on conditioned medium from a culture of tumour-
induced osteomalacia cells (Nelson et al, 2001) also suggested that the circulating factor 
was small (in this case ~5kD). These latter workers found no change in the amount of 
mRNA for the type 2 sodium-phosphate transporter in OK cells exposed to the 
conditioned medium, despite changes in phosphate transport. However, as control of 
activity of the type 2 sodium-phosphate transporter is usually primarily at the membrane 
insertion level rather than at the mRNA level, this finding does not disprove an 
involvement of this transporter in the actions of the phosphaturic factor. 
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1.4.3.2 Identification of circulating factors in tumour-induced osteomalacia 
 
De Beur and co-workers used a technique called serial analysis of gene expression 
(‘SAGE’) to study over-expressed genes in tumour-induced osteomalacia (De Beur et al, 
2002). This technique involves creating cDNA from the mRNA of tumour samples, then 
creating a ‘SAGE tag’ or small fragment by restriction enzyme digestion. These tags are 
then amplified, cloned and sequenced. Tags of 10 base pairs are short enough to be 
sequenced quickly but long enough to be unique. The frequency of tags is related to the 
frequency of the original mRNA message in the sample. These workers used other 
tumours, histologically similar to those involved in tumour-induced osteomalacia (TIO) 
but not associated with hypophosphataemia, as controls; they compared the tag frequency 
in osteomalacia-associated samples with that in these other tumours. Three osteomalacia-
associated tumours were studied and a large number of over-expressed genes was found. 
The genes with the highest ratio of expression in TIO tumours compared with other 
tumours were those encoding Matrix Extracellular Phosphoglycoprotein (MEPE, a protein 
previously isolated from a patient with TIO and discussed in greater detail below in 
section 1.4.3.3.4), a novel protein called Frizzled-Related Protein-4 (FRP-4 , see section 
1.4.3.3.3) and Dentin Matrix Protein-1 (DMP-1). Other genes so identified included those 
encoding the phosphate transporter pit1/glvr-1 (NaPT3), PHEX and FGF-23, along with a 
number of genes never previously identified. Many of these genes have subsequently 
emerged as important in the regulation of phosphate balance. These findings suggest that 
the phosphaturia of tumour-induced osteomalacia may involve the over-expression of a 
considerable number of genes, which may affect each other in complex ways. 
Interestingly, MEPE was the most over-expressed message in one tumour sample and one 
of the top five in both other tumour samples, while it was not seen at all in either of the 
control samples, thus being the most impressive positive result (though the authors chose 
to emphasise FRP-4).  
 
A technically different but intellectually similar approach was followed by Shimada’s 
group (Shimada et al, 2001). These workers constructed a cDNA library from frozen 
tumour tissue taken at operation from a patient with tumour-induced osteomalacia. The 
resection of the tumour had cured the patient, providing good evidence that this tumour 
was producing a phosphaturic factor. They also constructed a cDNA library from the 
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adjacent normal bone tissue. Probes were constructed against tumour and normal bone, 
and plaques generated from the tumour cDNA library were screened with both sets of 
probes. Any plaque hybridizing only with the tumour probes and not with the bone probes 
was considered as possibly significant and was therefore sequenced. In total, 456 clones 
were sequenced and the most frequent five sequences found were: DMP1, Heat Shock 
Protein 90 (HSP-90), osteopontin, FGF-23 and MEPE, in that order.  
 
 
1.4.3.3 Novel factors identified in tumour-induced osteomalacia 
 
1.4.3.3.1 Fibroblast growth factor-23 (FGF-23) 
 
FGF-23 was discovered by Yamashita and colleagues in 2000 (Yamashita et al, 2000). 
These workers were looking for genes similar to previously recognised fibroblast growth 
factors, and detected a sequence in the GenBank Nucleotide Sequence Database with 
marked similarities to other members of the family. They were able to find a cDNA for 
this novel protein in a library created from mouse skin poly(A) RNA, and they then 
amplified and sequenced this cDNA. As it was the 23rd member of the FGF family to be 
identified, they named the protein Fgf-23. They found Fgf-23 mRNA expression in adult 
mouse brain, thymus and small intestine, but not in kidney, muscle or spleen (nor, 
interestingly, in skin, even though the sequence was first found in a skin cDNA library; 
bone was not tested). At that time any function of Fgf-23 was purely speculative. 
 
After Shimada’s group had suggested that FGF-23 was expressed in cells from a tumour 
causing TIO (see above), Bowe and colleagues found that FGF-23 inhibited phosphate 
transport in OK cells (Bowe et al, 2001). They used experimentally conditioned medium 
from COS-7 cells transiently transfected with cDNA for FGF-23, mutant FGF-23 from a 
patient with ADHR, human PTH, osteopontin or DMP-1. Forty-eight hours after 
transfection, the medium was used to bathe OK cells, and phosphate uptake over the 
subsequent 30 minutes was determined by accumulation of 32P. Medium from cells 
transfected with osteopontin or DMP-1 had no effect on phosphate uptake. The medium 
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assumed to contain either form of FGF-23 caused a 60% reduction in phosphate uptake, 
slightly greater than the reduction seen with the presumed PTH-containing medium.  
In contrast, Shimada et al were unable to demonstrate an effect of purified FGF-23 on 
phosphate transport in OK cells (Shimada et al, 2001). It has subsequently been shown 
that FGF-23 has an effect on these cells only when heparin-like compounds are also 
present (Yamashita et al, 2002). This later paper identified the receptor FGFr3c as being 
important in the interaction between FGF-23 and OK cells and found evidence that the 
effects (reduction in phosphate transport, presumably by internalisation of sodium-
phosphate co-transporters) were mediated via the mitogen-activated protein kinase 
(MAPK) pathway and occurred without changes in sodium-phosphate co-transporter 
mRNA levels, at least in the short term.  
Klotho 
The Klotho gene was initially identified as a gene which might have importance in our 
understanding of ageing, since mice with abnormalities of this gene were found to have 
osteoporosis, vascular calcification and other diseases found in the old. They also had 
poor growth, short life-span and very abnormal calcium/phosphate metabolism (markedly 
elevated plasma phosphate, markedly elevated vitamin D, FGF-23 levels over 100 times 
normal, normal PTH levels). The very high levels of serum phosphate and vitamin D are 
similar to those found in knock-outs of Fgf-23 (see below) and further investigation has 
now demonstrated that Klotho interacts with the FGF receptor 3c  to convert this general 
FGF receptor into one specific for FGF-23 (Urakawa et al, 2006). In the absence of 
Klotho, FGF-23 does not seem to be able to interact with cells. Other functions of the  
Klotho gene remain speculative; it now seems possible that the ‘premature ageing’ 
phenotype caused by abnormal expression of the gene may be mainly a result of greatly 
increased levels of calcitriol in these animals (Lanske & Razzaque, 2007), although, 
interestingly, over-expression of Klotho in mice lengthens their lifespan. 
 
 
Genetic manipulation in animals 
FGF-23 has been shown to decrease serum phosphate, without altering serum calcium, 
when given by intravenous injection to mice; this effect took approximately 9 hours to 
become apparent (Shimada et al, 2004a). Calcitriol levels fell more rapidly (within 3 
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hours), probably due to an effect of FGF-23 on the enzymes 1α-hydroxylase and 24-
hydroxylase. It was also found that injection of vitamin D into mice could increase serum 
FGF-23 levels, suggesting that FGF-23 might act as a feedback inhibitor of vitamin D.  
Shimada’s group has also reported on transgenic mice over-expressing human FGF-23 
(Shimida et al, 2004b). These animals grew as well as their litter-mates until weaning, but 
subsequently more slowly. They had small spleens and thymus glands and females were 
usually infertile, but the brain, liver, kidneys and skeletal muscle were apparently normal. 
The FGF-23 construct was widely expressed, but interestingly not in the liver, the organ 
of highest mRNA expression in humans. The paper does not state whether these animals 
expressed FGF-23 in bone. Serum phosphate was about half normal in transgenic animals, 
with a large increase in fractional excretion of phosphate (FEPi). Levels of calcitriol and 
PTH were both very low; serum calcium was slightly low. The low calcitriol levels can be 
explained by the previously demonstrated effect of FGF-23 on 1α-hydroxylase protein 
(Shimada et al, 2001), but the low PTH levels are puzzling, as one might expect them to 
rise in the presence of low calcium and vitamin D levels. (Patients with tumour-induced 
osteomalacia usually have normal PTH levels.) Immunohistochemical study of the 
kidneys showed a low level of NaPT2a in the proximal tubules of the transgenic animals, 
suggesting that the renal phosphate leak was due to a reduction in the amount of this 
protein. 
In another transgenic mouse model, a different group of workers expressed human FGF-
23 in osteoblasts under the control of the α1(I) collagen promoter (Larsson et al, 2004). 
These animals had markedly elevated circulating FGF-23 levels and low serum phosphate 
concentrations. However, they had raised PTH and normal calcitriol levels. Bone density 
was greatly reduced in the transgenic animals and examination of the renal tubules 
disclosed reduced levels of NaPT2a, and also of NaPT2c and NaPT1. These differences 
between the two transgenic models are striking, unexplained and not commented on in the 
later report. 
In a third transgenic mouse model, a mutant form of FGF-23 derived from a patient with 
ADHR was over-expressed in the liver of transgenic animals (Bai et al, 2004). High levels 
of circulating FGF-23 were confirmed and animals developed hypophosphataemia, 
phosphaturia and low calcitriol levels. They had marked hyperparathyroidism and the 
activity of the 1α-hydroxylase enzyme was lower than in control animals. 
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Human FGF-23 has been expressed temporarily in rats by intravenous injection of naked 
DNA plasmids (Segawa et al, 2003). Under these circumstances the DNA is taken up, 
mainly by the liver, transcribed and the FGF-23 protein expressed for 2-4 weeks. Segawa 
and colleagues injected both a normal FGF-23 DNA sequence and one mutated at a 
consensus proteolytic site, similar to sequences seen in ADHR and known to prolong the 
half-life of FGF-23 in the circulation. Analysis of the animals’ serum indicated that the 
mutated, but not the normal, DNA injection led to greatly elevated circulating FGF-23 
levels. Animals on a normal diet had reduced serum phosphate after injection of the 
mutated DNA, and also reduced vitamin D levels. Animals fed a low-phosphate diet had 
reduced serum phosphate compared with those on a normal diet, and indeed a lower serum 
phosphate than was seen in the animals on a normal phosphate diet injected with the 
mutant DNA; there was no further change when they were injected with mutated DNA, 
although again they had much reduced vitamin D levels. These results confirm a 
connection between raised FGF-23 levels and low serum phosphate, but the absence of 
any effect in phosphate-deficient animals suggests that phosphaturic effects of FGF-23 
can be overridden under these circumstances. Analysis of sodium-phosphate co-
transporter numbers by Western blotting of renal extracts showed that animals injected 
with the mutant FGF-23 had greatly reduced levels of NaPT2a and (even more strikingly) 
NaPT2c, with no change seen in NaPT1; this was seen both in animals on the normal diet 
and in those on the low-phosphate diet. (This does not seem consistent with the absence of 
an effect of the injection on phosphate excretion in mice on a low phosphate diet, but is 
reported without comment in the paper.)   
A knock-out mouse strain lacking the Fgf-23 gene has been generated by Shimada et al 
(Shimada et al, 2004b). Homozygote Fgf-23 -/- mice were born at the expected Mendelian 
frequency, indicating that the absence of the FGF-23 protein does not significantly reduce 
embryonic survival. After birth, wild-type and Fgf-23+/- mice were indistinguishable, but 
there was growth retardation and shortened survival in Fgf-23 -/- mice. Serum phosphate 
was normal in the Fgf-23 null mice at birth and at 6 days, but was subsequently 
significantly elevated; serum calcium was more modestly elevated from two weeks. The 
most striking biochemical abnormality was a greatly elevated vitamin D level in the Fgf-
23 null mice. There were also abnormalities in lipid and glucose metabolism.  These 
results might be interpreted as suggesting that Fgf-23 does not play a central role in 
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phosphate physiology in utero or in early life but that its absence is significant in adults, at 
least in mice.  
Transgenic animals have made a significant contribution to our understanding of the 
physiology of FGF-23, but it is striking that different transgenic models show rather 
different patterns of disturbance to phosphate physiology; this underlines the fact the 
interpretation of data from transgenic animals can sometimes be difficult. 
 
 
Clinical studies 
FGF-23 has been assayed in patients with TIO and XLH (Jonsson et al, 2003). In most 
(but not all) patients with TIO, FGF-23 levels were markedly elevated. In patients with 
XLH, FGF-23 concentrations were on average significantly elevated, but many patients 
had levels within the normal range; although the authors point out that all XLH patients 
were on treatment (with phosphate and/or vitamin D), it is unclear whether this would be 
expected to alter FGF-23 levels, particularly as almost all the XLH patients had very low 
serum phosphates.  
It has been shown that dialysis patients have greatly elevated levels of circulating FGF-23 
(Larsson et al, 2003), whilst the levels in patients with chronic renal failure nearing 
dialysis are raised, but not to the same extent. It is not clear whether these results simply 
represent accumulation of FGF-23 in renal failure or are in part due to increased 
production of FGF-23, perhaps in response to hyperphosphataemia. The magnitude of the 
concentration difference between healthy individuals and dialysis patients (more than 
1000-fold) suggests that accumulation of FGF-23 in renal failure must be a large part of 
the explanation. A study of serum FGF-23 levels in men on dialysis (Imanishi et al, 2004) 
showed a significant correlation between serum inorganic phosphate and FGF-23 levels, 
but FGF-23 levels were grossly elevated even in those dialysis patients with normal or 
low serum phosphate concentrations and the scatter of the results is considerable. A small 
sub-study, not reported in detail, looked for changes in FGF-23 levels in healthy men in 
response to either dietary phosphate loading or phosphate deprivation (Larsson et al, 
2003). Although significant changes in FEPi were induced by these dietary manipulations, 
there were no changes in FGF-23 levels (nor, in agreement with previous studies, in either 
PTH or serum phosphate levels).  
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Another small study reports levels of FGF-23 in patients with primary 
hyperparathyroidism (in which the mean level of FGF-23 was slightly elevated compared 
with controls) and in patients with humoral hypercalcaemia of malignancy (in which FGF-
23 levels were more convincingly elevated) (Singh & Kumar, 2003); in neither patient 
group could a relationship between serum phosphate and FGF-23 levels be demonstrated. 
A second, larger, study of patients with primary hyperparathyroidism (Yamashita et al, 
2004) also failed to show a correlation between serum phosphate and FGF-23 levels; the 
main predictor of FGF-23 levels in these patients was creatinine clearance. This study 
reported that serum FGF-23 concentrations were not different between normal controls 
and patients with primary hyperparathyroidism and normal renal function. Multiple 
regression analysis suggested that serum calcium levels and creatinine clearance, but not 
serum phosphate or PTH levels, were correlated with FGF-23 levels. Further, the levels of 
FGF-23 did not fall after parathyroidectomy despite normalisation of serum calcium. 
Many of the patients with low serum phosphate levels had FGF-23 levels within the 
normal range. This study does not support the case for FGF-23 as a regulator of serum 
phosphate levels in patients with hyperparathyroidism. In patients with 
hypoparathyroidism, there is hyperphosphataemia and hypocalcaemia. A study (again 
very small) of such patients found that they had raised levels of FGF-23 compared with 
controls (Gupta et al, 2004). The authors attributed this to hyperphosphataemia, but other 
possible explanations might include significant influences of vitamin D treatment, renal 
function, age or removal of a suppressive effect of PTH, none of which were assessed in 
the report.  
 
Slightly surprisingly, in view of the wide acceptance of the hypothesis that PHEX 
mutations cause an excess of FGF-23, the data for raised FGF-23 levels in X-linked 
hypophosphataemic rickets (XLH) are not very conclusive. Initial studies (Yamazaki et al, 
2002) in 6 patients with XLH showed average serum FGF-23 levels to be around 150 
ng/L, with the normal range given as 8-53 ng/L. One of the six patients had an 
unequivocally normal value and two others had borderline elevation only. In addition, it is 
not clear whether any account was taken of the possibility of renal impairment in these 
patients. Given the strong relationship between FGF-23 and renal impairment noted 
above, this might have had a major influence on the results. A more recent paper, 
concerned mainly with assessing different methods of measuring FGF-23 levels in human 
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serum, found 5/29 patients with XLH had FGF-23 levels within the normal range (Ito et 
al, 2005, AP565). 
 
1.4.3.3.2 Fibroblast growth factor-7 (FGF-7) 
  
FGF-7 was identified as a potential cause of phosphaturia in tumour-induced osteomalacia 
by Carpenter et al (Carpenter et al, 2005). These workers established tissue cultures of 
cells grown from the tumours of two patients with TIO. Conditioned medium from these 
cultures was shown to inhibit phosphate transport in OK cells; some cultures subsequently 
lost this ability as the cells were repeatedly grown to confluence. Gene expression in cells 
that continued to elaborate a phosphate transport inhibiting substance was compared with 
gene expression in cells that had lost this effect (by RNA expression analysis using 
reverse transcription followed by endonuclease digestion, gel electrophoresis and 
fluorescence detection). By this means, FGF-7 was found to be greatly over-expressed in 
cells which inhibited phosphate transport. Subsequent renal clearance experiments have 
shown that FGF-7 increases renal phosphate clearance when given intravenously to rats 
(Shaikh et al, 2007). No information on levels of FGF-7 in human health or disease is yet 
available.  
 
1.4.3.3.3 Frizzled-related protein-4 (FRP-4) 
 
 
As indicated above, this protein was identified by Kumar’s group when they examined 
four tumours by serial analysis of gene expression (SAGE) to identify genes up-regulated 
in tumour-induced osteomalacia (De Beur et al, 2002). It had not been identified as 
significant in the earlier studies of Rowe et al (2000) or Shimada et al (2001). Kumar’s 
group also identified MEPE by this technique but were less interested in it. They 
subsequently cloned and expressed human FRP-4 in an insect expression system and 
performed experiments to determine whether it altered renal phosphate handling. 
Clearance experiments in rats demonstrated that acute FRP-4 infusions caused an increase 
in fractional phosphate excretion without significant changes in serum phosphate (Berndt 
et al, 2003). This was shown to be due to internalisation of the NaPT2a transporter in the 
renal tubular brush-border membrane, as assessed by immunoblotting of membrane 
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vesicles (Berndt et al, 2006). Longer-term infusions into rats (eight hours) caused a fall in 
serum phosphate and a marked increase in fractional phosphate excretion. One report, 
from the same group that originally isolated the protein, states that serum FRP-4 levels are 
not altered in patients with chronic kidney disease, or in those with renal transplants in 
whom phosphate balance is abnormal (Pande et al, 2006). All that can be said at present is 
that FRP-4 is a candidate phosphatonin about which little is known other than that it is 
expressed by tumours causing TIO and it is phosphaturic in rats. 
 
1.4.3.3.4 Matrix extracellular phosphoglycoprotein (MEPE) 
 
Matrix extracellular phosphoglycoprotein (MEPE) was first isolated in 2000 from tumour-
derived tissue from a patient with tumour-induced osteomalacia (Rowe at al 2000). 
Messenger RNA was obtained from resected tumour and reverse transcribed to cDNA. 
This was then cloned into a bacteriophage vector after the addition of suitable primers, 
and the clones amplified by use of E. coli. The patient’s preoperative serum was used to 
generate antisera by injection into rabbits, and the resulting rabbit antiserum was 
extensively pre-absorbed with normal human serum and with E. coli lysate. This 
antiserum was used to screen the bacteriophage library; the rationale was that proteins 
circulating pre-operatively in the patient with tumour-induced osteomalacia, but which 
were not present in ordinary human serum, would be recognised. Bacteriophage plaques 
that were recognised by the preabsorbed antiserum were transformed into plasmids, 
transfected into E. coli and sequenced. The entire procedure outlined above gave rise to 
nine clones. Three were human clusterin sequences and the remaining six were MEPE 
sequences of differing lengths, between 227 and 430 residues. The gene sequence 
suggests a 525 amino-acid protein, with a number of sequences which might be cleaved 
by proteases such as PHEX. The sequence contains no obvious transmembrane sections 
and suggests a protein which might be secreted. 
 
MEPE was independently described by another group as the product of a bone-specific 
gene, which they called osteoblast/osteocyte factor 45 or OF45 (Petersen et al, 2000). 
These workers used the fact that primary bone marrow cultures from the rat can be 
induced to differentiate into osteoblasts by the addition of differentiation factors such as 
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dexamethasone whereas, without the addition of such factors, primary bone marrow 
cultures do not contain osteoblasts. By using subtractive hybridisation of cDNA from 
dexamethasone-treated cultures vs. cDNA from untreated cultures, it is possible to obtain 
a cDNA library greatly enriched for genes induced during osteoblast differentiation. This 
technique produced a large number of clones of which the most frequent was osteopontin, 
a gene already known to be induced during osteoblast differentiation. This provides 
evidence that the technique is able to identify genes of importance in osteoblast 
differentiation. The second most common clone found, in 17% of all sequences, was a 
previously novel protein now known as MEPE.  
 
Mouse Mepe was subsequently isolated from a bone cDNA library (Argiro et al, 2001). 
Sequence analysis showed 56% overall homology between mouse and human cDNAs, but 
with large areas of close sequence homology. A section of 75 amino acids is present in the 
human sequence but absent from the mouse sequence. Northern blot analysis identified 
Mepe mRNA in bone, but not in brain, heart, liver, lung, muscle or kidney. MEPE 
expression was markedly increased in mineralising cultures of bone marrow cells, as 
opposed to non-mineralising cultures. Finally, Mepe expression in the bones and 
osteoblasts of Hyp mice (that is, the mouse homologue of X-linked hypophosphataemic 
rickets, known to be due to mutations in the mouse Phex gene; see section 1.4.1.1) was 
three times that seen in normal mice, suggesting the possibility of an interaction between 
MEPE and PHEX. 
 
The genes responsible for a number of inherited dental syndromes in humans are known 
to be located on chromosome 4q21; MacDougall et al noted that the MEPE gene is also 
found in this area and therefore investigated its expression in teeth (MacDougall et al, 
2002). They performed PCR analysis of a mouse tooth cDNA library and of cDNA 
generated by an odontoblast cell line and demonstrated Mepe expression in both, strongly 
suggesting that MEPE is expressed in developing teeth.  
 
Researchers employed by Pfizer have succeeded in creating a Mepe knock-out mouse 
(Gowen et al, 2003). Unfortunately, these workers were mainly interested in bone 
morphology and reported only briefly about other aspects of these mice. They found that 
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homozygote and heterozygote knock-out animals appeared healthy, grew normally and 
were fertile. Homozygous knock-out mice had increased bone mass and increased 
osteoblast numbers, by a mechanism yet to be characterised; there was also some change 
in bone structure in heterozygotes. Homozygous animals were reported as having normal 
serum calcium and phosphate concentrations, although there were modest differences 
between Mepe knock-outs and wild-type controls and the variability between animals was 
large. Further, serum phosphate was determined at only one time point (one year of age) 
and there was no determination of serum PTH.  These workers’ conclusion that mineral 
metabolism in the knock-outs is normal therefore requires further assessment. 
 
Fisher and Fedarko, in a mainly theoretical paper (Fisher and Fedarko, 2003), put forward 
the hypothesis that MEPE belongs to a gene family which they dubbed ‘SIBLING’ (Small 
Integrin Binding Ligand, N-linked Glycoprotein). Other described gene families are 
linked by sequence similarities and are usually assumed to have come about by gene 
duplication and subsequent divergent evolution, but this family is linked in terms of their 
chromosomal location and gene structure. The primary sequences of the six genes they 
place in the SIBLING family are unrelated, so a common origin with subsequent 
divergent evolution is ruled out. It is unclear what the authors feel is the implication of 
similarity of secondary features (see below) in the absence of primary sequence similarity; 
this might represent similar function of proteins with different evolutionary origins. I am 
unconvinced that the term ‘gene family’ is appropriately applied to this group of proteins 
and feel it is better reserved for genes with similar (and therefore presumably related, in an 
evolutionary sense) DNA sequences.  The paper presents data comparing the exon 
structure of six genes coded on the long arm of chromosome four, including MEPE, 
pointing out that the number and structure of exons is similar and that there are areas of 
potentially important sequence similarity, including the integrin-binding tripeptide 
ArgGlyAsp, a proline-rich region and a consensus sequence for casein kinase II 
phosphorylation. The authors therefore suggested that MEPE - in common with the other 
proteins in the SIBLING family - would have a role as a soluble protein involved in 
extracellular matrix accumulation and calcification. In a more recent publication these 
authors have dropped one of the original six SIBLINGs (Ogbureke & Fisher, 2004). One 
of the genes placed in the SIBLING group is Dentin Matrix Protein-1 (DMP-1); mutations 
in this gene cause autosomal recessive hypophosphataemic rickets (ARHR; see section 
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1.4.1.4). Work on this protein suggests that it is cleaved by PHEX at multiple points, and 
that it is the cleaved fragments which have biological activity; PHEX might act on MEPE 
in a similar way, producing active fragments (Qin et al, 2003). DMP-1 and three of the 
other genes placed in the SIBLING group have been shown to interact with specific 
matrix metalloproteinases (MMPs) (Ogbureke & Fisher, 2004). It is not known whether 
MEPE has a specific MMP partner. MEPE mRNA was found in human kidney 
homogenates by RT-PCR (note it was not found in rat kidney  by Agiro’s group, see 
above; this may represent a species difference or may be due to the different techniques 
used, PCR usually being more sensitive than Northern blotting), and MEPE protein was 
found by immunohistochemisty in the proximal tubule of the kidney in monkeys; staining 
was most marked on the luminal surface or luminal half of proximal tubular cells 
(Ogbureke and Fisher, 2005). The latter observations are consistent with binding of 
filtered MEPE to the luminal side of proximal tubular cells, particularly as the staining 
was strongest in the proximal convoluted tubule and less so in the straight tubule; there 
was no staining in the loop of Henle or the distal tubule. Ogbureke and Fisher hypothesise 
that the SIBLING proteins are involved in cell-cell interactions; since no MMP for MEPE 
has been identified, the role of MEPE in this remains speculative. These workers have 
also found Mepe mRNA (as well as RNA for other members of the SIBLING group) in 
mouse salivary glands; what it is doing there is unknown (Ogbureke and Fisher, 2004).   
 
A report by Rowe and colleagues (Rowe et al, 2004) gives some information on the 
effects of MEPE on renal phosphate handling. These workers used full-length human 
MEPE and injected it intraperitoneally into mice. PTH was used as a positive control. 
Two different doses of MEPE were used. Serum phosphate was not altered after 7 hours 
in any group but after 30 hours was significantly lower in animals given PTH or the 
higher dose of MEPE than in saline-injected control animals. Urinary excretion of 
phosphate was measured, but only in pooled samples, and ‘fractional excretion of 
phosphate’ was determined on the basis of measurements of creatinine clearance as an 
assessment of GFR. As determined in this (less-than-satisfactory) way, fractional 
phosphate excretion was increased by both MEPE and PTH.  Although these results are 
suggestive of an effect of MEPE on tubular phosphate handling, a more rigorous 
assessment is required. 
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Full-length MEPE has a molecular weight of about 44kD, and it is therefore possible that 
there are a number of active fragments, possibly with different activities. In this context, 
Liu and co-workers (Liu et al, 2004) have shown that a small (23 amino-acid) fragment 
from the centre of the full-length MEPE sequence can enhance dental pulp cell 
proliferation. They have called this fragment Dentonin. This report clearly leaves open the 
function of the remaining portions of the MEPE sequence. Another group (Hayashibara et 
al, 2004) studied the effects of the same peptide on bone. (Not being interested in teeth, 
they did not call it Dentonin.) They found that the peptide stimulated bone formation not 
only in organ culture but also in vivo, when injected directly next to the bone in mice. 
Subsequent work by this group has suggested that full-length MEPE decreases osteoclast 
formation in bone marrow cultures and might thus also have the effect of reducing bone 
breakdown or turnover (Hayashibara et al, 2007). Rowe and colleagues have speculated 
that a sequence at the C-terminal end of the MEPE molecule, called the ASARM motif 
(‘acidic serine aspartate rich motif’), might be the fraction of the molecule which is active 
in the kidney and the bones; these workers demonstrated raised levels of proteins carrying 
this motif in both Hyp mice and humans with XLH (Bresler et al, 2004). In Hyp mice, the 
abnormal mineralization of the bones could be improved significantly by treating the 
animals with protease inhibitors; this improvement in bone histology was associated with 
a reduction (towards normal) of circulating ASARM peptides and of local bony 
accumulation of ASARM peptides (Rowe et al, 2006). It should be noted, however, that 
MEPE is not the only protein to carry this motif, so these data do not prove that the raised 
levels were MEPE-derived. 
It has been shown that the Hyp phenotype is not rescued by transgenic expression of Phex 
restricted to osteoblasts; although bone mineralization is improved in these animals they 
remain hypophosphataemic (Liu et al, 2002; Bai et al, 2002). When this problem was 
approached from the other direction and two groups of  mice were created, one with 
global Phex knock-out and the other  with conditional (osteocalcin-promoted, therefore 
bone-limited) Phex inactivation, the two groups of mice had similar (low) levels of serum 
phosphate, equally reduced renal NaPT2a levels and osteomalacia (Yuan et al, 2008). 
FGF-23 levels were increased in both groups of mice, whereas Mepe mRNA (in bone 
samples) was greatly increased in animals with the global Phex mutation but not in those 
with the mutation limited to bone cells. The authors interpreted these findings as 
suggesting that FGF-23, but not MEPE, is involved in the hypophosphataemia in Phex-
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mutated animals, since animals with Phex loss limited to bone cells had normal MEPE 
levels but low serum phosphates. In my view it is not certain that this is the correct 
conclusion, since it is hard to be sure that Phex inactivation in this model is limited to 
bones and alternative experimental approaches (as noted above) lead to contradictory 
results. 
 
It has been shown that the PHEX protein is able to interact with MEPE (Rowe et al, 2005) 
and that the ASARM fragment of MEPE is the part of the molecule that mediates this 
interaction (Martin et al, 2008). Both MEPE protein and ASARM motifs (which can also 
come from other proteins, including DMP-1) are increased in Hyp mice, and this has led 
to the hypothesis that it is the ASARM peptides that lead to the bone mineralization defect 
in XLH (Martin et al, 2008); in view of the apparent phosphaturic effect of MEPE, either 
the full length  molecule or the ASARM fraction might also be responsible in part for the 
phosphaturia found in this condition. 
 
It has been demonstrated by Jain et al (2004) that MEPE circulates in normal humans. 
These workers had previous experience in the measurement of other members of the 
SIBLING family, including DMP-1, and had found that they circulate bound to 
complement factor H. They developed a protocol based on reducing and processing serum 
so as to separate these proteins, and found that it could be applied to detect MEPE using a 
competitive ELISA. They reported a very wide range of values for serum MEPE levels, 
which were approximately normally distributed in healthy adults, but declined with age. 
MEPE levels were negatively correlated with serum PTH and positively correlated with 
serum phosphate. The decline in MEPE levels with age might indicate a relationship to 
bone turnover, which also declines with age. It was also found that serum MEPE 
concentration was correlated with bone density in people over 60 (Jain et al, 2004). The 
positive correlation between MEPE levels and serum phosphate might be consistent with a 
physiological effect of MEPE on serum phosphate. 
Preliminary work has suggested that MEPE fragments are elevated in the circulation of 
patients with XLH and also in those with tumour-induced osteomalacia (Jan de Beur et al, 
2004). These authors developed ELISA assays for both full-length MEPE and a C-
terminal fragment; they found that although full-length MEPE concentrations did not 
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differ between controls and patients with hypophosphataemic syndromes, the C-terminal 
fragment was markedly elevated in each group of patients. In two cases of TIO in which 
pre-and post-surgical samples were available, the C-terminal fragment concentration fell 
after surgery while serum phosphate normalised. These data are clearly consistent with 
MEPE being a circulating phosphaturic substance in these patients, although it should be 
noted that they have yet to appear in a full publication. 
 
 
In summary, several lines of evidence lead towards the conclusion that MEPE might be a 
significant regulator of phosphate balance. The results from patients with tumour-induced 
osteomalacia suggest that it circulates in at least some of these patients and might have 
direct phosphaturic effects. Analysis of predicted molecular structure is consistent with an 
excreted, perhaps circulating, protein. The fact that MEPE can be found in normal human 
serum is supportive of a role in normal phosphate physiology, potentially linking the 
kidneys (the main controllers of overall phosphate balance) and the bones (the main 
source of accessible phosphate).  
 
 
1.5 Summary paragraph 
 
Phosphate homeostasis depends on inter-regulated control of the gastrointestinal tract (site 
of phosphate uptake), the kidney (site of phosphate excretion) and the bones (main store 
of inorganic phosphate). The PTH/vitamin D axis alone does not explain the complexity 
of normal phosphate homeostasis, nor does it account for many of the hereditary or 
acquired phosphaturic states. Phosphaturic syndromes have been shown to be caused by 
mutations in genes transcribed both in the kidney (NaPT2c) and the bones (DMP-1, 
PHEX, FGF-23). There is increasing interest in peptides (‘phosphatonins’) that might link 
bone biology and renal phosphate handling; MEPE is one such peptide. 
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1.6 Objectives of the present study 
 
The present study aimed to establish and quantify the effect of MEPE on phosphate 
excretion in rats; to determine, using clearance experiments, whether the effect was 
tubular in origin; and to assess, using micropuncture experiments, which nephron segment 
is responsible. In order to measure phosphate concentrations in tubular fluid samples, it 
was necessary to develop a suitable microassay technique. 
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Chapter 2 
Measurement of phosphate in biological samples 
using capillary electrophoresis  
  73 
2.1 Introduction 
 
2.1.1 Need for microanalysis 
 
The study of renal tubular transport requires the ability to measure accurately ion 
concentrations in samples taken from single tubules as well as in plasma and urine. A 
wide variety of methods has been used over the past fifty years, but all have 
disadvantages. Sample collection and analysis are laborious, so methods allowing 
determination of several ion species in a single small volume sample would have 
advantages. My interest was primarily the measurement of phosphate in small volumes, 
but capillary electrophoresis also allows for analysis of other anions. This chapter 
describes the development of a method for the simultaneous analysis of anions at 
physiological concentrations in nanolitre volumes of tubular fluid or other biological 
samples. 
Much micro analytical work is currently performed using radioisotopes. These have a 
number of advantages, particularly that they allow accurate determination in very small 
volumes. The health risks to workers using tritiated compounds (most commonly used for 
single-nephron GFR determination) are very low, but the bureaucratic burden is 
significant. The health risks of using 32P are more significant and the bureaucratic and 
safety requirements correspondingly greater. Use of radioactivity is also expensive, so 
there is considerable interest in using non-radioactive means to perform microanalyses 
and to measure single-nephron GFR; in particular non-radioactive iothalamate has been 
proposed as an alternative to radioactive inulin (Capasso et al, 2002 ). 
 
2.1.2 Methods used previously, their advantages and 
disadvantages 
 
The routine analytical technique for the simultaneous determination of small anions is ion 
chromatography. This technique has been applied to samples with low ion concentrations 
but requires sample volumes of 30-600 µL (Meissner et al, 1999; Schminke & Suebert, 
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2000; Tanaka et al, 2000). These sample volumes are large compared with those collected 
during micropuncture experiments, in which tubular fluid volumes of significantly less 
than one microlitre are usually obtained. 
For measurements in very small sample volumes, a range of different techniques has been 
employed. Bicarbonate concentration has been determined by calorimetry (Vurek et al, 
1975) and fluorometry (Star, 1990) and by the use of microelectrodes (Yoshitomi & 
Fromter, 1984). Chloride concentration has been determined by spectroscopic (Levinson, 
1976; Illsley & Verkman, 1987; Zhelyaskov et al, 2000), electrochemical (Yoshitomi & 
Fromter, 1984; Fujimoto & Kokota, 1976) and radio-isotopic methods (Isozaki et al, 1989; 
Ando et al, 1989). Phosphate has been measured in micropuncture samples using 
microcolorimetric techniques (Vurek, 1981; Woda et al, 2001), which were first 
developed by Chen and colleagues (Chen et al, 1956), and by the use of the radioisotope 
32P. Although all these techniques are capable of quantifying individual anion species in 
small volumes at physiological concentrations, they require specialized equipment and do 
not have the advantage of allowing simultaneous analysis of several anions.  
2.2 Capillary electrophoresis 
 
Capillary electrophoresis (CE) is a technique based on passing samples in solution along a 
narrow capillary and using the different mobilities of charged species in solution to 
provide separation of species. It can provide a method of separating and quantifying 
numerous anions quickly and with high efficiency (Jandic & Jones, 1991); moreover, it 
can be applied to a wide range of samples and analytes (Monnig & Kennedy, 1994). 
Because the method uses very small-bore capillaries, the sample volumes required are 
intrinsically small. For applications in which sample volume is a limiting factor, such as 
the analysis of tubular fluid, this is potentially a significant advantage. Dilution of the 
original sample is required to prevent overloading of the capillary, but the dilution factor 
can be altered to optimize detection limits. 
Capillary electrophoresis has previously been used for the analysis of small ions in non- 
biological aqueous samples (reviewed in Doble & Haddad, 1999) and has been used to 
study airway surface fluid, a biological fluid available only in nanolitre volumes (Cowley 
et al, 1997). Furthermore, Wildman et al have previously published a method for the 
detection and quantification of multiple anions in urine using capillary electrophoresis 
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(Wildman et al, 1991). However, they did not publish on linearity of response, detection 
limits or repeatability. Moreover, their method required large sample volumes, such as are 
available in the analysis of human urine but not in that of laboratory rodents. Only one 
previous study has used capillary electrophoresis to analyse tubular fluid: colleagues in 
the renal laboratories at UCL have reported simultaneous analysis of cations in tubular 
fluid using conductivity detection (Stocking et al, 1999), but this is now a somewhat dated 
technique which has been largely supplanted by the more flexible and sensitive UV 
detection.                                                                                                                                                                 
2.3 Methods 
 
Capillary electrophoresis machines are available off the shelf from a variety of 
manufacturers; innovation in the use of these machines lies in the modification of the 
experimental conditions to optimise detection limits, separation of analytes and 
reproducibility. A large number of variables can be altered to improve analytical results. 
A pictorial representation of a standard capillary electrophoresis apparatus is shown in 
Figure 2.1. Samples are place in vials on a rotating tray. The samples can be loaded into 
the capillary by a potential difference, by pressure injection or under the influence of 
gravity. They are then moved in the liquid phase along the hollow capillary, under the 
influence of a potential difference between the two ends of the capillary. Anions are 
surrounded by hydration spheres of water molecules and movement of these spheres 
towards the cathode creates bulk flow of fluid along the capillary. Different anions move 
at different speeds according to their charge and the size of their hydration spheres and are 
therefore separated. Peaks corresponding to different anion species are generated in this 
system by indirect UV detection, which allows a considerable number of different species 
to be seen at the expense of a lower sensitivity than can be found in direct detection 
systems. A high background signal is generated by including chromium ions in the run 
buffer; these provide a constant and high level of UV absorption. When other ions are 
present in the capillary they displace chromium, and lead to a reduced level of absorption 
and more UV light reaching the detector.  
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Figure 2.1 Capillary electrophoresis apparatus 
 
In order to make interpretation easier, the output trace is inverted, so that troughs in 
detector output appear as peaks - this is purely a visual change and does not alter the data 
in any way. Detector output is plotted against time by the machine software, leading to 
traces showing peaks corresponding to each anion passing the detector. Peak area (in 
arbitary units) is proportional to anion concentration, a relationship demonstrated over 
several orders of magnitude later in this chapter for each of the important anions in tubular 
fluid and urine. Between samples the capillary is flushed either with the run buffer or with 
other solutions. 
 
2.3.1 Capillary electrophoresis system 
 
A Beckman P/ACE 5500 capillary electrophoresis system with a 254 nm filter and a 
photomultiplier tube UV detector, controlled by a Beckman P/ACE station version 1.1 
(Beckman Coulter UK Ltd, High Wycombe, Bucks, UK), was used in all the CE 
experiments described in this thesis. This station and its software were also used for the 
analysis. The analysis capillary was fused silica: 50 µm internal diameter, 375 µm 
 
Inlet
Rotating Tray
Outlet
Detector
Temperature Controlled Cartridge
Capillary
High Voltage Supply
- +
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external diameter, 37 cm total length [30 cm to detector] (Composite Metal Services Ltd, 
Hallow, Worcs, UK).  The instrument parameters are shown in Table 2.1 and the run 
conditions in Table 2.2. Prior to each batch of measurements, the capillary was flushed 
with run buffer at 20 p.s.i. for 10 minutes, followed by a series of five blank samples. This 
procedure was found to be sufficient to produce a stable baseline, which was confirmed at 
the beginning of each day’s work. Large volume samples, such as urines and calibration 
samples, were loaded into the machine in 0.5ml plastic vials. Tubular fluid samples were 
loaded in microvials, smaller vials which were conical in shape and held up to 50µl. 
 
 
Separation parameters 
                 Voltage                         8 kV 
 
              Temperature 
 
                       25 oC 
Detection parameters 
             Wavelength                         254 nm 
        Attenuated range                      0.200 AU 
       Data collection rate                         10 Hz 
              Rise time                         1 sec 
             Signal type                      Indirect 
 
 
Table 2.1 Instrument parameters for capillary electrophoresis 
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Time 
point 
(min) 
Function Duration 
Applied 
potential 
(kV) 
Pressure 
(p.s.i) 
Inlet 
vial 
Outlet 
vial 
Pre Rinse 1min 0 20 Buffer Waste 
Pre Inject 5 sec 0 0.5 Sample Waste 
0 Separate 4 min 8 0 Buffer Buffer 
 
Table 2.2 Capillary electrophoresis run conditions 
 
 
2.4 Results and Discussion 
 
2.4.1 Use of capillary electrophoresis to measure anions  
 
The predominant anions in tubular fluid and urine are chloride, bicarbonate and 
phosphate. My initial work therefore concentrated on analysis and quantification of these 
anions, with a view to focusing on phosphate in the subsequent investigation. 
As an example of the results produced by the capillary electrophoresis technique described 
above, an electropherogram demonstrating separation and detection of the anions chloride, 
phosphate and bicarbonate (and also nitrate and citrate) under the conditions described is 
shown in Figure 2.2. The trace shows a combined standard made up from commercially 
available solutions of these anions. 
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Figure 2.2 Separation of anions by capillary electrophoresis  
 A standard solution, containing chloride 50 mmol/L, nitrate 6 mmol/L, 
citrate 10 mmol/L, phosphate 11mmol/L and bicarbonate 15 mmol/L, was 
used. 
 
Standard curves for phosphate and chloride covering the expected range in urine are 
shown in Figure 2.3 and Figure 2.4. For each of these anions the correlation coefficient (r) 
was 0.999. Figure 2.5 shows a standard curve for bicarbonate; the correlation coefficient 
was 0.997. These results demonstrate that the relationship between analyte concentration 
and peak area is linear through a wide range of concentrations for all three anions. 
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Figure 2.3 Calibration curve for phosphate 
The solid line represents the best-fit line determined by linear regression. 
y=20.91x -10.08; r=0.999 
 
 
Figure 2.4 Calibration curve for chloride 
y=9.30x+20.15; r=0.999 
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Figure 2.5 Calibration curve for bicarbonate 
y=9.63x+48.6; r=0.997 
  82 
The detection limit was calculated using the standard technique of determining the mean 
baseline noise plus three standard deviations of the baseline noise in a sample of de-
ionized water. On this basis the detection limits in the original samples were 0.3 mmol/L 
for chloride, 0.3 mmol/L for phosphate and 1.8 mmol/L for bicarbonate, when samples 
were diluted by a factor of 200. These detection limits compare favourably with those of 
the NANOFLO system (see section 2.4.3.3.1 below). The actual volume of diluted sample 
loaded onto the column is only 8.0 nL (Beckman CE Expert Software); therefore, the 
amount of anion present in the capillary at the detection limit is 12 fmol for chloride, 12 
fmol for phosphate and 72 fmol for bicarbonate. The use of the amount of substance in the 
analysed sample to define the detection limit is very widespread (for example, Zhelyaskov 
et al in their NANOFLO paper (Zhelyaskov et al, 2000) and Stocking et al in their 
capillary electrophoresis work (Stocking et al, 1999)). It can be rather misleading in the 
case of CE, because the system as a whole is unable to analyse amounts as small as this 
implies, as most of the sample remains in the vial. However, this value does represent a 
fundamental property of the detection system. In my view, the detection limits of 
micromethods are best expressed as concentrations in volumes, so as to eliminate 
ambiguity. For example, in this CE system when optimised for phosphate detection, we 
can comfortably detect 0.2mmol/L phosphate in a 30nL sample. Further work on reducing 
the vial size might allow a considerable improvement in practical detection limits, by 
reducing the proportion of the sample left behind in the sample vial.  
 
The repeatability (intra-assay variation) of the method was determined by repeat analysis 
(n=6) of a commercially available quality control (chloride 76.6 mmol/L, phosphate 5.1 
mmol/L and bicarbonate 3.4 mmol/L). The standard deviation in concentration was 
determined as 1.3 mmol/L for chloride, 0.3 mmol/L for phosphate and 0.4 mmol/L for 
bicarbonate. The standard deviation in migration time was determined as 0.084 s for 
chloride, 0.33 s for phosphate and 0.078 s for bicarbonate, in a total run time of 4 minutes. 
This small variability in migration time for a given species  between runs means that 
peaks can be unambiguously identified by their migration time. 
 
 
 
  83 
The reproducibility (inter-assay variation) of the method was determined using certified 
quality control material. Four levels of control material were analyzed with each 
calibration; the results are summarized in Table 2.3.  
 
 
Table 2.3 Reproducibility of capillary electrophoresis results 
For the urine control material, n=14, and for the serum control material, 
n=11. 
 
 
 
2.4.2 Measurement of anions in urine 
 
A pair of overlaid traces showing analysis of actual urine samples is shown in Figure 2.6. 
These samples came from one animal during a clearance experiment, during which MEPE 
Analyte Quality control material Target mean, +/- SD (mmol/L) 
Measured 
mean 
(mmol/L) 
Standard 
deviation 
(mmol/L) 
Cl 
Sigma Urine level 1 79 (75-83) 81 4.0 
Sigma Urine level 2 220 (209-231) 228 21.0 
Accutrol Serum Normal 100 (89-111) 105 4.7 
Accutrol Serum Abnormal 113 (101-125) 116 10.4 
PO4 
Sigma Urine level 1 11 (8-14) 11.8 1.0 
Sigma Urine level 2 28 (21-35) 29.2 3.2 
Accutrol Serum Normal 1.2 (0.9-1.4) 1.1 0.7 
Accutrol Serum Abnormal 2.3 (2.0-2.6) 2.4 0.5 
HCO3 
Accutrol Serum Normal 16 (10-22) 16.6 2.8 
Accutrol Serum Abnormal 26 (18-34) 29.6 4.1 
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was infused. As can be seen from these traces, the predominant anion found in urine 
samples is chloride, with variable amounts of phosphate (in this case very little before, 
and significantly more after, MEPE infusion, see chapter 3).  
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Figure 2.6 Capillary electrophoresis traces of rat urine 
Two traces taken at different time points from the same animal are overlaid. 
 
 
2.4.2.1 Unknown peaks 
 
Various unknown peaks are seen in some of the urine samples, as well as the chloride and 
phosphate peaks identified above. These can be unambiguously identified only by 
addition of standard solutions of possible anions and demonstration of co-migration of the 
  85 
resulting peaks. Despite performing this procedure with a range of plausible anions 
(including urate, oxalate, citrate, sulphate and sulphite), some peaks remain unidentified, 
although the presence of significant amounts of citrate and oxalate in rat urine was 
confirmed. Other workers also frequently find unidentified peaks (Wildman et al, 1991; 
Capasso et al, 2002).   
 
2.4.2.2 Extension of the capillary electrophoresis technique to measurement 
of other anions 
 
2.4.2.2.1 Iothalamate 
 
Radiolabelled iothalamate has been widely used as a marker of GFR, as this substance is 
cleared from the plasma by glomerular filtration without significant reabsorption or 
secretion by the renal tubules (Levey et al, 1993). Direct comparison with DTPA and 
inulin clearances, two other standard techniques for determining GFR, showed virtually 
identical results in patients with renal disease (Perrone et al, 1990). Because of the 
advantages of avoiding radioactivity use, there has been interest in using non-
radiolabelled iothalamate, measuring iothalamate in the urine by a range of techniques, 
e.g. high-performance liquid chromatography (HPLC) (Agarwal, 2003).  Iothalamate 
determination by CE has also been used to determine GFR in humans (Wilson et al, 
1997). These workers injected iothalamate subcutaneously and measured it in serum and 
urine by CE, reporting excellent correlation with an isotopic method. It is not clear 
whether the lack of subsequent reports on this technique represents indifference or 
widespread acceptance, but the former seems more likely, despite advantages including 
avoidance of radioactivity and possible cost reduction.  
Iothalamate detection by capillary electrophoresis has also been used to determine single-
nephron tubular fluid reabsorption in isolated rat tubular preparations, in which the 
iothalamate was added directly to the tubular fluid (Capasso et al, 2002). 
I therefore performed experiments to determine whether this anion could be detected using 
our method, as an addition to the detection of other anions. Figure 2.7 shows an 
electropherogram of a chloride, bicarbonate and phosphate multi-anion standard with 
iothalamate added at 8 µmol/L (equivalent to 1.6 mmol/L before 200 fold dilution). The 
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iothalamate peak is quite distinct from all the other anions; there is no overlap or 
interference. The iothalamate peak is negative rather than positive in orientation because 
the other anions are detected indirectly (by displacement of chromium ions in the running 
buffer) whilst iothalamate is detected directly from its absorbance at 254nm. Figure 2.8 
shows an overlay of peaks produced by a range of concentrations of iothalamate, and 
demonstrates that peak area is proportional to iothalamate concentration. These results 
indicate that the described technique can potentially be expanded to allow detection of 
iothalamate simultaneously with the other anions. 
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Figure 2.7 Electropherogram of a standard solution containing 
iothalamate, chloride, phosphate and bicarbonate.  
The standard solution contained chloride 50 mmol/L, phosphate 11 mmol/L, 
bicarbonate 15 mmol/L and iothalamate 1.6 mmol/L.  
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Figure 2.8 Overlay of iothalamate peaks at a range of concentrations 
 
 
2.4.2.2.2 Citrate and oxalate 
 
Citrate and oxalate are clinically important anions in urine, because they are significant in 
the development of kidney stones. Citrate acts to reduce the risk of calcium-containing 
stones, whilst excessive oxalate can lead to calcium oxalate stones. Capillary 
electrophoresis has been used to assay these anions in clinical urine samples as part of a 
stone screening process (Garcia et al, 2001). Direct detection was used by these workers 
as they were interested in organic acids only.  I looked for citrate and oxalate not only in  
urine but also tubular fluid using indirect detection and found it was possible to 
demonstrate citrate in both, as shown below. Urinary oxalate was usually too low to be 
detected by this method, although the method will allow detection of high levels of 
oxalate. The identity of peaks was confirmed by spiking samples with known 
Time, minutes 
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concentrations of the anions in question; see Figure 2.9 for an illustration of the 
identification of a citrate peak in urine.  
Time (minutes)
A
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Initial trace
Trace after addition of citrate solution
 
Figure 2.9 Illustration of identification of citrate peak in a urine sample 
The peak is positively identified by spiking the sample with a citrate solution 
and repeating the analysis; the citrate peak is increased whilst other peaks 
are little changed. 
 
2.4.2.2.3 Urate 
 
Urate represents the final means of disposal of purines and is often present in significant 
concentrations in the urine, at or near its solubility limit. I tested for the presence of urate 
peaks by spiking samples with urate solutions. Because urate is not very soluble in 
aqueous solutions, I used a few drops of 10M sodium hydroxide to help get the urate into 
solution (final hydroxide ion concentration approximately 5mmol/L in the urate standard 
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solution); the initial traces showed a pair of peaks when I was expecting only one. 
Subsequent work demonstrated that these two peaks corresponded to hydroxide and urate, 
respectively. Examination of urine samples for urate confirmed that capillary 
electrophoresis was able to detect urate in urine. As my main interest was in phosphate 
measurement, I did not attempt to quantify urinary urate levels, but was able to confirm 
that the urate peak lay well away from the areas of interest for phosphate, chloride or 
bicarbonate.  
 
 
2.4.3 Use of capillary electrophoresis to measure anions 
in tubular fluid 
 
2.4.3.1 Adaptations to the technique 
 
There are a number of important differences between tubular fluid and urine that have a 
bearing on analysis of tubular fluid. The most obvious and important is the question of 
sample volume. Urine samples in rats are usually available in volumes measured in 
millilitres (baseline urine output in a free-living rat is quoted as approximately 1ml/hr [e.g. 
in Shirley et al, 1989], although experimental urine output depends largely on the rate of 
intravenous fluid infusion during the procedure). In contrast, tubular fluid obtained by 
micropuncture is available in volumes measured in nanolitres, with end-proximal tubular 
flow rates of 10-20nl/min and distal tubular flow rates of around 5-10nl/min (Walter et al, 
1988).This means that a range of techniques for working with and analyzing such small 
volumes is required. Capillary electrophoresis is suited to the analysis of such small 
volumes because it uses (indeed requires) diluted samples - for example, a 30nl sample 
becomes a more manageable  6µl after dilution to 200 times its original volume in water. 
 
2.4.3.2 Microvials 
 
When analyzing a sample, the vial containing the sample is placed in a rotating tray in the 
CE machine. The machine is able to use either standard 1ml vials, holding 200-500µl of 
diluted sample, or microvials, holding 5-50µl of diluted sample, which allow smaller 
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sample volumes to be analysed. These microvials have a different shape from normal 
vials, and one consequence is a considerable increase in surface-to-volume ratio (see 
Figure 2.10 for a diagrammatic representation of this). This has implications for analyses 
of ions that might be susceptible to interactions with the atmosphere - in particular 
bicarbonate - and might lead to concerns about evaporation. 
microsample
microvial
sample
vial
vial microvial
sample microsample
 
 
Figure 2.10 Conventional and microvials used for capillary 
electrophoresis 
 
 
 
Figure 2.11 shows two standard curves for bicarbonate; one is with conventional vials 
(and has already been shown in Figure 2.5) whilst the other is with the microvials. It can 
be seen that there is a somewhat greater degree of scatter of the data when using 
microvials; with microvials the correlation coefficient was 0.981, and with standard vials 
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it was 0.997. In contrast, chloride and phosphate gave identical curves with the two types 
of vial; for a comparison between the results for phosphate with the two types of vial, see 
Figure 2.12. A further difference to note between the analysis of bicarbonate and of 
phosphate and chloride is that for the latter two ions the calibration curve passes through 
zero, while for bicarbonate it does not: when the blank (water) was tested a (small) peak 
was seen. These observations suggest that there is significant uptake of atmospheric 
carbon dioxide by the sample. It may be that this uptake of carbon dioxide from the 
atmosphere is more variable in microvials than in standard vials, leading to the less 
accurate determination of bicarbonate in microsamples. 
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Figure 2.11 Calibration curves for bicarbonate in standard vials and in 
microvials 
The solid lines represent the best-fit line determined by linear regression. 
(A) standard vials ;    y=9.63x+48.62; r= 0.997 
(B) microvials ;          y=7.78x+60.10; r=0.981 
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Figure 2.12 Calibration curve for phosphate in standard vials and in 
microvials 
The solid lines represent the best-fit line determined by linear regression.  
(A) standard vials;   y=20.68x-5.65; r=0.999 
(B)  microvials;        y=21.02x-11.4; r=0.999 
 
 
  95 
Figure 2.13 shows the results from a series of tubular fluid samples collected by free-flow 
micropuncture from intact and thyroparathyroidectomised rats (for micropuncture 
methods, see chapter 4; the thyroparathyroidectomised rats were purchased from Harlan 
UK, Bicester, Oxfordshire, UK), indicating that the CE techniques described in this 
chapter are applicable to biological micro-samples and can demonstrate changes in 
phosphate and chloride concentrations under experimental conditions. Note that, in 
contrast to the findings in intact animals, phosphate was undetectable (as can be seen in 
Figure 2.13 C) in the distal tubular fluid of thyroparathyroidectomised animals. Note also 
that the results demonstrate that distal tubular fluid chloride concentrations are less than 
half those found in the proximal tubule, in keeping with current knowledge of tubular 
function.
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Figure 2.13 Tubular samples obtained during free-flow micropuncture  
 (A) Proximal tubular fluid from an intact animal. Chloride is 134 mmol/L 
and phosphate 1.7 mmol/L. (B) Distal tubular fluid from the same animal. 
Chloride is 47 mmol/L and phosphate 2.1 mmol/L. (C) Distal tubular fluid 
from a thyroparathyroidectomised animal. Chloride is 55 mmol/L and 
phosphate is below 0.3 mmol/L; this corresponded with undetectable 
urinary phosphate excretion. 
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Figure 2.14 shows a urine sample from an intact rat, collected at the same time as the 
tubular samples in Figure 2.13 A and B. Note that, in comparison with the tubular 
samples, urine has a much higher chloride concentration, no bicarbonate and detectable 
amounts of nitrate and citrate; the identity of these last two peaks was confirmed by 
‘spiking’ the urine samples with standard solutions. 
 
 
 
Figure 2.14 Urine sample from a normal rat, collected simultaneously 
with tubular fluid samples shown in Figure 2.13 A and B. 
In this sample, chloride is 239 mmol/L and phosphate 29 mmol/L. Note that 
bicarbonate is undetectable in the urine, and that the urine contains 
detectable amounts of nitrate and citrate. 
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2.4.3.3 Direct comparison with the NANOFLO technique 
 
Other than CE, no straightforward method of determining non-radioactive phosphate in 
biological microsamples using off-the-shelf equipment is available. I wanted to assess the 
CE technique for anion measurements by comparison with an established technique, and 
therefore compared CE results for chloride (rather than phosphate) with those obtained 
using an established alternative technique for the determination of chloride in tubular fluid 
samples - the NANOFLO, a commercially available system based on flow-through 
microfluorometry of directly injected samples (Zhelyaskov et al, 2000). The latter 
technique uses the fluorescent reaction of lucigenin with chloride ions to generate a signal. 
The fluorescent dye lucigenin reacts with halides to produce quenching of fluorescence, 
which is greatest around the 500nm wavelength (Wissing & Smith, 2000). The dye also 
responds to other halides, but as none of these is present in significant quantity in tubular 
fluid it is reasonable to assume that all the reaction is due to chloride ions. There is also 
some potential quenching with citrate, but again the concentration difference expected 
between chloride and citrate in tubular samples means that this is not likely to be a 
significant source of error.  
Samples of known volume are injected into a capillary system, through which there is a 
continuous and constant flow of lucigenin in buffer. The sample is then carried past a 
detector, where the quenching reaction between chloride ions and lucigenin produces a 
change in detector output. The change is related to the amount of chloride in the injected 
sample, and chloride concentration can thus be calculated from a standard curve. The 
standard curve is generated by injection of solutions of known chloride concentration and 
plotting of trough height over background. 
 
This method of detecting chloride in microsamples is used routinely in several 
micropuncture laboratories. 
 
2.4.3.3.1 Technical details of the NANOFLO method 
 
The NANOFLO instrument is commercially available, produced by World Precision 
Instruments Inc (Sarasota, Florida, USA). Results were acquired and analysed using the 
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DUO18 software, also produced by WPI. Solutions of saline and lucigenin were produced 
from analytical grade chemicals (Sigma-Aldrich, Poole, Dorset, UK) and reverse-osmosis 
purified water. An illustration of the machine is shown in Figure 2.15. 
Light source Sampling pipette
detector
Fibre-optic
cable
syringe
Buffer solution
 
Figure 2.15 Schematic diagram of the NANOFLO instrument 
Buffer solution (containing lucigenin) is continuously pulled through the 
apparatus by the syringe at a rate of 0.3ml/hr. Samples are injected, using a 
calibrated sampling pipette, through a small port in the top of the apparatus 
and then mix with the lucigenin, before being passed in front of the detector 
and illuminated with light at the desired wave-length.  
 
I followed exactly the published NANOFLO method of Zhelyaskov et al (Zhelyaskov et 
al, 2000) but found that this gave very large biphasic peaks which overwhelmed the 
sensitivity of the detector. Subsequently, I tried using much lower concentrations of 
lucigenin, but then had difficulty with the detection limit. After personal correspondence 
with the author of the previous work, a wratten (neutral) filter was placed in the light path 
(Eastman Kodak, Rochester, New York, USA) and this produced results which closely 
duplicated the previously published work. Results with the NANOFLO showed greater 
variability than with CE and the machine is technically challenging to use. In addition, the 
detection limit is significantly higher than with CE, at about 10mmol/L chloride in a 10nl 
sample. One further point to make is that the original paper on the NANOFLO does not 
include any biological samples, but only pure standards made up in water. My experience 
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with the NANOFLO was that it was a great deal easier to get reproducible results with 
standards than with biological samples, perhaps because the standards were not stored 
under oil.  
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Figure 2.16 Illustrative trace showing results from the NANOFLO using 
saline standards 
 
An illustrative trace showing a series of samples used to construct a calibration curve 
using the NANOFLO is shown in Figure 2.16. These samples were made from standard 
sodium chloride solutions made up in HEPES buffer. Representative traces from the 
machine in operation are shown in Figure 2.17. Note that chloride is detected as a negative 
peak, and that the depth of each trough compared to the preceding background signal is 
used to calculate the ratio F1/F0. Injection of water or buffer alone gave no trough. The 
calibration curves were generally satisfactory, with r>0.99, but there was a tendency for 
the baseline to fall with time as the fluorescence became bleached. Consequently, the 
method is limited in the number of samples per day that can be analysed. All samples 
were analysed in duplicate, as can be seen from the example traces shown. 
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Figure 2.17 Illustrative NANOFLO trace with two samples and a 
standard 
 
 
2.4.3.3.2 Comparison of results between the NANOFLO and 
capillary electrophoresis methods 
 
Comparison of results between the two methods (with respect to chloride concentration) 
showed reasonable agreement. Results are presented directly against one another in Figure 
2.18. Each point represents a biological sample (not a standard solution), either urine or 
tubular fluid, analyzed by both methods. The correlation coefficient was 0.980.  
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Figure 2.18 Comparison between values obtained for chloride 
concentration (in urine and tubular fluid) by capillary electrophoresis 
and NANOFLO 
y=1.041x-2.856; r= 0.98. 
 
Correlation coefficients alone say little about the level of agreement between two 
measurement methods. Given that the two methods are attempting to measure the same 
thing (in this case chloride ion concentration), it is almost inevitable that they will be 
correlated. For this reason, results were also compared by the use of a Bland-Altman plot 
(Bland & Altman, 1986) in Figure 2.19. This contains the same data as Figure 2.18, but 
for each data point the difference between the values found using the two methods 
(calculated by subtracting the value found by CE from the value found by NANOFLO) 
was plotted against the average value. This form of analysis allows both a better measure 
of the agreement between the two methods and a visual check of the scatter of the data. It 
also allows a check for any systematic bias in which scatter depends on the value being 
measured. As all but two points fell between the lines indicating two standard deviations, 
and as these two points are in the middle of the range of values, this demonstrates an 
absence of systematic bias between the two methods. 
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Figure 2.19 Bland-Altman plot showing difference against mean for 
chloride concentration determined by capillary electrophoresis and by 
NANOFLO 
 The solid line represents the mean difference (in this case, close to zero) 
while the dashed lines represent two standard deviations of the difference. 
 
 
 
2.4.4 Use of capillary electrophoresis to measure anions 
in plasma 
 
2.4.4.1 Adaptations to the technique 
 
There is a limit to the volume which can be taken from a rat’s circulation (typical blood 
volume 15-20ml) during an experiment without disturbing renal and systemic 
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haemodynamics. If serum phosphate is to be measured repeatedly during an experiment, it 
must be measured in very small volumes, as blood is also being taken hourly for GFR 
determination. Many workers get round this by measuring the serum chemistry only at the 
end of the experiment, when larger volumes of blood can be obtained by aortic puncture 
and there is no concern about affecting the GFR.  However, this obviously cannot measure 
changes in phosphate during the experimental period. I therefore modified the capillary 
electrophoresis method to measure anions in small samples of plasma.  
The major difficulty encountered in the analysis of anions in plasma samples by capillary 
electrophoresis is the presence of plasma proteins in the samples. These proteins coat the 
capillary, altering transit times and peak heights. I decided against trying to deproteinate 
the samples, as has been reported by others (Wilson et al, 1997), on the basis that repeated 
washings with sulphuric acid and sodium hydroxide would introduce too many potential 
contaminants. I decided instead to wash the capillary after each run. Repeated 
experimentation showed that highly reproducible results could be obtained by rinsing the 
capillary with 0.1 M sodium hydroxide between each sample and by alternating protein-
containing samples (for example, plasma) with non-protein containing samples (for 
example, standards). Davydova and coworkers, using direct UV detection, measured 
plasma at a dilution of 1:10 (Davydova et al, 1999). Despite a deproteination step, they 
also found that plasma assays required extensive rinsing with sodium hydroxide and 
water, steps not required when assaying tubular fluid or urine.  
 
 
2.4.4.2 Results for plasma 
 
My principal interest was in plasma phosphate. Plasma samples were taken 
simultaneously with the urine (and tubular fluid) samples; plasma phosphate 
determinations allowed calculation of phosphate clearances. However, I also determined 
plasma chloride routinely as it provided a check on the dilution of the samples - dilution 
error being a potential source of misleading results. As plasma chloride in rats is around 
105mmol/l (Cowley et al, 1997), samples in which chloride values differed substantially 
from this were rejected, and duplicate samples reanalysed. 
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A typical trace of normal rat plasma is shown in Figure 2.20. The main anions present are 
chloride, bicarbonate and phosphate, in that order. 
 
 
 
Figure 2.20 Illustrative capillary electrophoresis trace of normal rat 
plasma 
Chloride concentration is 104 mmol/L, phosphate 2.1 mmol/L and 
bicarbonate 22 mmol/L 
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2.5 Conclusions  
 
The capillary electrophoresis technique described has been developed to the point where it 
is an accurate and reproducible means of measuring numerous anions in small biological 
samples, including plasma, urine and tubular fluid. It has particular advantages for very 
small samples, allowing multiple assays on a single sample, although there are problems 
with the measurement of bicarbonate, possibly owing to carbon dioxide uptake by 
microsamples. The method is nevertheless extremely useful for the measurement of 
phosphate in tubular fluid samples, a requirement of a major section of this thesis. 
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Chapter 3 
Investigation of the renal effects of MEPE: 
clearance studies 
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3.1 Introduction 
 
Clearance experiments allow quantification and analysis of the effects of postulated 
regulators of renal function on the handling of substances by the nephron. The renal 
clearance of a marker substance that is freely filtered and neither secreted nor reabsorbed 
by the kidney (for example, inulin) is a measure of  GFR. Comparison of this with the 
clearance of the substance of interest, for example phosphate, allows calculation of net 
reabsorption or secretion. 
 
Clearance experiments have been used extensively to investigate renal phosphate 
reabsorption, going back to the original demonstration that the process could be saturated. 
Frick (Frick, 1968) infused increasing concentrations of phosphate into anaesthetised rats 
and demonstrated that, as plasma phosphate levels were increased, reabsorption of 
phosphate increased and eventually reached a maximum level. The inference drawn by 
this author (and subsequently shown to be correct, see Chapter 1) was that, rather than 
being reabsorbed by simple diffusion, phosphate transport must involve carrier proteins 
that can be saturated.   
 
As discussed in Chapter 1, Rowe and colleagues have previously reported on the effects of 
MEPE on phosphate excretion in mice (Rowe et al, 2004). In this work they gave MEPE 
by repetitive intraperitoneal injection and measured urine and serum phosphate and 
creatinine. Their results suggested that MEPE increased fractional phosphate excretion. 
However, creatinine clearance is not a reliable marker of GFR in rodents, as creatinine has 
been shown to be both secreted and extensively reabsorbed (Namnum et al, 1983). 
Furthermore, because the urine samples in Rowe’s study were of small volume, urine 
samples from all the animals were pooled for analysis.  The experiment was performed 
twice and the results described as ‘the same’, but no statistical measure of variability was 
provided. Therefore, it is not possible from this previous work to be sure that tubular 
reabsorption of phosphate was altered.  
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The key issue to be investigated initially in the present study was whether MEPE is in fact 
a phosphaturic substance. Since PTH is known to be phosphaturic and its action has been 
extensively studied, I chose to use it as a positive control. The chief biological actions of 
PTH are due to its first 34 amino-acids (reviewed in Mannstadt et al, 1999), so most 
workers in this field use PTH (1-34); this compound was used in the present study.  
 
3.1.1 A note on rat models in the study of human 
physiology 
 
Some areas of phosphate physiology are relatively well studied in human populations - for 
example, the hereditary hypophosphataemias and phosphate balance in renal failure and 
dialysis patients - usually when abnormalities of phosphate balance lead to obvious 
disease states. Other areas of phosphate physiology will never be straightforward to study 
in humans, for example the nephron sites involved in phosphate reabsorption, or changes 
in phosphate transporter numbers in response to stimuli. In these areas, research is 
performed in animals - historically in rats, more recently (because of greater ease in 
genetic manipulation) also in mice. The rat (Rat Genome Consortium, Gibbs et al, 2004) 
and mouse (Mouse Genome Consortium, Waterston et al, 2002) genomes have been 
sequenced, as, of course, has the human genome. The similarities between genomes are 
more striking than the differences, and almost every significant disease-causing gene in 
humans has been found to have mouse and rat homologues. Care should however always 
be taken when extrapolating from rodents to humans - clearly there are some significant 
differences! 
 
3.2 Aims of the present study 
 
As discussed in Chapter 1, MEPE is a novel protein first isolated from patients with 
oncogenic osteomalacia, a syndrome in which there is a circulating phosphaturic 
substance. I aimed to discover whether MEPE would cause phosphaturia when infused 
into intact animals. To this end, I infused a range of doses of MEPE so as to construct a 
dose-response curve. In addition, I measured GFR and the filtered phosphate load, so as to 
allow calculation of the tubular reabsorption of phosphate.  
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3.3 Methods 
 
3.3.1 Experimental protocol 
 
Prior to the clearance surgery, rats were kept in the university’s animal facility and fed a 
standard diet (Rat and Mouse No.1 maintenance, Special Diets Services, Witham, Essex 
UK). They were allowed unlimited access to food and water, and the food contained 0.5% 
total phosphorus and 600 IU/kg of Vitamin D3.   
 
Adult male Sprague-Dawley rats, of mean body weight 247g (range 225-300g), were 
anaesthetised with intraperitoneal sodium thiopentone (100mg/kg body weight; Link 
Pharmaceuticals, Horsham, Sussex). Animals were monitored throughout the experiments 
for any sign of responsiveness by assessing the reaction to pinching the feet, and further 
anaesthetic was given as required in the form of intravenous boluses of 5-10 mg/kg body 
weight of sodium thiopentone. Temperature was monitored continuously by means of a 
rectal thermometer; animals were placed on a thermostatically controlled warming table 
which maintained their temperature at 370C. At the end of the experiments, animals were 
killed by overdose of sodium thiopentone without recovery of consciousness. 
 
The right jugular vein was cannulated with two cannulae made from polyethylene tubing 
(Portex Plastics, Hythe, Kent), which were used for infusions of saline, tritiated inulin, 
MEPE or PTH, as required.  NaCl  0.9% solution was infused throughout the experiment 
at 4ml/hr. The skin was divided in the anterior neck and a tracheotomy was performed 
using cautery; the trachea was supported for the remainder of the experiment by means of 
a polyethylene tube placed under it. A lower abdominal incision was used to expose the 
bladder, which was then catheterised using shaped polyethylene tubing. This bladder 
catheter was sutured into place, with the sutures round the bladder ensuring a minimal 
residual volume. The left femoral artery was cannulated using polyethylene tubing and the 
arterial catheter was primed with saline containing heparin. Arterial blood pressure was 
monitored continuously throughout the experiment using a blood pressure transducer 
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(model 1050.1, UFI, Morro Bay, CA, USA) and MacLab recording system (AD 
Instruments, Chalgrove, Oxon, UK) attached to the arterial catheter.  
 
Thirty minutes after surgery was completed, animals were given a bolus of tritiated inulin 
(2 µCi, Amersham Biosciences, Little Chalfont, Bucks, UK) followed by a continuous 
infusion of tritiated inulin at 2 µCi/ hour. Urine output was determined hourly by 
weighing the urine produced (and assuming a specific gravity of 1.0). 
 
After a further hour of equilibration, excretion rates and clearances were determined for 
one hour (control period). Blood samples were collected hourly from the arterial catheter. 
Each sample was approximately 100µl and was collected by unclamping the catheter and 
allowing blood to flow slowly under arterial pressure into a sample collection vial. The 
arterial catheter was then re-primed with a small volume of heparinised saline. Blood 
samples were spun at 1500g for five minutes and the plasma samples thus generated were 
split for tritium and phosphate analysis. Urine samples obtained from the bladder catheter 
were mixed briefly, and then aliquots were taken for tritium and phosphate analysis.  
 
After the one-hour control period, the infusion was changed to include PTH (20 μg/h; 
PTH 1-34, Sigma Ltd, Watford, Herts UK) or MEPE (at doses of 30 μg/h [MEPE 1], 100 
μg/h [MEPE 2] or 300 μg/h [MEPE 3]; recombinant full-length human MEPE, raised in 
insect Spodoptera Frugiperda cells, a gift from Acologix, Hayward, CA, USA), or 
continued as saline alone (vehicle controls), for the following two hours (n=6 rats per 
group). The second of these two hours was designated the experimental period, during 
which time excretion rates and clearances were determined again. The experimental 
procedure is summarised in Figure 3.1. 
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Control hour Experimental hour
Completion of surgery Saline, PTH or MEPE
Time, hours
1 3 42
3H inulin infusion
3H inulin bolus
0
 
Figure 3.1 Clearance protocol 
 
 
 
3.3.2 Analyses 
 
The activities of tritiated inulin in plasma and urine were determined by scintillation 
counting of 10 µl aliquots of spun plasma and urine (Packard Tricarb, Model 2900TR; 
Pangbourne, Berks, UK) after dispersal in Ultima Gold scintillation fluid (PerkinElmer, 
Beaconsfield, Bucks, UK). Three aliquots were taken from each sample; values obtained 
from the three were averaged unless one was clearly much different from the other two, in 
which case the two agreeing values were averaged. Plasma and urine phosphate levels 
were measured by capillary electrophoresis (CE) as described in Chapter 2. Urine samples 
were diluted 1:200 in ultrapure water, then frozen for later CE analysis. Plasma samples 
were diluted 1:100 in ultrapure water, then frozen for later CE analysis. 
Sodium concentrations in urine were measured by flame photometry (model 543, 
Instrumentation Laboratory, Warrington UK), following appropriate dilution if required.  
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3.3.3 Calculations 
 
 
Glomerular filtration rate was calculated as inulin clearance: 
 
             GFR= Cin = [Uin ] x VU/[Pin], where 
 
Cin  = inulin clearance  
[Uin]  = urinary inulin count 
VU  = urine flow rate  
[Pin]  = plasma inulin count. 
 
  
Phosphate clearance (CPi) was calculated as: 
 
               CPi = [UPi] x VU /[PPi], where  
 
[UPi]  = urinary phosphate concentration 
[PPi]  = plasma phosphate concentration. 
 
For clearance values during the control period, the plasma phosphate concentration in the 
first blood sample was used; for clearance values during the experimental period, the 
plasma phosphate concentration in the final blood sample was used. 
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Fractional excretion of phosphate (FEPi) was calculated as: 
 
             FEPi = CPi/GFR. 
 
Filtered load of phosphate at the glomerulus was calculated, on the assumption that 
phosphate is freely filtered, as: 
 
    Filtered load = GFR x [PPi]. 
 
3.3.4 Statistics 
 
Results are presented as mean values ± standard error of the mean (SEM). Comparisons 
between the results during the control and experimental periods in each group of animals 
were made using Student’s paired t-test. One-way ANOVA was used to compare the five 
groups during the control period and during the experimental period. Two-way ANOVA 
was used when groups in both control and experimental periods were compared 
simultaneously, followed, where appropriate, by Bonferroni’s test for multiple 
comparisons. Comparison of the change in FEPi in each MEPE-treated group with that in 
the vehicle group was made by one-way ANOVA followed by Dunnett’s multiple 
comparisons test. In all cases, a p- value of less than 0.05 was considered statistically 
significant.  
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3.4 Results 
 
3.4.1 Blood pressure 
 
Figure 3.2 shows the mean arterial pressure in each group of animals. There was no 
significant difference between any of the groups during either the control period or the 
experimental period. 
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Figure 3.2 Mean arterial pressure  
Results are presented as mean values ± SEM. In each group, n=6 rats. 
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3.4.2 Glomerular filtration rate (GFR) 
 
GFR was measured during the control and experimental period in each animal. Figure 3.3 
shows the mean (± SEM) values for GFR for each of the five groups of animals.  
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Figure 3.3 Glomerular filtration rate 
Results are presented as mean values ± SEM. In each group, n=6 rats 
 
There was no significant difference between groups either before or after treatment. 
Although there was a slight tendency for GFR to fall over the period of the experiment in 
some animals, this did not reach significance in any of the groups. 
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3.4.3 Sodium excretion 
 
These data are shown in Table 3.1. 
 
 
Table 3.1 Sodium excretion  
 Results (µmol/h) are given as mean values ± SEM; n=6 rats in each group.  
P values refer to differences between the control and experimental periods 
within each group, compared using Student’s paired t-test. 
 
 
There was no significant difference in urinary sodium excretion between groups before or 
after treatment.  Mean sodium excretion rose in every group during the course of the 
experiment, but the variance was large and the only statistically significant increase in any 
group was in that receiving the intermediate dose of MEPE.  
 
 
 
 Control period 
P 
Experimental period 
Saline 219 ± 46 0.74 240 ± 40 
PTH 193 ± 22 0.63 241± 88 
MEPE 1 189 ± 56 0.37 257 ± 26 
MEPE 2 175 ± 44 0.05 213 ± 40 
MEPE 3 222 ± 46 0.34 237 ± 40 
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3.4.4 Absolute phosphate excretion 
 
Baseline (control period) urinary phosphate excretion was highly variable between 
animals, but the mean values in each group were similar; see Figure 3.4. 
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Figure 3.4 Absolute phosphate excretion 
Results are presented as mean values ± SEM. In each group, n=6 rats. 
 
 
Absolute phosphate excretion did not change between control and experimental periods in 
control (saline-infused) animals. In animals treated with PTH, there was a marked increase 
in phosphate excretion, as expected. In animals infused with the lowest dose of MEPE, 
there was a small (but statistically significant) rise in phosphate excretion, and in those 
treated with the two higher doses there was a large increase in phosphate excretion, which 
was statistically significant in both cases. 
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3.4.5 Plasma phosphate 
 
Plasma phosphate did not differ between groups during the control period or during the 
experimental period. Although there was a trend towards a fall in plasma phosphate 
between control and experimental periods in all groups, this did not reach statistical 
significance (see Table 3.2). The largest fall was in the PTH-treated rats, but even here it 
just failed to reach significance.  
 
 
Table 3.2 Plasma phosphate concentrations 
Results are in mmol/L, expressed as mean values ± SEM. In each group, n = 
6 rats. 
 
 Control period 
P 
Experimental period 
Saline 2.18 ± 0.09 0.37 2.00 ± 0.07 
PTH 2.15 ± 0.12 0.09 1.92 ± 0.15 
MEPE 1 2.14 ± 0.09 0.63 2.05 ± 0.06 
MEPE 2 2.12 ± 0.12 0.84 2.02 ± 0.11 
MEPE 3 2.10 ± 0.03 0.55 2.02 ± 0.12 
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3.4.6 Filtered load of phosphate 
 
The measurements of GFR and plasma phosphate concentration indicated that the PTH- 
and MEPE-induced increases in phosphate excretion could not be attributed to the filtered 
load of phosphate. However, in order to confirm that changes in urine phosphate excretion 
were due to a change in renal tubular phosphate handling, the filtered load of phosphate 
was calculated for each animal. These results are shown in Figure 3.5. The filtered load 
fell slightly between control and experimental periods in every group of animals, but only 
in the MEPE 1 group did this fall reach statistical significance.  
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Figure 3.5 Filtered load of phosphate 
Results are presented as mean values ± SEM.  In each group, n= 6 rats. 
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3.4.7 Fractional phosphate excretion 
 
Fractional phosphate excretion (FEPi; Figure 3.6) echoed the absolute excretion rates. 
Thus, FEPi remained unchanged in the control animals; there was a marked increase in 
FEPi in animals given PTH; and there was a dose-dependent increase in FEPi in animals 
infused with MEPE.   
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Figure 3.6 Fractional phosphate excretion  
Results are presented as mean values ± SEM. In each group, n=6. 
 
 
 
 
In order to determine the dose-response curve for MEPE, the results shown in Figure 3.6 
were recalculated, taking the change in FEPi between the control and experimental periods 
for each rat (∆FEPi). These data are shown in Figure 3.7. 
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Figure 3.7 Dose-response curve for the effect of MEPE on FEPi 
Results are expressed as mean values ± SEM. In each group, n=6. 
Note that the x-axis of this graph is a log scale. 
* p<0.01 compared with vehicle- infused rats. 
 
 The change in fractional phosphate excretion was significantly larger than that seen in the 
control animals (p<0.01) for both of the higher doses of MEPE, but not for the low dose.  
 
 
 
 
Statistical note 
In addition to using paired and unpaired t tests, all the data in this chapter were analysed 
by two-way ANOVA, examining the interaction between time and treatment. For blood 
pressure, GFR, sodium excretion, filtered phosphate load and serum phosphate, there were 
no significant changes for either time or treatment effects. However, significant changes 
were seen for absolute and fractional phosphate excretion. Post-hoc testing of these data 
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using Bonferroni’s multiple comparisons test showed significant treatment effects for 
PTH and both of the larger doses of MEPE, but not (for fractional phosphate excretion) 
for the low dose of MEPE (see Table 3.3) . 
 
Experimental group 
p-value for Bonferroni 
post-hoc testing of 
absolute phosphate 
excretion 
p-value for Bonferroni 
post-hoc testing of FEPi 
Vehicle ns ns 
PTH <0.01 <0.01 
MEPE 1 <0.05 ns 
MEPE 2 <0.01 <0.01 
MEPE 3 <0.01 <0.01 
 
Table 3.3 Post-hoc testing of results significant by 2-way ANOVA 
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3.5 Discussion 
 
Typical GFR values for clearance experiments using adult Sprague-Dawley rats are in the 
range 1.5-3 ml/min (Webster & Haramati, 1985). Many authors used slightly larger 
animals than I did (for example Burnatowska-Hledin et al, 1985: average weight 300g, 
GFR 2.3ml/min; Carney and Thompson, 1982: average weight 330g, GFR 2.6ml/min). 
For animals of 250g, as used in the experiments described in this chapter, a mean GFR of 
around 2ml/min is well within the range of values quoted by others.  
Fractional excretion of phosphate (FEPi) at the start of an experiment  depends  in part on 
the animals’ diet, and might vary between workers depending on this; mean values in 
control animals (male Sprague-Dawley rats) used in the clearance experiments of Berndt 
et al (Berndt et al, 2003) were 10%, with some increase over time in saline-infused 
animals. Other workers have found values for FEPi in control animals ranging from 10 - 
15% (Burnatowska-Hledin et al, 1985; Rybczynska et al, 2006) to almost 30% (Pflueger 
et al, 1998). The values I found (around 10%) are therefore at the lower end of these 
previously reported observations. 
 
The dose of PTH used in the present experiments is similar to that used by Murer and 
colleagues (Kempson et al, 1995), and in their hands it also caused a highly significant 
change in urinary phosphate excretion, with fractional excretion of phosphate roughly 
doubled by PTH infusion. Some workers (e.g. Zhang et al, 1999) have reported that PTH 
infusion into rats causes a significant diuresis and natriuresis. In addition, clearance 
experiments using PTH infusions have shown significant effects on GFR in humans 
(Jespersen et al, 1997). However, these reports are offset by other clearance studies 
(Harris et al, 1979; Gloor et al, 1979) in which no significant effect of PTH on either GFR 
or fractional sodium excretion were observed. I found no significant effect of PTH 
infusion on either GFR or urine sodium excretion. Although there was a tendency for 
urine sodium excretion to increase in all groups of animals over the course of the 
experiment, this increase was only statistically significant in one of the MEPE-infused 
groups.   
 
In previous work on mice, Rowe and his group used MEPE intraperitoneally (Rowe et al, 
2004). They used a protocol of repeated injections at two doses, totalling 40µg/kg and 
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400µg/kg. At the lower of these two doses they reported no significant effect of MEPE on 
‘fractional’ phosphate excretion (assessed by use of a single, pooled urine sample). At the 
higher dose, significant effects were seen. After correspondence with this group (P. Rowe, 
personal communication), I performed pilot experiments using an intravenous dose of 
MEPE (30 µg/hr over two hours), which is less (per kg body weight) than the higher of 
Rowe’s two doses. After obtaining modest increases in fractional phosphate excretion 
using this dose, I went on to construct a dose-response curve using this dose and 
successive multiples of it. 
 
The clearance results presented in this chapter demonstrate that MEPE infusions cause a 
dose-dependent phosphaturia and a dose-dependent increase in fractional phosphate 
excretion, without any significant change in GFR, serum phosphate concentration or 
filtered load of phosphate. The increase in phosphate excretion must therefore be due to a 
change in tubular phosphate handling. It is notable that the phosphaturia following the 
highest dose of MEPE approached that achieved by PTH. 
 
MEPE was originally isolated from patients with tumour-induced hypophosphataemia. 
The results presented here demonstrate that this protein might at least partly account for 
the renal phosphate wasting seen in these patients, and MEPE can therefore be put 
forward as a putative phosphatonin under these circumstances. This is not to ignore the 
fact that other substances have also been identified as putative phosphatonins in these 
patients (see Chapter 1); it may be that different patients have different proteins 
circulating or that numerous proteins circulate in some or all of these patients. It is more 
difficult to comment on a possible physiological role of MEPE (if any) as there is little 
information about the plasma concentration of MEPE in healthy humans or in healthy 
animals. Preliminary work has indicated that significant levels of MEPE do circulate in 
humans and suggests wide variations in plasma MEPE concentration between individuals 
(Jain et al, 2004). 
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3.6 Conclusions 
 
MEPE has been shown in this chapter to be phosphaturic in anaesthetised rats. A dose-
response curve has been obtained, and comparisons made with the phosphaturic effect of 
PTH, a substance known to be of physiological importance in the regulation of serum 
phosphate. The MEPE-induced phosphaturia was due to a reduction in fractional 
phosphate reabsorption rather than to changes in the filtered load of phosphate. 
 
The site of action of MEPE along the nephron could not be ascertained from the 
experiments described in this chapter, but, given the magnitude of the response and the 
fact that the bulk of phosphate reabsorption occurs in the (early) proximal tubule, this 
nephron segment must be the most likely candidate.   In support of this, in vitro studies by 
others have shown that phosphate uptake in cultured renal proximal tubule cells is reduced 
during incubation with MEPE (Rowe et al, 2004), while a recent study has reported 
MEPE immunoreactivity and mRNA in the proximal tubule (Ogbureke & Fisher, 2005). 
However, in order to assess this issue directly, examination of segmental phosphate 
transport using micropuncture experiments is required. 
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Chapter 4 
Localisation of the site of action of MEPE 
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4.1 Introduction 
 
4.1.1 Clearance methods for assessment of segmental 
reabsorption 
 
As indicated in Chapter 3, measurement of GFR can tell us how much of a substance is 
filtered at the glomerulus, and comparison with the amount excreted in the urine allows 
calculation of the overall whole-kidney and whole-nephron handling of filtered 
substances. Localisation of the nephron segment(s) responsible for the reabsorption or 
secretion of a substance requires the use of further techniques. A number of indirect 
methods, based on renal clearance measurements, have been suggested for assessment of 
proximal tubular function without recourse to invasive techniques. 
4.1.1.1 Urate clearance 
 
Urate is freely filtered at the glomerulus and is reabsorbed only in the proximal tubule. 
However, it is an unsatisfactory marker of proximal tubular function because urate 
clearance measures the balance of reabsorption and secretion in the renal tubule, and urate 
secretion in the proximal tubule is highly variable (see Shirley & Walter, 1993).  
4.1.1.2 Lithium clearance 
 
Renal lithium clearance has been widely used as an indirect way of assessing segmental 
tubular function, as it has been shown that lithium clearance acts as a reasonable marker of 
sodium and water delivery from the proximal tubule (reviewed in Thomsen & Shirley, 
1997). This is based on the assumptions that lithium is reabsorbed in the proximal tubule 
in the same proportion as sodium and water, and is neither secreted nor reabsorbed in the 
remainder of the nephron. These assumptions have been extensively tested and are not 
absolutely valid (about 10% more lithium than water is in fact delivered to the end of the 
proximal tubule, while there is also a small amount of lithium uptake in the loop of 
Henle), but the errors are modest and in opposite directions, tending to cancel one another 
out; thus lithium clearance can provide reliable qualitative information (Shirley & Walter, 
1993). Use of lithium clearance has the advantages of allowing experiments on conscious 
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animals and in humans, and the technique has been widely used to study renal sodium and 
water handling. 
 
In contrast to sodium, phosphate makes up only a small proportion of total ions and 
osmolality in tubular fluid (less than 5% even under extreme conditions), and therefore 
even large changes in proximal phosphate handling will not alter end-proximal water (and 
lithium) delivery substantially; for this reason lithium clearance is unlikely to allow 
detection of specific changes in renal phosphate handling. However, if there are large 
changes in proximal solute and water handling in general, phosphate is likely to be 
affected.  
 4.1.1.3 Phosphate clearance 
 
At one time it was suggested that phosphate itself could be used as a marker of end-
proximal fluid delivery. However, although most phosphate reabsorption undoubtedly 
does occur in the proximal tubule (see below),  it is now clear that the amount of 
phosphate absorbed in the proximal tubule is not related to sodium and water reabsorption 
in any fixed way, but depends on a number of  regulatory factors (see Chapter 1). 
Therefore, the ratio of tubular fluid-to-plasma phosphate (TF/PPi ) varies enormously, 
depending on the circulating concentration of PTH ( see Figure 4.1) and other 
phosphaturic factors. In addition, there is evidence for at least some phosphate 
reabsorption beyond the late proximal tubule.  
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Figure 4.1 Approximate ratio of proximal tubular fluid-to-plasma 
phosphate (TF/PPi) concentrations under various conditions 
The figure is adapted from Knox et al, 1973  
 
It is clear, therefore, that indirect methods as outlined above are not likely to be of help in 
assessing the sites(s) of altered phosphate transport. Even the most reliable clearance 
technique (lithium clearance) can only point to changes in proximal tubular reabsorption 
of water (and sodium); a selective change in phosphate reabsorption will not be detectable. 
 
4.1.2 Micropuncture 
 
Renal tubular micropuncture allows direct access to renal tubular fluid, and thus provides 
direct information about the functions of discrete sections of the nephron. The techniques 
of renal micropuncture were developed in the 1920s and 1930s by the pioneering figures 
of Wearn and Richards (Wearn & Richards, 1924, reviewed in Gottshalk, 2000). These 
techniques are time-consuming and technically difficult (Velazquez & Wright, 1992) and 
there is also a requirement for accurate determination of very small volumes and analytes 
within these small volumes. A further problem with the technique is that it is invasive and 
can only be performed on anaesthetised animals. Despite these difficulties, micropuncture 
techniques have the overwhelming advantage of allowing direct in vivo demonstration of 
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changes in tubular fluid composition in response to stimuli in intact animals, information 
which cannot be obtained in any other way. 
 
Micropuncture has identified the site of reabsorption and secretion of all physiologically 
important ions and molecules along the nephron, and has told us most of what we know 
about how the kidney actually works, from elucidating the counter-current mechanism for 
generating concentrated urine (Gottschalk & Mylle, 1959) to direct evidence for tubulo-
glomerular feedback (Thurau & Schnermann, 1965). Micropuncture has also provided 
direct demonstration of the filtering role of the glomerular membrane, by allowing 
comparison of the filtered fluid in Bowman’s space with plasma. 
It must be emphasised that only certain parts of the nephron - those on the surface of the 
kidney - are generally accessible by means of micropuncture techniques. Further, it is 
usually only possible to access those nephrons which lie at the surface, which may not be 
typical of all nephrons. Therefore, only the first two-thirds of the proximal tubule of 
superficial nephrons (the proximal convoluted tubule; pars convoluta) is accessible; the 
final third (the pars recta) is not. Moreover, in most animals the glomeruli are not visible 
on the renal surface and so, other than in certain strains of animals in which a small 
fraction of glomeruli are found on the surface, the initial segment of the proximal 
convoluted tubule (the S1 segment) is not accessible. See Figure 4.2 for a diagrammatic 
representation of a typical superficial and deep nephron, illustrating these points.  
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Figure 4.2 Diagram of structure of a superficial and a deep nephron 
(Adapted from Kriz &  Bankir, 1988)  
.
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4.1.2.1 Micropuncture assessment of renal phosphate handling 
 
Glomerular filtration 
If the glomerular membranes provided no barrier to phosphate (that is, if phosphate were 
freely filterable), the concentration of phosphate in Bowman’s space would be slightly 
higher than in plasma, for two reasons. Firstly, plasma contains (non-filterable) proteins 
and is only about 94% water. Secondly, the Gibbs-Donnan effect means that filterable 
anions will be present on the tubular side of the membrane in higher concentration than on 
the plasma side, because at plasma pH non-filterable proteins are negatively charged and 
so their overall negative charge is retained in the plasma, balanced by retention of a slight 
excess of cations. Set against these two effects is the fact that about 10% of plasma 
phosphate is protein-bound and not filterable (Suki & Rouse, 1996). In the event, data 
obtained from Munich-Wistar rats (in which some of the glomeruli are located 
superficially and so can be directly accessed by micropuncture) indicate that the phosphate 
concentration in glomerular ultrafiltrate is on average slightly lower than that in plasma 
water (Harris et al, 1974). Surprisingly, these authors found that the glomerular 
fluid/plasma water phosphate concentration ratio was different in male and female rats, 
averaging 0.96 in female rats and only 0.79 in male rats, whereas no significant 
differences between males and females in the filterability of sodium, calcium, inulin or 
chloride were demonstrated. In contrast, another group (also working on Munich-Wistar 
rats) found that the glomerular fluid/plasma water phosphate concentration ratio was 
almost exactly unity in male rats and around 0.95 in female rats (Grimellec et al, 1975). In 
view of these conflicting micropuncture findings, I have elected to follow most others in 
this field and equated filtered phosphate concentration with that of plasma.  
 
Tubular handling 
Strickler and colleagues (Strickler et al, 1964) reported in the 1960s that proximal tubular 
fluid /ultrafiltrate phosphate ratios were 0.73 in the rat, indicating that phosphate was 
normally reabsorbed in excess of water in the proximal tubule. They reported that 24% of 
filtered phosphate was delivered to the distal tubule and 22.5% was present in the final 
urine, suggesting little distal reabsorption or secretion of phosphate, at least under the 
conditions of this experiment. 
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Free-flow micropuncture experiments in the 1970s (Boundry et al, 1975) confirmed that 
most phosphate reabsorption takes place in the proximal tubule, particularly the early 
proximal tubule, with a steady decline in the fraction of phosphate remaining further along 
the proximal tubule. These authors did find, however, that the fractional excretion of 
phosphate in the urine was lower than the fractional delivery to the late part of the distal 
tubule, suggesting that there might be some net reabsorption of phosphate along the 
terminal nephron. Indeed, free-flow micropuncture experiments in dogs (Knox & 
Lechene, 1975) suggested that part of the phosphaturic effect of PTH in these animals was 
due to actions in the distal nephron. An alternative (or additional) explanation is that 
inaccessible deep nephrons might reabsorb proportionately more phosphate than the 
accessible superficial ones. These deeper nephrons feed into the same collecting ducts as 
the superficial nephrons (see Figure 4.2), potentially explaining why there appears to be 
less phosphate in the urine than is delivered to the superficial distal tubules. 
 
Microinjection studies using 32P (Brunette et al, 1973) agreed that the majority of 
phosphate reabsorption was in the proximal convoluted tubule, while a significant 
proportion was reabsorbed in the inaccessible part of the nephron between late proximal 
convoluted tubule and early distal tubule (that is, in the anatomical loop of Henle); no 
phosphate reabsorption occurred distal to injections into the early distal tubule. A 
technically very demanding stationary microperfusion study in rats also provided evidence 
for phosphate reabsorption in the proximal convoluted tubule and additionally in the 
adjacent descending part of the proximal tubule (pars recta). Again, no evidence was 
found for phosphate reabsorption in the distal tubule; nor was any reabsorbed in the 
ascending limb of the loop of Henle (Lang et al, 1977).   
 
Rouffignac’s group has addressed the issue of phosphate reabsorption in the distal 
nephron in more detail by means of injection of 32P into early distal tubules of various 
strains of rats and analysis of urinary recovery (Poujeol et al, 1977). In the Munich-Wistar 
strain there was no phosphate reabsorption beyond the distal tubule, whilst for two other 
strains (Sprague-Dawley and Long-Evans) significant reabsorption was seen. In a 
subsequent series of experiments in the Munich-Wistar strain (Poujeol et al, 1980), 
microinjection experiments were performed in juxtamedullary (deep) nephrons by 
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exposing the papilla through a small hole in the ureter. It was shown that these nephrons 
reabsorbed a considerable amount of phosphate between the tip of the loop of Henle and 
the urine, whereas in superficial nephrons there was no net phosphate reabsorption when 
radiolabelled phosphate was injected into the distal tubule. These experiments suggest that 
in the Munich-Wistar strain of rats, tubular phosphate handling differs between superficial 
and deep nephrons.  
 
Immunohistochemistry also reveals some differences between superficial and deeper 
nephrons: Segawa et al (2002 ) showed that staining for the NaPT2c transporter is much 
greater at the proximal tubule brush border of juxtamedullary nephrons than in superficial 
or midcortical nephrons, whereas NaPT2a is found more widely and uniformly.  
 
In summary, although there is some equivocal evidence for a small amount of phosphate 
reabsorption in the distal nephron, the consensus is that the vast majority of renal 
phosphate reabsorption normally occurs in the proximal tubule. Immunolocalisation data 
and results from knock-out animals suggest that most of this regulated renal phosphate 
reabsorption is due to the activity of the NaPT2a co-transporter (see Chapter 1).  
 
4.1.3 Location of the action of MEPE 
 
As discussed in Chapter 1 and above, most currently recognised regulated phosphate 
reabsorption takes place in the proximal convoluted tubule, particularly the S1 segment. 
PTH acts by altering the number of NaPT2a co-transporters in the proximal tubule brush-
border membrane (see Chapter 1). Most other factors (for example, thyroxine and growth 
hormone) known to affect renal phosphate reabsorption are also believed to act on the 
proximal tubule, but little direct evidence for this has been produced. No data concerning 
the location of the site of activity of MEPE are currently available. A preliminary report 
by Bresler and colleagues (Bresler et al, 2004) found that antibodies to ASARM peptides 
(the ASARM motif is a putative active part of the MEPE molecule, see Chapter 1) bind to 
the proximal tubules, and this suggests that there could be an interaction between MEPE 
and the proximal tubule. In addition, immunohistochemisty of renal sections showed 
strong staining for MEPE in the proximal tubule, and particularly around the area of the 
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apical surface of the proximal tubule, which was suggested as showing possible binding of 
MEPE to an as yet uncharacterised receptor in this area (Obureke & Fisher, 2005). 
Nevertheless, no study has assessed whether MEPE can act at this nephron site. 
 
4.2. Aim of the present experiments  
 
The present experiments were designed to investigate the mechanism of the phosphaturia 
induced by MEPE, using micropuncture to assess directly proximal tubular function. For 
consistency, and so as to demonstrate the maximal change in tubular fluid phosphate 
handling, the most distal accessible part of the proximal tubule was used for sampling in 
every experiment. Experiments were performed using saline infusion as a time control and 
PTH infusion as a positive control. The dose of MEPE was based on the dose-response 
curve constructed in the clearance experiments (Chapter 3). Each experiment included an 
initial baseline control period, that is, a period before infusion of MEPE or PTH, to take 
into account the considerable between-animal variation in baseline phosphate handling. 
 
4.3 Methods 
 
4.3.1 Experimental protocol 
 
Adult male Sprague-Dawley rats, of mean body weight 249g (range 240-260g), were 
anaesthetised with intraperitoneal sodium thiopentone (100mg/kg body weight; Link 
Pharmaceuticals, Horsham, Sussex) and prepared surgically for micropuncture studies. 
The surgery was as described in Chapter 3 for the clearance experiments, but with the 
addition of a flank incision to expose the left kidney. Perirenal fat was removed and the 
kidney was placed in a specially designed Perspex dish, with a gap for entry and exit of 
the renal artery and vein and the ureter; the dish was clamped to the operating table in 
order to minimise movement of the exposed kidney during respiration. The kidney was 
bathed continuously in mineral oil heated to 37oC. The left ureter was catheterised with 
polyethylene tubing (Portex Plastics, Hythe, Kent). Animals were infused with 0.9% NaCl 
solution at 4ml per hour throughout. Experiments were begun after a two-hour 
  136 
equilibration period; after the first hour of the equilibration period a bolus of tritiated 
inulin (60 µCi) was given, followed by an infusion of tritiated inulin at a rate of 60 
µCi/hour. During an initial one-hour control period, urine was collected from the ureter 
and 3-4 micropuncture samples were collected from late proximal convoluted tubules (see 
Figure 4.3). Samples were obtained using micropipettes, tip internal diameter 9-10µm, 
inserted into candidate proximal tubular loops. Microdroplets of Sudan black-stained oil 
were then injected into the tubules; no reappearance of the droplet or only one 
reappearance was taken to indicate that the puncture site was appropriate, i.e., in the late 
proximal convoluted tubule. Multiple reappearances of the droplet indicated placement 
too proximally, in which case the pipette was withdrawn and a new nephron was selected 
for a further attempt. Once a suitable nephron segment had been entered, a column of oil 
4-5 tubular diameters in length was injected and allowed to flow just distal to the puncture 
site. Gentle aspiration was then applied to the pipette so that tubular fluid arriving at the 
collection site was drawn into the micropipette. By maintaining the position of the oil 
column, it was ensured that the tubular fluid was collected at the same rate as it arrived at 
the puncture site. Thus, complete collection of tubular fluid was confirmed. Tubular fluid 
was collected continuously for periods of six to twelve minutes; once each collection was 
completed the pipette was withdrawn and the tubular sample deposited under oil onto a 
watch-glass. After any puncture, the next puncture site was selected following a 
systematic pattern that ensured that no nephron was sampled more than once. At the end 
of each collection, Microfil (Flow-Tec, Carver, MA, USA) was injected into the nephron 
through another micropipette, filling the nephron lumen. This substance hardens into a 
cast of the nephron which can be examined under the microscope at the end of the 
experiment. Subsequent examination of these Microfil casts confirmed late proximal 
location of tubular fluid collection points. Immediately following the control period, the 
intravenous infusion was changed to MEPE in seven animals (100µg/hr), or changed to 
PTH in seven animals (20µg/hr) or continued as saline alone in another seven animals, for 
the next two hours (see figure 4.3). During the second of these two hours (the 
experimental period), urine and micropuncture collections were performed again, using 
identical methodology. 
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Figure 4.3 Protocol for micropuncture experiments 
 
 
Blood samples were collected hourly from the arterial catheter. Each sample was 
approximately 100µl and was collected by unclamping the catheter and allowing blood to 
flow slowly under arterial pressure into a sample collection vial. Blood samples were spun 
at 1500g for five minutes and the plasma samples thus generated were then split for 
tritium and phosphate analysis. 
 
4.3.2 Analyses 
 
Urine, plasma and tubular fluid [3H] inulin activities were determined using 
β−scintillation spectroscopy (Packard Tricarb, Model 2900TR; Pangbourne, Berks, UK) 
after dispersal in Ultima Gold scintillation fluid (PerkinElmer, Beaconsfield, Bucks, UK). 
Urine [3H] inulin was determined by triplicate counts of 5µl samples after first diluting the 
urine 200-fold. Plasma [3H] inulin was determined by triplicate counts of 5µl samples of 
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the plasma fraction of centrifuged blood samples (aliquoted using ‘Supracaps’, Scientific 
Laboratory Supplies, Nottingham, UK); plasma inulin at any given time (for comparison 
with corresponding tubular fluid samples) was calculated assuming that counts altered 
linearly between successive hourly determinations. The tubular fluid samples under oil 
were subdivided; using previously calibrated constriction pipettes, duplicate samples were 
deposited in ultrapure water in CE microvials for subsequent ion analysis (62 nl sample in 
200 times dilution of ultrapure water) and duplicate samples (of 38nl) were deposited in 
scintillation vials for [3H] inulin determination. Urine samples were diluted 1:200 in 
ultrapure water and then frozen for later CE analysis. Plasma samples were diluted 1:100 
in ultrapure water and then frozen for later CE analysis. 
 
Sodium concentrations in urine were measured by flame photometry (model 543, 
Instrumentation Laboratory, Warrington UK), following appropriate dilution if required.  
 
4.3.3 Calculations 
 
GFR was calculated as inulin clearance, where  
 
GFR = Cin = [Uin ] x VU/[Pin], where 
 
Cin  = inulin clearance  
[Uin ]  = urinary inulin count 
VU  = urine flow rate  
[Pin]  = plasma inulin count. 
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Single-nephron GFR (SNGFR) was calculated correspondingly as single-nephron inulin 
clearance: 
 
SNGFR = [TFin] x VTF/[Pin], where 
 
[TFin ]  = tubular fluid inulin count 
VTF  = tubular fluid flow rate. 
 
Phosphate clearance was calculated as in Chapter 3.  
 
 
The fractional excretion of phosphate (FEPi ) was calculated as  
                 
                FEPi = CPi/Cin, where CPi = phosphate clearance.  
 
The fractional delivery of phosphate to the late proximal convoluted tubule (FDPi) was 
calculated as the tubular fluid: plasma concentration ratio for phosphate divided by that 
for inulin: 
                
                FDPi  =  TF/PPi/in. 
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4.3.4 Statistics 
 
Results are presented as means ± SEM. Comparisons between the micropuncture and 
contralateral kidney in each group were made using Student’s paired t-test. Comparisons 
between results obtained during the control period and the experimental period in each 
group were likewise compared using Student’s paired t-test. One-way ANOVA was used 
to make comparisons between all three groups during the control period and during the 
experimental period. Two-way ANOVA was used when groups in both control and 
experimental periods were simultaneously compared, followed (if significance was 
indicated) by Bonferroni’s test. In all cases, a P value of less than 0.05 was considered 
statistically significant. 
 
4.4 Results 
 
 
4.4.1 Whole-kidney GFR 
 
GFR data were collected to allow calculation of the amount of phosphate filtered during 
each collection period. Values were obtained for both the micropuncture kidney and the 
contralateral kidney, in order to assess whether the extra micropuncture surgery altered the 
overall function of the exposed kidney. The results are shown in Figure 4.4 and Table 4.1.  
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Figure 4.4 Single-kidney GFR  
Values are presented as means ± SEM; there were 7 rats in each group. 
Results are for the micropuncture kidney (only) 
 
 
 Control period Experimental period 
 
Micropuncture 
kidney 
 
 
p 
Contralateral 
kidney 
Micropuncture 
kidney 
 
 
p 
Contralateral 
kidney 
Saline 1.40 ± 0.14 0.89 1.43 ± 0.18 1.09 ± 0.21 0.79 1.14 ± 0.26 
PTH 1.32 ± 0.20 0.76 1.52 ± 0.28 1.02 ± 0.12 1.00 1.02 ± 0.16 
MEPE 1.26 ± 0.13 0.33 1.16 ± 0.12 1.16 ± 0.10 0.99 1.15 ± 0.08 
 
Table 4.1 Single-kidney GFR 
Values (means ± SEM) are in ml/min; there were 7 animals in each group 
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The mean GFRs were not significantly different between the three groups, either during 
the control period or the experimental period. In all groups there was a modest fall 
between control and experimental periods, though this was not statistically significant. 
There was good agreement between the GFRs obtained from the micropuncture side and 
the contralateral side, with no significant differences when analysed using paired t-tests 
(Table 4.1), providing some reassurance that exposure of the micropuncture kidney and 
placing it in a dish did not significantly alter its overall function.  
 
4.4.2 Single-nephron GFR 
 
Single-nephron GFR for each group is shown in Figure 4.5. The value used for each 
animal in each period was an average of several (at least three) determinations.  
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Figure 4.5 Single-nephron GFR (SNGFR) 
Values are presented as means ± SEM; there were 7 animals in each group  
 
Single-nephron GFRs were almost identical in the three groups during the control period. 
As with the whole-kidney GFR results presented above, SNGFRs were slightly (though 
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not significantly) lower during the experimental period, but there were no significant 
differences between groups.  
 
4.4.3 Urinary sodium excretion 
 
These results are shown in Table 4.2. Mean sodium excretion rose in every group during 
the course of the experiment (although the variance was large), but overall sodium 
excretion (left plus right kidneys) did not increase significantly in any of the groups. The 
only statistically significant increase was that in the contralateral kidney of MEPE-infused 
animals. There were  no significant differences in sodium excretion between the three 
groups in either time period. 
Finally, there were no significant differences in sodium excretion between micropuncture 
and contralateral kidneys, except in the saline group during the experimental period.  
 
 Control period Experimental period 
Micropuncture 
kidney 
 
 
P 
Contralateral 
kidney 
Micropuncture 
kidney 
 
 
P 
Contralateral 
kidney 
Saline 94 ± 39 0.11 134 ± 59 110 ± 41 0.03 151 ± 46 
MEPE 103 ± 29 0.69 95 ± 35 145 ± 47 0.77 138 ± 43* 
PTH 84 ± 30 0.37 76 ± 27 90 ± 20 0.68 84 ± 25 
 
Table 4.2 Single-kidney sodium excretion  
Values are absolute sodium excretions in µmol/h, means ±  SEM; n=7 rats 
in each group. P values refer to differences between urine collected from the 
micropuncture and contralateral kidneys, assessed by paired t-test.  
 * P=0.014 compared with the corresponding value during the control 
period; for other paired comparisons of control vs. experimental periods, 
P>0.05 
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4.4.4 Plasma phosphate concentration 
 
During the control period, plasma phosphate concentrations were 2.05 ± 0.08 mmol/l in 
the saline group, 2.03 ± 0.12 mmol/l in the PTH group and 2.15 ± 0.12 mmol/l in the 
MEPE group. In the experimental period the corresponding values were 1.93 ± 0.12, 1.87 
± 0.03 and 2.08 ± 0.06 mmol/l. There were no significant differences between the groups 
during either period, and no significant change in any group between control and 
experimental periods. 
 
4.4.5 Urinary phosphate excretion 
 
Results for absolute single-kidney phosphate excretion by the micropuncture kidney are 
shown in Figure 4.6. There was a wide variation in baseline urine phosphate excretion in 
individual rats, but closely comparable means in the three groups. When absolute 
phosphate excretion in the experimental period was compared with that in the control 
period in each group, there were significant increases in the PTH and MEPE groups, but 
no significant change in the saline group.  
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Figure 4.6 Absolute excretion of phosphate 
Values are means ± SEM; n=7 rats in each group 
 
When the results were re-analysed as fractional rather than absolute phosphate excretion, 
similar results were obtained (Figure 4.7). In this case, however, the change in excretion 
was significant in the saline-infused group as well as in the PTH and MEPE groups, 
although the size of the change was much smaller in the saline group. 
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Figure 4.7 Fractional excretion of phosphate 
Values are means ± SEM; n=7 rats in each group. 
  146 
4.4.6 Tubular fluid phosphate 
 
Tubular fluid/plasma phosphate concentration ratios are shown in Figure 4.8. Each data 
point is the mean (± SEM) calculated from seven animals, and the value in each animal is 
the average of at least three tubular fluid samples. Once again the raw data showed 
considerable variation between animals.  Although there was a trend towards an increase 
in TF/P phosphate in the MEPE group, there was no statistically significant change in any 
of the three groups. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 TF/P phosphate in the late proximal convoluted tubule 
Values are means ± SEM; n=7 rats in each group. 
 
 
In order to correct for fluid reabsorption along the tubule, the data are also presented as 
fractional phosphate delivery (FDPi), calculated as tubular fluid:plasma phosphate/inulin 
concentration ratios (as inulin is not reabsorbed by the tubules). In control animals infused 
with saline alone, there was no significant change in FDPi between the control and 
experimental periods. In contrast, there was a significant increase in FDPi in the animals 
infused with PTH and in those infused with MEPE. These data are presented both in the 
form of mean results for each individual animal (Figure 4.9),  in which each line 
represents a different experiment and in the form of aggregated data with all the 
micropuncture results summed (Figure 4.10). 
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There was considerable variability between fractional phosphate deliveries in different 
nephrons of the same animal, which cannot be attributed only to time-dependent changes 
in phosphate transport. Even when tubular fluid collections were made within 15 min of 
each other there were sometimes large differences in tubular phosphate delivery, 
indicating that nephrons are markedly heterogeneous with regard to their phosphate 
handling.  
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Figure 4.9  Fractional delivery of phosphate (calculated as TF/P Pi/inulin) 
at the late proximal  convoluted tubule 
Rats infused with (a) saline alone, (b) PTH, or (c) MEPE. Each line connects the mean 
values in one animal; there were seven  rats in each group. Mean (± SEM) data from each 
group of seven animals are also shown; the bold lines join up those means.  
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Figure 4.10 Fractional phosphate delivery, using all measured           
values individually 
In each group, for each period, n = 21-24. Statistical comparisons between 
control and experimental periods were by means of Student’s unpaired t 
test. 
  
 
 Statistical note 
In addition to using paired and unpaired t tests, all the data in this chapter were analysed 
by two-way ANOVA, examining the interaction between time and treatment. These 
analyses confirmed the significance of time but in no case did they show a statistically 
significant difference between any of the treatments for any of the variables measured. 
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4.6 Discussion  
 
Most micropuncture workers have used Sprague-Dawley, Wistar or Long-Evans strains of 
rat for their experiments (Velazquez & Wright, 1992), in most cases (as in my work) using 
whichever strain is available in their local university colony. Important work has also been 
done on naturally occurring mutants of these strains, for example the Munich-Wistar rat 
with accessible surface glomeruli and the Brattleboro rat which is a Long-Evans rat with a 
hereditary lack of vasopressin. All research strains are highly inbred, in contrast to most 
human populations which are outbred, and even colonies of the same strain of rat in 
different centres will tend to diverge over time. Thus, results from different laboratories, 
even when ostensibly working on identical strains of animal, might differ significantly.  
 
Values for TF/Pin  in the late proximal convoluted tubule (PCT) were in the range 2-3. 
These values are similar to those reported by others in rats, and indicate that between 50% 
and 66% of filtered water is reabsorbed between the glomerulus and the collection site. 
Control values for TF/P Pi  at the late PCT were approximately 0.6, which again agrees 
with previously reported values (Asplin et al, 1996). 
 
The values for SNGFR are also broadly in line with previously published data (Greger et 
al, 1977; Woda et al, 2001). SNGFRs in the present experiments were approximately 40-
50nl/min. The rat kidney contains about 30,000 nephrons (Bonvalet, 1978; Larsson et al, 
1980), so a rough calculation (ignoring differences between the filtration rates of 
superficial and deep nephrons) would equate an SNGFR of 40nl/min with a single kidney 
GFR of about 1.2ml/min. This is in fact approximately the GFR found in the present 
experiments. If anything, the SNGFR/GFR ratio is a little higher than would be expected 
on this basis, but this small discrepancy may be accounted for by the fact that proximal 
tubular collections disrupt the tubulo-glomerular feedback mechanism by stopping distal 
flow. This has the effect of slightly increasing the measured filtration rate in the sampled 
nephron, but does not  alter whole-kidney values (Navar et al, 1974). 
 
Saline was infused into the animals at 4ml/min throughout the experiment, equivalent to 
an infusion of 600µmol of sodium/hour. The urine sodium data demonstrated modestly 
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increasing urine sodium excretion during the course of the experiments and a wide range 
of baseline urine sodium excretions. However, since the average excretion rates were 
approximately 200µmol/hour, the animals were clearly in a state of overall sodium 
retention. Urinary sodium excretion has previously been shown to be reduced after 
surgery in a wide range of situations, in both humans (Paut & Lacroix, 2006) and 
experimental animals (Maddox et al, 1977; Shirley et al, 1990). Shirley et al (1990) 
showed, using lithium clearance as a marker of end-proximal fluid delivery, that the 
anaesthesia/surgery-induced antinatriuresis resulted from enhanced sodium reabsorption 
in the distal nephron. 
I found large variations in the phosphate concentration of tubular fluid sampled from 
adjacent nephrons even when the sampling was only a few minutes apart. It is worth 
noting that immunostaining work by Murer’s group (Levi et al, 1994) showed very 
considerable differences between even directly adjacent nephrons in the amount of 
NaPT2a present in the brush-border membrane. Moreover, data reported by Baum et al 
(Baum et al, 2005) from experiments on isolated proximal convoluted and straight tubules 
in vitro show phosphate transport varying by at least 50% between tubules. On the basis 
of these reports, the large variations in tubular phosphate found between spatially and 
temporally proximate collections are perhaps not surprising. 
 
The phosphaturic effects of MEPE (and PTH) were demonstrated not to be due to 
increases in filtered phosphate load. Neither single-kidney GFR nor single-nephron GFR 
was significantly altered by MEPE in the dose used in these experiments, and there was 
no significant change in serum phosphate concentrations (which in fact went down 
slightly). Therefore, as previously observed in the clearance experiments, the observed 
increases in urinary phosphate excretion could only be due to altered tubular handling of 
phosphate. 
 
During the control period in all groups, and during the experimental period in saline-
infused animals, fractional delivery of phosphate to the end of the PCT was found to 
average 20-25%, whereas overall fractional excretion was only 4-8%. Although this 
difference between fractional delivery to the late PCT and fractional excretion in the urine 
seems considerable, in fact it suggests that nearly 80% of filtered phosphate is reabsorbed 
in the PCT and only a maximum of 16% in more distal nephron segments. It is likely that 
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this difference represents the contribution of the (inaccessible) pars recta to phosphate 
reabsorption, although an element of phosphate reabsorption in the distal nephron cannot 
be ruled out. An additional potential explanation is nephron heterogeneity, with the 
superficial nephrons accessible to sampling perhaps not being typical of all nephrons.  
 
One obvious difference between the data presented in this chapter and those in the 
preceding one is that baseline fractional phosphate excretion in the animals undergoing 
micropuncture was somewhat lower. This effect was consistent in all three groups of 
animals and occurred despite normal GFRs and SNGFRs in the animals subjected to 
micropuncture. If anything, GFRs were higher in the micropuncture experiments than in 
the clearance experiments. Both MEPE and PTH were demonstrated to be phosphaturic 
under micropuncture conditions, as they were in the clearance experiments, but the final 
values for fractional phosphate excretion were lower than in clearance experiments using 
corresponding doses, probably reflecting the lower baseline values. These differences 
most likely reflect changes related to the differences in surgery, as the animals used in the 
two series of studies came from the same colony, were the same size (and age), were on 
the same diet and were given the same anaesthetic.  
 
Initial statistical analyses were by t testing, with comparisons between each variable in the 
control and experimental period, which showed significant effects of MEPE and PTH not 
only on overall phosphate excretion but also on phosphate reabsorption in the PCT. 
Further analyses by two-way ANOVA confirmed that there were differences between the 
initial and experimental periods, but were unable to demonstrate significant differences 
between the three treatments given. This underlines the difficulty of obtaining statistically 
robust effects when using a technically demanding method that is subject to significant 
experimental error as well as reflecting natural variation between animals and tubules. (It 
is notable that most previous micropuncture workers have reported t testing only.) 
 
The main conclusion from the experiments described in this chapter is that MEPE appears 
to cause a reduction in fractional proximal tubular phosphate reabsorption, which would 
explain the effects of MEPE on renal phosphate handling demonstrated in the preceding 
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chapter. These experiments have also confirmed that PTH also acts proximally in a 
broadly similar fashion.  
 
4.7 Conclusions 
 
The phosphaturic effect of MEPE results largely from inhibition of fractional phosphate 
reabsorption in the proximal tubule, as does the phosphaturic effect of PTH. It is most 
likely that this is due to internalisation of the NaPT2a protein from the proximal tubular 
brush-border membrane. 
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Chapter 5 
Concluding chapter 
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Concluding chapter 
 
 
It has long been clear that the actions of PTH and vitamin D alone do not explain either 
normal phosphate balance or the abnormalities seen in the hereditary hypophosphataemias 
and oncogenic osteomalacia. It was consequently hypothesised that a single mysterious 
substance - ‘phosphatonin’- existed which could explain the otherwise inexplicable data. 
In recent years a number of candidate phosphatonins have been described; it is becoming 
clearer that several of these substances act on the kidneys and/or bones to regulate serum 
phosphate. It is therefore more accurate to talk of ‘phosphatonins’ in the plural.  
 
The most widely studied phosphatonin is FGF-23. As indicated in Chapter 1, it has been 
demonstrated that in some patients with oncogenic osteomalacia FGF-23 levels are greatly 
elevated, and that the syndrome of autosomal dominant hypophosphataemia is due to 
mutations in the gene coding for this protein. FGF-23 levels are also elevated in some 
patients with other phosphate-losing conditions, including fibrous dysplasia of bone and 
post-transplant hypophosphataemia. However, it is clear that FGF-23 does not alone 
provide an explanation for all the clinical data. It has been unequivocally shown that it is 
possible to have phosphaturia in tumour-induced osteomalacia without a raised FGF-23 
concentration (Jonsson et al, 2003). It is also possible to have phosphaturia and 
hypophosphataemia in fibrous dysplasia of bone, and after a renal transplant, without 
raised FGF-23 (Riminucci et al, 2003; Bhan et al, 2006). Moreover, it is possible to have 
very high FGF-23 levels without significant hypophosphataemia, at least after a renal 
transplant (Bhan et al, 2006). Other putative phosphatonins may therefore be playing a 
role in these situations, for example FRP-4, FGF-7 and MEPE - the subject of this present 
investigation. 
 
 
Much previous work on renal phosphate handling has depended on the use of the 
radioactive isotope 32P; this allows determination of small amounts of phosphate but is 
potentially dangerous to use and is associated with difficulties in safe acquisition and 
disposal as well as requiring extensive staff training. Previously published 
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micromeasurement techniques for non-radioactive phosphate have required specialist 
hand-made equipment. In the present investigation, a novel method of measuring 
phosphate concentrations in biological samples was developed, allowing the 
determination of phosphate along with other anions in samples as small as 20 nanolitres. 
This method, based on capillary electrophoresis and using only components available off 
the shelf, was shown to be reliable and reproducible. The capillary electrophoresis method 
was compared with an alternative method, the NANOFLO, which requires specialist 
custom-made equipment and can measure only certain ions (and these only one at a time); 
results using NANOFLO and the new method were comparable. The capillary 
electrophoresis method was adapted, and used, to measure phosphate in urine, tubular 
fluid and plasma. Preliminary experiments were performed to show that the method also 
detected citrate and oxalate, and could be used to determine the marker substance 
iothalamate; capillary electrophoresis could therefore have wider application in the study 
of tubular function in the future. 
 
In the present investigation, renal clearance experiments were performed to determine 
whether MEPE is phosphaturic. It was demonstrated that MEPE causes dose-dependent 
phosphaturia when infused into rats. This phosphaturia is not caused by alterations in the 
filtered load of phosphate (as it was demonstrated that neither GFR nor plasma phosphate 
was significantly altered by MEPE infusion at the doses used) and must therefore be due 
to alterations in renal tubular phosphate reabsorption. The phosphaturic response to a 
range of MEPE doses was investigated, with evidence of a dose-response relationship and 
of a maximal effect; this maximal effect was similar to, but perhaps slightly less than, that 
seen with the well-studied phosphaturic hormone PTH. 
 
The tubular effects of MEPE were studied more closely by means of micropuncture 
experiments in rats. It was confirmed that PTH reduced fractional proximal tubular 
phosphate reabsorption and it was found that MEPE, infused at a dose previously 
demonstrated to cause phosphaturia in clearance experiments, also reduced fractional 
proximal tubular phosphate reabsorption. Although both of these results were significant 
when assessed using t-testing, neither reached statistical significance when assessed by 
two-way ANOVA. Considerable variability in tubular phosphate reabsorption was found 
even in closely adjacent nephrons, as well as between individual animals, while even with 
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PTH (known previously, and demonstrated in Chapter 3 of this thesis, to cause a doubling 
or more in urinary phosphate when infused intravenously), changes in proximal tubular 
fluid phosphate were modest; in my view this is why I failed to demonstrate statistically 
significant changes by two-way ANOVA.  
 
Following the completion of the present studies, immunoblotting of renal tissue obtained 
after infusion of MEPE into rats (performed by Dr Joanne Marks and reproduced here 
with her permission) has demonstrated a reduction in NaPT2a numbers at the proximal 
tubular brush-border membrane (see Figure 5.1); this finding is what would be expected, 
given that NaPT2a is generally considered the main regulated phosphate transporter in the 
proximal tubule and a key player in regulation of serum phosphate levels; and it parallels 
the previous demonstration by others that internalisation of NaPT2a is the mode of action 
of PTH in renal clearance experiments in animals. Nevertheless, it is reassuring to find 
that the MEPE-induced reduction in proximal tubular reabsorption described in this thesis 
is  associated with apparent internalisation of apical NaPT2a. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Western blot of renal brush-border membrane tissue 
obtained after MEPE infusion, or after infusion of saline alone, showing 
significant reduction in NaPT2a in the brush-border membrane after 
MEPE infusion (data from Dr J Marks). 
NaPT2a 
Actin 
 MEPE   Saline  
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Much work has been performed measuring phosphatonin levels in situations where they 
are likely to be in excess - such as in oncogenic osteomalacia. Results have often been 
variable or ambiguous. It would be interesting to measure levels of putative phosphatonins 
in situations in which they should be suppressed - for example, if MEPE and FGF-23 are 
involved in the regulation of serum phosphate, the plasma levels of both should be very 
low in patients with malnutrition or phosphate depletion. I do not think these 
measurements have yet been made, although it has been reported that in two patients with 
very low serum phosphate levels  due to HHRH (caused by a known mutation in the 
NaPT2c gene) FGF-23 levels were normal, not suppressed (Yamamoto et al, 2005). 
 
It is clear that there is a great deal of redundancy in the human phosphate control 
mechanisms. Thus, patients with inactivating mutations of the main regulated intestinal 
phosphate transporter (NaPT2b) have been reported as having normal serum phosphate 
concentrations (Corut et al, 2007), while a patient reported as having a dominant negative 
mutation of the main renal phosphate transporter (NaPT2a) did have a low serum 
phosphate and kidney stones but had normal growth and no other reported health 
problems (Prie et al, 2002). Patients with mutations in the PHEX gene, which causes 
XLH, often (but by no means invariably) have raised FGF-23 levels, but these have been 
demonstrated to move towards normal over time; this suggests that there are counter-
regulatory mechanisms which can alter the postulated effects of PHEX on FGF-23 and 
perhaps on other phosphatonins. 
 
 
It is interesting to note that two independent groups (Shimada et al, 2001; De Beur et al, 
2002), using different methodologies, both identified a number of genes which might 
cause phosphaturia in tumour-induced osteomalacia, and that several of these candidate 
phosphatonins were identified by both groups. These techniques are based on looking for 
genes transcribed more frequently in TIO tumours than in normal bone. What is not clear 
is whether these genes directly regulate each other - in other words, whether one of them 
is abnormal as a primary abnormality and the others as a response to this. The search 
strategy used by Rowe et al (2000) was based on looking at circulating factors and found 
only two proteins, one of which was MEPE. This strategy might allow identification of 
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actual circulating proteins (‘phosphatonins’) as opposed to all proteins upregulated in 
cancer cells producing TIO, which could include up- or down-stream factors.  
 
In conclusion, MEPE is a protein found in bone and over-expressed in at least some 
tumours causing phosphaturia. It has been found in the circulation of healthy humans, and 
in excess in some people with phosphaturia. I have demonstrated that it increases 
fractional phosphate excretion when infused intravenously. It does this mainly, perhaps 
entirely, by acting on the proximal tubule. Immunofluorescence experiments suggest that, 
like PTH, it inhibits proximal tubular phosphate reabsorption by triggering the 
internalisation of NaPT2a. It is conceivable, therefore, that MEPE might be a link between 
bone metabolism and renal phosphate handling, signalling changes in bone turnover 
which require alterations to the body’s phosphate balance.  
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Abbreviations 
 
 
 
ADHR Autosomal dominant hypophosphataemic rickets (also known as 
autosomal dominant hypophosphataemia) 
 
ANOVA  Analysis of variance 
 
ARHR  Autosomal recessive hypophosphataemic rickets 
 
ASARM motif  Acidic serine aspartate rich motif 
 
BBM  Brush-border membrane (of the proximal renal tubule or the intestine) 
 
cAMP  Cyclic AMP 
 
CE  Capillary Electrophoresis 
 
CRF  Chronic renal failure 
 
CKD  Chronic kidney disease 
 
DMP-1  Dentin Matrix Protein 1 
 
DMP-2  Dentin Matrix Protein 2 
 
ELISA  Enzyme-linked immunosorbant assay 
  189 
 
ESRD  End-stage renal disease (that is, dependent on dialysis) 
 
FD  Fibrous dysplasia (of bone) 
 
FEPi  Fractional excretion of phosphate 
 
FGF-23  Fibroblast Growth Factor 23 
 
FRP-4  Frizzled-related Protein 4 (sometimes called sFRP-4) 
 
GFR  Glomerular filtration rate 
 
HHRH  Hereditary hypophosphataemic rickets with hypercalciuria 
 
HPLC  High-performance liquid chromatography 
 
HPT  Hyperparathyroidism 
 
HSP-90  Heat Shock Protein 90 
 
MEPE  Matrix extracellular phosphoglycoprotein 
 
MMP  Matrix metalloproteinase 
 
mRNA  Messenger ribonucleic acid 
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n.s. Not statistically  significant (indicating a probability of >0.05 according 
to the relevant statistical test) 
 
NHERF-1 Sodium/hydrogen exchanger regulatory factor 1 
 
OF45  Osteoblast/osteocyte factor 45 (synonymous with MEPE) 
 
OK cells  Opossum kidney cells 
 
OMIM             Online Mendelian Inheritance in Man (online database of inherited                
diseases, hosted by the (US) National Centre for Biotechnology 
Information  and freely available at 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim) 
 
PCT   Proximal convoluted tubule 
 
PEX  see PHEX 
 
PHEX Phosphate-regulating gene with Homology to Endopeptidases on the X 
chromosome (in some early work this gene is referred to as PEX) 
 
PTH  Parathyroid hormone 
 
PTHrP  Parathyroid hormone related protein 
 
SIBLING Small Integrin Binding Ligand N-linked Glycoprotein 
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SAGE  Serial Analysis of Gene Expression 
 
SEM  Standard error of the mean 
 
SNGFR  Single-nephron glomerular filtration rate 
 
STC1  Mammalian homologue of fish stanniocalcin 1 
 
STC2  Mammalian homologue of fish stanniocalcin 2 
 
TIO  Tumour-induced osteomalacia (synonymous with OHO) 
 
XLH X-linked hypophosphatemia, also known as X-linked hypophosphatemic              
rickets 
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Gene and protein nomenclature 
 
As genes and their associated proteins are discovered by a range of workers, often near-
simultaneously, each of whom names the results according to their own ideas and 
interests, there is much confusion and ambiguity in gene and protein naming. 
 
It is generally agreed that genes and their proteins should take their names from the human 
homologue, if one exists. 
 
In accordance with the recommendations of the Rat Gene Symbol Tracker (see ‘RatMap’, 
www.ratmap.org), I have used (or at least tried to use) consistent symbols for human and 
animal genes. Human genes are in italics and capitals. Animal (rat and mouse) genes are 
in italics with the first letter capitalized. Proteins are capitalized if human, and in lower 
case with the first letter capitalized if animal. Arabic numerals are favoured over Roman 
ones to avoid ambiguity (so most workers now use NPT2a rather than NPTIIa). Mixed 
capital and lower-case letters in human protein designations are discouraged but not 
always avoided - thus some workers use NPT rather than NaPT. 
 
It is worth noting that these conventions are not universally followed, particularly in older 
work.  
 
There is an additional problem when new genes or proteins are discovered which are 
closely related to a previously named gene. Thus NaPT2 becomes NaPT2a once a second 
NaPT2 type protein is described. 
 
 
 
 
